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Abstract 
Despite the magnitude of the HIV pandemic, the events involved in the initial HIV-
1 entry into the body are not yet fully understood. Although the principle mode of HIV-1 
transmission is through mucosal surfaces, the oral epithelium appears to be less 
susceptible to HIV-1 infection than vaginal epithelium. In addition, infections with co-
pathogens that elicit immune activation, such as Candida albicans, may also promote 
HIV-1 infection. 
The project objectives are to determine whether (i) HIV-1 is able to bind and 
integrate into oral and vaginal epithelial cell lines, (ii) epithelial cell lines are able to 
transfer viable virus from their surface to permissive cells, (iii) epithelial cells are 
responding to HIV-1 with changes in intracellular signalling or gene expression profiling, 
and (iv) Candida albicans can affect epithelial susceptibility to HIV-1 or whether it can 
bind and/or transfer HIV-1 to permissive cells. 
We demonstrate that oral, oro-pharyngeal and vaginal epithelial cell lines do not 
express canonical receptors for HIV-1 but they do express other receptors known to 
promote HIV-1 binding, including GalCer and syndecan-1. Oral and vaginal epithelial cell 
models can capture HIV-1, which subsequently does not appear to integrate into the 
epithelial genome. Therefore, viral replication is not supported. Notably, HIV-1 captured 
on the epithelial surface remains infectious and can be transferred to permissive cells. 
Furthermore, like epithelial cell lines, C. albicans can also directly bind and transfer HIV-
1 to permissive cells. The carbohydrate moieties chitin and β-glucan appear to play a 
role in mediating viral binding. Notably, transfer of HIV-1 to permissive cells occurs from 
chitin but minimally from β-glucan. This indicates that fungal-viral interactions may occur 
at mucosal surfaces that potentially promote HIV-1 infection.  
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Chapter 1 Introduction 
 
1.1  The HIV epidemic 
According to the World Health Organization in 2009, 33.3 million people were 
living with human immunodeficiency virus (HIV) worldwide with an estimated 2.6 million 
new infections that year (United Nations Program on HIV/AIDS, 2010). Despite the 
magnitude of this global pandemic, the precise events involved in initial HIV entry to the 
body are not yet properly characterised (Shattock et al., 2008). Although the principle 
mode of HIV transmission in humans is through exposure to mucosal surfaces, the 
interaction of mucosal epithelial cells with HIV is not fully understood (Shattock et al., 
2008; Wu et al., 2003). 
Although the total number of HIV positive people in the world appears to be on 
the decrease, there are still significant areas of concern with respect to transmission of 
the virus that causes acquired immunodeficiency syndrome (AIDS). At the moment, 
heterosexual transmission is the most common (Hladik and McElrath, 2008) with women 
and girls bearing the greatest burden of infection, accounting for more than 50% of 
people living with AIDS and 76% of young people (aged 15–24 years) living worldwide 
with HIV (United Nations Program on HIV/AIDS, 2010). A greater risk for transmission is 
associated with receptive intercourse for men (Jaffe et al., 1985) and women (United 
Nations Program on HIV/AIDS, 2010). Mother to child transmission is decreasing due to 
preventative pre-natal drug regimens and the knowledge that there is an oral 
transmission risk for breast feeding infants. However, intravenous drug users still lack 
access to sterile needles (United Nations Program on HIV/AIDS, 2010). Men who have 
sex with men have a staggeringly high burden in Sub-Saharan Africa with greater than 
40% infection in the South African and Kenyan capitals (United Nations Program on 
HIV/AIDS, 2010). Thus, understanding the mechanisms of mucosal infection is critical in 
continuing the management of the epidemic. 
 
1.2  HIV-1 genomic structure 
HIV-1 is a retrovirus consisting of approximately 10 kilobases (Kb) of genetic 
material encoding nine genes (Figure 1.1). These genes are: gag encoding structural 
proteins, pol encoding viral enzymes, env encoding gp120 and gp41, and six genes 
coding for regulatory and accessory proteins tat, rev, nef, vpu, vpr and vif  (Freed, 2004; 
Komano et al., 2005; Trkola, 2004).  
 










Figure 1-1: Organization of the HIV-1 genome. The location of the long terminal repeats (LTRs) 
and the genes encoded by HIV-1 are indicated: Gag, Pol, Env, Vpr, Vif, Vpu, Rev, Tat, Nef. 
Polyproteins Gag, Pol and Env are cleaved by protease digestion. Pol protein is cleaved to form 
PR: viral protease, RT: reverse transcriptase p51 and p66 and IN: integrase. Env is cleaved to 
form envelope gp120 and gp41 that form heterotrimers in the virus envelope. Gag is cleaved to 
form MA: matrix, CA: p21 capsid, NC: nucleocapsid p6 and p7. The sizes of the genes and 
encoded proteins are not to scale (schematic from Freed, 2004). 
 
Figure 1-2: HIV virion structure.  Diagram from (Dandekar et al., 2008). Note that envelope 
gp120 and gp41 are in hetero-trimeric conformation in the membrane of the virus particle and that 
approximately 14 of these virus spikes exist on a typical particle (Zhu et al.,2006) . 
Polyproteins Gag, Pol and Env are cleaved by proteases in order to form viral 
particles. Gag polyprotein encompasses the viral capsid protein p24 (Figure 1.2, 6.), the 
nucleocapsid p6 and p7 (Figure 1.2, 7.) and the matrix p17 (Figure 1.2, 4.). Pol is 
processed to release the viral protease, reverse transcriptase and integrase enzymes 
(Figure 1.2, 7.). Reverse transcriptase is an error prone RNA-dependant DNA 
polymerase that is required to convert the HIV RNA genome to complementary DNA that 
1. Env gp120  
2. Env transmembrane 
protein gp41 
3. Cell derived lipid 
bilayer 
4. Matrix proteins p17 
5. Two single stranded 
RNA HIV genomes 
6. p24 capsid  
7. Viral proteins: protease 
p10, integrase p32, 
reverse transcriptase p66 
and p51 subunits and 
nucleocapsid protein p7. 
Vif, Nef and Vpr are 
located inside virion. 
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can be trimmed and integrated into the host DNA genome by the integrase enzyme 
(Dandekar et al., 2008). The viral envelope comprises a host cell phospholipid bilayer 
that is gathered from the infected cell as the virus is released (Figure 1.2, 3.). The viral 
envelope polyprotein gp160 is highly glycosylated as it is folded in the endoplasmic 
reticulum (ER), the glucose residues are trimmed in the ER and cis-golgi, resulting in 
hererogeneously sized high mannose structures as it moves further down the secretory 
pathway and finally glucose transferases act in the trans-golgi, producing complex outer 
branching of the sugars (Fenouillet et al., 1995).  Gp160 is processed by cellular 
proteases to form gp120 (Figure 1.2, 1.) and gp41 (Figure 1.2, 2.) that remain non-
covalently associated and  form a hetero-dimers in trimeric conformation in the virion 
membrane surface (Chan et al., 1998). Over half the molecular weight of gp120 ends up 
composed of sugars (Allan et al., 1985; Checkley et al., 2011) : this glycosylation is not 
necessary for its function but rather its proper folding for biological activity(Fenouillet et 
al., 1994).    A conformational change in gp120 on binding CD4 results in gp41 coming 
into close contact with the cell membrane and mediates membrane fusion (Chan et al., 
1998).  
The virion also contains two regulatory proteins. Tat is the “trans-activator of 
transcription” and regulates HIV transcription by binding the transactivation response 
element (TAR) in the HIV-LTR (long terminal repeats), the HIV promoter. Tat promotes 
elongation of full length transcripts (Dandekar et al., 2008; Flint and American Society for 
Microbiology., 2009) by its interaction with P-TEFb.  The P-TEFb protein kinase complex 
then stimulates elongation by phosphorylating the negative elongation factor (NELF), 
and similarly activates the polymerase activity by phosphorylation of  RNA Polymerase II 
and Spt5 (Karn, 2011).  Rev is the regulator of the virion and binds the Rev-response 
element (RRE) in env RNA and mediates its nuclear export. It facilitates the production 
of viral structural proteins and accumulates to promote the late phase of the viral 
replication cycle (Dandekar et al., 2008). 
Four accessory proteins of HIV have been described, so called because they are 
not essential for the virus life cycle but increase the virus’ fitness. Vif, or viral infectivity 
factor, accumulates in infected cells and increases infectivity by targeting cellular anti-
viral APOBEC3G for degradation. Nef or negative regulatory factor has many functions 
including down regulating CD4 (see section 1.4) and major histocompatibility complex 
class I surface expression. Vpr or viral protein R may facilitate nuclear import of the HIV 
pre-integration complex and promotes cell cycle arrest. Vpu is viral protein U and is  
required for the incorporation of a single viral core in budding (Dandekar et al., 2008; 
Flint and American Society for Microbiology., 2009). 
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1.3 HIV-1 Classification 
There are four main groups of HIV-1 arising from 4 transmission events of 
zoonoses from non-human primates to humans : M “major”, O “outlier”, N “new” 
(Dandekar et al., 2008) and P “preliminary” (Plantier et al., 2009). The majority of HIV-1 
(99.6%) infections are of the M group (Kandathil et al., 2005). 
The clades or subtypes of group M are A1, A2, B, C, D, F1, F2, G, H, J, K and 
some circulating recombinant forms (CRF) represent different genetic lineages of HIV-1 
and are associated with certain geographic regions (Baeten et al., 2007; HIV database, 
2012; McCutchan, 2006). Although clades were originally defined based on the 
sequence of env and gag genes, these are now classified by comparing whole virus 
sequences in order to establish the genetic phylogeny of the queried virus (Robertson et 
al., 2000). CRF arise when a cell is infected with two subtypes of HIV-1. If two viruses 
infect the same cell, then virions can be packaged containing one single-stranded RNA 
from each infecting subtype, since two copies of single stranded RNA comprise the core 
genetic material. When reverse transcription occurs, the viral reverse transcriptase may 
switch between the two RNA templates, resulting in the creation of a mosaic virus by the 
dual virally infected cell (HIV database, 2012). In addition, there are strict criteria for the 
definition of a CRF: the CRF must be sequenced in full and must be found in three or 
more individuals that are not linked epidemiologically (Hemelaar et al., 2011). Unique 
recombinant forms (URF) are recombinant viruses in the population that do not fit the 
criteria for CRF. Thus, there are many forms of HIV-1. This diversity has a great impact 
on diagnostics and prognosis for the virus carriers, since subtype may affect the rate of 
disease progression (Baeten et al., 2007; Kiwanuka et al., 2008). In addition, this implies 
that any vaccine would need to be group and clade specific as well as directed against 
the most conserved portions of viral genes and proteins. HIV has a very high mutation 
and recombination rate (Rambaut et al., 2004). Furthermore, the characteristics of the 
immune systems of the human populations receiving the vaccine will also affect the 
efficacity of the vaccine. Thus, vaccine development will be challenging. 
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Figure 1-3: Global distribution of subtypes or clades of HIV-1. The world is divided into 15 
geographic regions that appear in the same shade of grey. The overlaid pie charts have a surface 
area proportional to the number of people infected with HIV in the region. The colours represent 
the subtypes, CRFs and URFs (Hemelaar et al., 2011). 
 
1.4 Classical cycle of HIV-1 infection 
The canonical course of HIV-1 infection first requires binding of HIV-1 to 
permissive cells expressing the CD4 receptor and a chemokine co-receptor (CCR5 or 
CXCR4). This results in a conformational change in envelope heterotrimers: gp120 and 
exposes regions of gp41 that are needed for fusion of the virus particle to the cell 
membrane. Entry of viral capsid containing the viral RNA is followed by uncoating of the 
virus and reverse transcription of the viral RNA into complementary DNA (Figure 1.4) 
(Turner and Summers, 1999). Double stranded retroviral circular DNA is imported into 
the nucleus as part of the viral pre-integration complex (composed of Vpr, viral matrix 
and integrase that contains a nuclear localisation signal) and integrated into the host 
genome by viral integrase (Dandekar et al., 2008). These two key stages (reverse 
transcription and integration) are targeted by highly active anti-retroviral therapy 
(HAART) for the treatment of HIV and AIDS patients. For example, Azidothymidine (AZT) 
is a chemical analogue of thymidine acting as a reverse transcription inhibitor, and 
integrase inhibitors (e.g. 4-[3-(azidomethyl)phenyl]-2-hydroxy-4-oxo-2-butenoic acid ) 
target HIV-1 genome integration into newly infected cells. Transcription is regulated by 
the long terminal repeat (LTR) sequence of the proviral DNA and the viral regulatory 
proteins Tat, Rev and Nef are the first proteins to be produced in the early phase of 
infection. The accumulation of Tat and Rev increases transcriptional activity and initiates 
the late phase of infection (Sierra et al., 2005). Late phase transcription allows viral 
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structural proteins to be synthesized. This is followed by glycosylation of envelope 
proteins, transport, assembly of the virion: packaging  the viral genomic RNA at the cell 
membrane in lipid raft rich areas (Dandekar et al., 2008).  Ultimately budding from the 
infected cell involves the cleavage of Gag and Gag-Pol polyproteins (Hladik and 
McElrath, 2008).  
 
 
Figure1-4: HIV-1 Life Cycle. General features of canonical HIV-1 infection. The early phase 
begins with CD4 recognition and involves events up to and including integration of the proviral 
DNA: gp120 is bound by CD4 and recruits the chemokine receptor CXCR4 or CCR5. The virus 
and cell membranes fuse and the viral DNA is uncoated, reverse transcribed and integrated into 
the host DNA. The virus can remain in a latent state (for an indeterminate amount of time) or 
proceed to the late phase. The late phase comprises transcription of the integrated DNA, 
translation of accessory proteins, virus assembly, virus budding and maturation. Figure from 
Turner and Summers, 1999. 
 
HIV-1 establishes and conceals itself in the in the Gut Associated Lymphoid 
Tissue (GALT), CD4+ T cells, macrophages, dendritic cells and B-lymphocytes. HIV-1 
can also infect endothelial cells and affects the central nervous system, reducing the 
number of CD4+ T cells until cellular mediated immunity is lost. HIV-1 infection 
progresses over time (Figure 1.5) from an acute infection where flu-like symptoms and a 
spike in viral load occur, to a chronic HIV infection (associated with co-infections) and, 
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finally, to AIDS where the immune system collapses due to the large scale death of CD4+ 
T cells. This allows potentially fatal infection by opportunistic pathogens and cancers 
(Flint and American Society for Microbiology., 2009). 
 
Figure 1-5: Typical course of HIV infection. Increase in immune activation (red), spiking of 
CD4+ T-cells (blue, circulating; black, mucosal) and their decline as well as early spike in viremia 
that decreases, then fluctuates and finally increases dramatically (grey) (Forsman and Weiss, 
2008). 
 
1.5 Receptors and co-receptors 
Canonical HIV-1 infection is initiated through binding of the trimeric envelope 
heterodimers to CD4 that then recruit the chemokine co-receptors CCR5 or CXCR4 
(Flint and American Society for Microbiology., 2009). Viruses that are designated R5 
trophic use the CCR5 co-receptor for entry to monocytes and macrophages (Alkhatib et 
al., 1996; Deng et al., 1996), while X4 trophism refers to the virus’ use of CXCR4 as a 
fusion co-receptor to CD4+ T cells (Feng et al., 1996). Dual trophic viruses also exist that 
can utilize either co-receptor with CD4. R5 viruses tend to be first to establish the 
infection while X4 emergence appears to be associated with clinical deterioration (Xiao 
et al., 2000). CD4, CCR5 and CXCR4 have naturally occurring ligands: IL-16, β-
chemokines (RANTES, MIP-1α and MIP-1β) and SDF-1, respectively (Flint and 
American Society for Microbiology., 2009). Binding of CD4 to gp120 triggers a 
conformational change in envelope  heterotrimers to reveal gp41 which mediates 
membrane fusion (Gonzalez-Scarano et al., 1987). 
 
1.6  Non-canonical HIV-1 receptors or binding factors 
Many alternative co-receptors for HIV-1 entry exist. The glycosphingolipid 
galactosylceramide (GalCer) has been proposed as an alternative receptor for HIV-1 in 
CD4 negative cell types (Cook et al., 1994; Fantini et al., 1993; Yahi et al., 1992). 
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Syndecans are the most common type of heparan sulfate proteoglycan (HSPG) on 
eukaryotic cells (Bobardt et al., 2003; de Witte et al., 2007) and include Syndecan-1 
(SDC-1) which binds HIV Tat and increases endothelial cell movement, and Syndecan-4  
(SDC-4) which forms complexes with CXCR4 in human primary lymphocytes, 
macrophages and HeLa cells.   Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN) also has an affinity for HIV-1 and can enhance trans 
infection of dendritic cells (Geijtenbeek et al., 2000). There is the mannose receptor that 
binds HIV-1 (Turville et al., 2002; Cardona-Maya et al., 2006; Nguyen and Hildreth, 
2003; Trujillo et al., 2007) through gp120 on vaginal epithelium  (Fanibunda et al., 2011). 
In addition, other C-type lectins other than DC-SIGN and mannose receptor have been 
shown to have a role in mediating HIV’s interaction with Dendritic cells (such as 
Langerin) (Turville et al., 2002). Two papers specifically implicate the human scavenger 
receptor gp340 on female genital tract epithelium in facilitating the transcytosis of HIV-1 
(Stoddard et al, 2007; 2009). β-1 integrin has also been implicated (Maher et al., 2005). 
Equally, α4β7 integrin was identified as an env binding factor in T-cells (Arthos et al., 
2008) but recent work suggests that blocking this molecule doesn’t impair transmission 
of  founder and chronic subtype C HIV-1 (Parish et al., 2012).  However, interaction of 
HIV-1 with alternative receptors may not necessarily lead to fusion and active entry into 
cells. Interaction instead could promote association with the entry receptors in cis and in 
trans. These molecules might thereby protect bound virus from degradation or passively 
allowing its dissemination in the body through viral presentation to susceptible immune 
target cells below the mucosal surface (Bobardt et al., 2003; Saidi et al., 2007). 
 
1.7 HIV-1 and the epithelium 
Vaginal transmission of the virus is facilitated when epithelial barriers are 
breached: ex vivo, HIV-1 can quickly infect intraepithelial vaginal Langerhans cells and 
CD4+ T-cells when the epithelial barrier is damaged by chemical treatment (Hladik et al, 
2007). However, in nature, transmission of cell-free or cell-associated viral particles may 
occur via several mechanisms, including (1) epithelial breach by micro-tears in the 
epithelium, (2) the attraction of immune cells to the epithelial lumen by inflammatory 
signals, and (3) passive transcytosis (Hladik and McElrath, 2008), 4) transmigration of 
infected cells (Anderson et al., 2010; Shattock et al., 2003). Host cells that could 
potentially be infected by HIV-1 are vaginal epithelial cells (Asin et al., 2004; Asin et al., 
2003; Tan et al., 1993), intraepithelial CD4+ T cells, dendritic cells and macrophages 
(Hladik and McElrath, 2008).  
Although normal human oral keratinocytes and oral epithelial cells may be 
susceptible to productive infection by HIV-1 in vitro (Liu et al., 2003; Moore et al., 2002; 
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Moore et al., 2003; Vacharaksa et al., 2008), others dispute this finding (Quinones-Mateu 
et al., 2003), while one study found that HIV-1 is inactivated when it passes through adult 
oral epithelium (Tugizov et al., 2011). However, the fact that oral transmission is seldom 
reported in vivo (Challacombe and Naglik, 2006; Rothenberg et al., 1998) fuels the 
debate. 
Greenhead et al. (2000) used primary cervical and vaginal explants in order to 
shed light on the nature of the cells that were the primary tagets of HIV in the genital 
epithelium. Although immune activation, as modelled by PHA and IL-2 treatment,  in the 
genital mucosal explants appeared to predispose to greater accumulation of p24, the 
cells positive for p24 in the explants were also CD68 positive, a marker for macrophages 
and monocytes (Greenhead et al., 2000). The epithelial cells themselves did not appear 
to become infected or to foster transcytosis of the the two HIV strains tested (Greenhead 
et al,, 2000).. However, more recent work in primary female genital tract epithelium 
disputes that epithelial cells are not involved in transcytosis of HIV and implicate HSPG 
(Bobardt et.al., 2007; Stoddard et al., 2009) and gp340 in the active traversal of HIV-1 
through the mucosal barrier (Stoddard et al., 2009). 
Thus, a systematic review of the data is required. Firstly, mRNA and protein 
expression of HIV receptors and related co-factors in and on oral and vaginal epithelium 
and HIV-1 binding to epithelium will be explored. Next, experimental outcomes of HIV-1 
infection and transfer to susceptible cells will be examined. Finally, epithelial responses 
to HIV-1 and HIV-1 in combination with co-infections will be reviewed.   
1.7.1 Canonical and non-canonical receptor expression in epithelium 
1.7.1.1 mRNA expression 
1.7.1.1.1 Oral epithelium 
Currently, there is mRNA expression data on primary human salivary gland 
epithelial cells, oral keratinocytes, gingival and adenoid epithelial cells in the literature 
that are summarized in Table 1.1. However, the data is often semi-quantitative as shown 
by the intensity of an RT-PCR band. In 2002, Moore et al. examined two salivary gland 
epithelial lines; both were negative for CD4 but positive for CXCR4 . One of the two lines 
expressed CCR5 (Moore et al., 2002). This was closely followed by another publication 
characterizing two keratinocyte and two adenoid epithelial cell lines (Moore et al., 2003). 
All four lines expressed CCR5 and CXCR4 while only the adenoid epithelial cells 
expressed CD4 (Moore et al., 2003). The study by Acheampong et al. only showed 
quantitative RNA data for primary human oral keratinocytes in terms of fold increase in 
expression when treated with HIV-1 gp120 or Nef or Tat (Acheampong et al., 2005). 
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Therefore, resting levels of expression were not detailed, preventing comparison of this 
data set with the other studies.  
Giacaman et al., in a study on the effect of Porphyromonas gingivalis on oral 
keratinocytes showed (using an agarose gel), that in unstimulated TERT-2 cells, that 
CXCR4 and to a lesser extent CCR5 were expressed in this immortalized human oral 
keratinocyte line (Giacaman et al., 2007).  Also, Moutsopoulos et al. used seven gingival 
keratinocyte biopsies in a microarray to show that these samples were weakly positive 
for CD4, CCR5 and CXCR4 as well as having expression of SDC-1 and low levels of 
DC-SIGN (Moutsopoulos et al., 2007). However, no unit for the level of expression was 
given in this study, making it difficult to evaluate this work.  
Thus, mRNA expression appears to depend on the type of oral epithelial cell 
studied (see summary in Table 1.1). Some oral epithelial cells appear to express CD4, 
although not the majority. However, many express at least a small amount of one or both 
HIV-1 co-receptors (CCR5 or CXCR4). Data pertaining to mRNA expression of non- 
canonical HIV-1 binding factors is limited. Thus, there needs to be more elucidation of 
quantitative mRNA expression of HIV-1 receptor related genes in oral epithelial cells. 
 
Table 1-1: HIV-1 receptor related mRNA expression in oral epithelial cells 
Type of epithelium CD4 CXCR4 CCR5  Reference 
Salivary gland HSY - + + Moore et al. 2002 
Salivary gland HSG - + - 
Gingival Keratinocyte A + + +/-  
Moore et al. 2003 Gingival Keratinocyte B + + +/- 
Adenoid isolate A - + + 
Adenoid isolate B - + + 
Primary  Oral Keratinocyte Not able to determine from 
publication: comparative 
microarray data only 
Acheampong et al. 2005 
TERT-2 (floor of the mouth) n/a + +/-  Giacaman et al. 2007 
Gingival Keratinocytes (7 
samples) 
 
+/- +/- +/- Moutsopoulos et al. 2007 
from microarray data 
Tonsil epithelium (5 samples) +/- + +/- 
+: expressed 
+/-: low but detectable 
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-: not expressed 
n/a: not applicable 
A and B represent different isolates 
1.7.1.1.2 Oro-pharyngeal epithelial cells 
Few studies have examined mRNA expression of HIV-1 receptor related genes in 
pharyngeal cells. Moutsopoulos et al (2007) have shown microarray data expression 
levels for five tonsil epithelium samples in comparison with gingival samples. The tonsil 
samples expressed CD4 and more CXCR4 and CCR5 as compared to the gingival 
biopsies (Moutsopoulos et al., 2007). However, as mentioned above, no expression units 
for this data were given. Also, in the same study they list gene expression for GalCer 
(Moutsopoulos et al 2007). However, GalCer is not detectable by microarray as it is a 
non-protein encoding glycosphingolipid - it can only be detected by antibody. This brings 
the findings of the study into question as the data deals only with mRNA expression 
rather than surface detection of GalCer by antibody. 
1.7.1.1.3 Vaginal epithelial cells 
Studies analysing mRNA expression of HIV-1 receptor related genes in vaginal 
epithelial cells were not found in recent literature.  
1.7.1.1.4 Other epithelial sites 
To our knowledge, only one study has quantified HIV-1 receptor related mRNA 
expression in other epithelial cell types. This was undertaken with the HT-29 colonic 
carcinoma cell line, which appears to be negative for CD4 expression by Northern blot 
(Omary et al., 1991).  
 
1.7.1.2 Surface protein expression 
1.7.1.2.1  Oral epithelium 
Detection of surface-expressed canonical and non-canonical HIV-1 related 
receptors by flow cytometry is more commonly investigated than detection of mRNA 
expression, and the data are listed in Table 1.2. However, the results are often 
presented in a semi-quantitative manner with histograms depicting the fluorescence 
distribution of the cells for any given molecule. Moore et al. showed that two salivary 
gland epithelial lines expressed surface GalCer and CXCR4 and one expressed a small 
amount of CCR5 and no CD4 (Moore et al., 2002), while gingival keratinocytes 
expressed CXCR4, CCR5 and GalCer (Moore et al., 2002; Moore et al., 2003). Liu et al 
(2003) assayed normal human oral keratinocytes by flow cytometry and after two weeks 
of culture found no CD4 expression, minimal CCR5 expression and some GalCer and 
CXCR4 expression.  
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Giacaman et al. (2007) showed that the TERT-2 oral keratinocyte line expressed 
CXCR4 but very low levels of CCR5 on their surface. Vacharaksa et al (2008) followed 
with more quantitative data for tonsil biopsies grown in culture and TERT-2 where they 
quantified the epithelial marker CD104β integrin, HSPGs, GalCer, CD4, and HIV-1 co-
receptors. Overall, the flow cytometry data showed that the TERT-2 cells were epithelial 
(83%+/-4%, using the epithelial marker CD104β integrin), expressed high amounts of 
HSPGs (91% +/- 20), <1% of CD4, GalCer and CCR5, and minimal CXCR4 (3.5%). This 
showed that TERT-2 cells provided consistent data between studies. 
Most recently, Tugizov et al. (2011) published flow cytometry data on adult 
tongue and tonsil epithelium versus foetal tongue and oropharyngeal epithelium. Oral 
epithelial from adult tongue HSC-3sort (immortalised) and ATNG#1, and foetal tongue 
FTNG#1 will be discussed in this section and the oropharyngeal samples discussed in 
section 1.6.1.2.3. The authors did not detect CD4 on any of these epithelial cells while 
HIV-1 co-receptors (on HSC-3sort) and HSPGs were expressed at relatively low levels. 
However, samples expressed relatively higher levels of GalCer surface protein 
expression as compared with the other moieties. The number of experiments this data 
represents is not specified. 
1.7.1.2.2 Thus, the overall consensus is that minimal or no CD4, CCR5, CXCR4 
are expressed on the surface of oral epithelial cells but this is variable dependant on the 
exact origin of the cells. RNA expression was overall consistent with the flow cytometry 
findings. Prior to the Vacharaksa et al. (2008) study, only one representative experiment 
from three or four was shown. However, with this many repeat experiments, it should 
have been possible to quantify the percentages of positive cells and show error bars or 
undertake statistical analysis. This would have allowed more straightforward inter paper 
comparisons.Female genital epithelium 
Detection of surface-expressed canonical and non-canonical HIV-1 related 
receptors by flow cytometry in vaginal epithelium is summarized in Table 1.2. Asin et al 
(2003) examined two uterine epithelial lines (ECC1, RL95-2) and HEC-1A (endometrial) 
and showed that all three expressed CD4, CXCR4 and minimal GalCer. Saϊdi et al 
(2007) studied the HEC-1A line and found high levels of GalCer (contradicting the 
previous study) and very high levels of CXCR4. Bobardt et al (2007) studied primary 
vaginal genital epithelial cells from four donors showing average values in mean 
fluorescence units. The cells expressed very low levels of CD4, CXCR4, CCR5 and 
GalCer but high levels of HSPGs, including SDC-1 and SDC-2. However, with no 
standard deviations listed, it is difficult to evaluate whether this data set shows 
agreement between samples or not. 
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Most recently, Tugizov et al (2011) did not detect CD4 on the surface of HEC-1A 
or cervical biopsy samples (CERV#1). High expression of GalCer was detected on HEC-
1A cells, like Saϊdi et al (2007), with some expression of HSPGs and low CCR5 and 
CXCR4 expression. The cervical sample, on the other hand, expressed GalCer poorly, 
with higher CCR5 and CXCR4 expression and similar HSPG levels as compared with 
HEC-1A cells. 
Therefore, overall, the data for uterine and vaginal epithelium suggests that these 
cell types express low levels of CD4 but higher co-receptor levels, especially in cell lines. 
They also seem to express the alternate HIV-1 receptor GalCer, again more so on cell 
lines than primary cells. Therefore, based on the surface-expression of HIV-1 related 
receptors, it would appear that female genital epithelial cells may have a greater 
potential to bind HIV-1 than oral epithelial cells. 
Table 1-2: HIV-1 receptor related surface expression in epithelial cells by flow cytometry 
Epithelial 
cell type 
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2007 
TZMbl ++++ ++ +++ n/a n/a n/a n/a Wen, 2010 
supplement-
al  fig 2 
++++, +++,++: Highest to high levels of expression 
+: positive surface expression 
+/-: low expression levels 
-: not detected  




1.7.1.2.3 Pharyngeal epithelium 
Few studies have investigated oropharyngeal cells with regard to surface-
expression of HIV-1 related receptors (summarized in Table 1.2). Vacharaksa et al. 
(2008) published quantitative flow cytometry data for tonsil biopsies grown in culture 
where the epithelial marker CD104β integrin, HSPGs, GalCer, CD4, and HIV-1 co-
receptors were assessed. Overall, the FACS data showed that the tonsil cells were 
epithelial (80% +/-11%) and expressed lower levels of HSPGs but slightly greater levels 
of GalCer compared with TERT-2 cells. However, like TERT-2 cells, the tonsil cells 
expressed <1% CD4 and CCR5. In effect, the tonsil biopsy samples were globally similar 
to the TERT-2 cells. 
Tugizov et al. (2011) also examined adult tonsil (ATNSL#1) and foetal tonsil 
(FORPH#1) cells by flow cytometry. CD4 was not detected in either sample. However, 
these samples expressed higher levels of GalCer than age matched tongue-derived 
epithelium. FOROPH#1 was also slightly higher in HSPG than FTNG#1 (Foetal tongue 
cells). 
Therefore, according to these two studies, oropharyngeal epithelium does not 
appear to express canonical HIV-1 receptors or DC-SIGN, but does express differential 
levels of GalCer and HSPGs. Therefore, oropharyngeal epithelium may bind HIV-1 
despite poor expression of canonical HIV-1 receptors. 
 
1.7.1.2.4 Other types of epithelium 
Few studies have investigated the surface-expression of HIV-1 related receptors 
in other types of epithelium. Colon cancer lines HT29 and HUT78 were shown to be CD4 
negative but SW620 tested CD4 positive (Omary et al., 1991). HT-29 colonic epithelium 
also expresses high levels of CCR5, CXCR4 and GalCer (Saïdi et al. 2007). 
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1.7.1.2.5 Data comparison between epithelial studies 
In the studies described above, different data were often found and therefore 
contradictory conclusions reached, even if the same cell line was used. There are many 
potential reasons for this but probably the most relevant are utilising cells at a different 
passage number, minor differences in culture media and growth conditions, and the use 
of different antibodies (and their differing efficiencies) in detecting surface moieties. The 
phase of the cell cycle at mRNA isolation or flow cytometry could also alter surface 
expression. Therefore, many variables can influence the results obtained by any given 
study. 
There is also evidence that the female genital tract has a differing capacity to 
capture HIV-1 during the menstrual cycle because expression of the canonical receptors 
may vary with hormonal changes as shown by fluorescence microscopy (Yeaman et al., 
2003). CD4 and CCR5 appear to be highly expressed during the proliferative phase, with 
a concomitant increase in CXCR4 expression. However, during the secretory phase, 
CD4 and CCR5 expression decrease, while CXCR4 remains elevated. GalCer, on the 
other hand, is highly expressed during the secretory phase but reduced in the 
proliferative phase (Yeaman et al., 2003).  
Overall, epithelial cells in general tend to express canonical HIV-1 receptors 
poorly but do express some of the alternate non-canonical receptors for HIV-1, GalCer 
and HSPGs. Thus, epithelial cells from many mucosal sites could potentially bind HIV-1.  
 
1.7.2 HIV-1 Capture by Epithelium 
Some of the early studies gained insight into the interaction between HIV-1 and 
the epithelium by interfering with HIV-1 binding using antibodies or other molecules. Anti-
CD4 antibodies blocked infection of some colonic epithelial lines but not HT29 (Fantini et 
al., 1991; Omary et al., 1991). However, GalCer peptides that interfered with binding of 
gp120 to GalCer decreased HIV-1 infection by 50%. In the same study, the gp120 V3 
loop was implicated in binding GalCer (Yahi et al., 1995). Next, heparin was shown to 
compete with 90% of HIV-1 RF (X4) binding as measured by p24 ELISA compared with 
untreated and D-mannose treated cells (Wu et al., 2003). Enzyme removal of cellular 
heparin (with heparinatase) also reduced HIV-1 binding to uterine epithelial cells as 
determined by p24 detection (Wu et al., 2003). Later, using HEC-1A endometrial cells 
stripped of HSPGs, it was shown that the majority of HIV-1 X4 and R5 interactions were 
abolished (Saidi et al., 2007). In addition, fucose, N-acetylglucosamine and 
mannosylated-residues inhibited the transcytosis of HIV-1, implicating mannose 
receptors in the interaction of HIV-1 with epithelium (Saidi et al., 2007). Finally, binding of 
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HIV-1 to primary vaginal epithelial cells was confirmed to be independent of CD4, 
CXCR4 and CCR5 using inhibitors and neutralising antibodies (Bobardt et al., 2007).  
Other studies have provided physical/visual evidence for an interaction of HIV-1 
with epithelium. Particles coated with HIV-1 gp120 were seen to be captured by gingival 
epithelial cells, suggesting that the virus could be taken up by epithelium (Kage et al., 
1998). Correlating this finding, the co-localization of HIV-1 RNA with keratinocytes in oral 
biopsies from HIV-1 patients was observed (Rodriguez-Inigo et al., 2005).  
Methods have been developed for visualising the direct interaction between the 
epithelial membrane and HIV-1 but these investigations still do not satisfactorily 
demonstrate whether a direct binding event had occurred. Since the advent of GFP as a 
molecular label, the HIV field has used this molecule to track virus particles via fusion 
with the viral protein Vpr, since the protein is packaged in the virus particle.  HIV-1 GFP-
Vpr was shown to bind to exposed differentiated oral epithelial models (Nittayananta et 
al., 2009) as well as adult tonsil biopsies (Tugizov et al., 2011) as determined by 
confocal microscopy. However, it was difficult to visualize distinct virus particles 
interacting directly with the epithelium. Electron microscopy has also been used to 
visualize HIV-1 infected peripheral blood mononuclear cell (PBMC) interacting with 
intestinal (Alfsen et al., 2005) or foreskin epithelial cells (Ganor et al., 2010) but, again, in 
both studies it was difficult to visualize distinct virus particles attached to the epithelial 
surface. Amidst this apparent confusion, a reliable and sensitive method to directly 
visualize HIV-1-epithelial interactions would enhance understanding in the field.  
 
1.7.3 HIV-1 integration and productive infection 
HIV-1 infection is difficult to define. As shown in Figure 1.4, there are many steps 
that are characteristic of infection: binding, reverse transcription, integration, reactivation, 
replication and particle formation. Productive infection is less ambiguous since it refers 
specifically to the release of de novo made infectious virus particles. Although various 
epithelial cell types appear to bind and be infected by HIV-1 in vitro, consensus states 
that the oral mucosa is a privileged site resistant to HIV-1 infection. Data exists with 
respect to whether oral epithelial cells can be infected by HIV-1, but many different cell 
types have been studied using a variety of conditions with contradictory results and 
readouts (see Table 1.3). Infection was often measured by p24 accumulation in epithelial 
culture supernatant or p24 accumulation associated with oral and vaginal cells (Asin et 
al., 2004; Asin et al., 2003; Han et al., 2000; Moore et al., 2003; Pang et al., 2000). More 
recently a publication examining the TERT2 immortalized cell line as a surrogate for oral 
epithelium reported viral integration but abortive replication (Vacharaksa et al., 2008).  
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However, the integration assay in this study was not carried out in the same manner as 
described in the proof-of-principle publications to assess HIV-1 integration by this 
method (Brussel and Sonigo, 2003, 2004). The authors conclude that productive 
infection occurred in the TERT2 cells because trypsin-treated TERT2 cells could infect 
susceptible cells (Vacharaksa et al., 2008). However, studies in vaginal epithelium found 
that trypsin treatment did not remove all virus from the epithelial cell surface as p24 
could still be detected on the epithelial cell surface (Dezzutti et al., 2001; Wu et al., 
2003). Therefore, the studies demonstrating epithelial p24 accumulation data and HIV-1 
transfer may not actually be reporting productive viral infection from 
 
 Table 1-3: HIV-1 infection of oral epithelial cells. 
Cell type Reference Binding, productive infection, transfer of 
infectious virus  
Epithelial cell lines from 
salivary gland: HSY, HSG 
(Han et al., 
2000) 
Productive infection (p24, provirus in cells and 
competent to infect T-lymphoblastoid cell line) 
Oral carcinoma cell lines: 
TU139 and TU177. 
Cervical cancer HeLa and 
HeLa CD4.  
(Pang et al., 
2000) 
Productive infection leading to EGFP expression 
(p24, GFP expression blocked by anti-retroviral 
azidothymidine (AZT) and neutralizing anti-gp120 
antibody) 
Primary human oral 
keratinocytes 
(Liu et al., 
2003) 
Productive infection by X4 and dualtrophic virus in 
presence of polybrene (p24 peak at 10 fold less 
than infected peripheral blood lymphocyte levels, 
proviral DNA detection by PCR and could infect 
activated peripheral blood lympocytes in co-
culture) 
Primary human oral 
epithelial cells 
(Quinones-
Mateu et al., 
2003) 
No infection after 5 days exposure by RT activity in 
culture supernatant and real time PCR for proviral 
DNA.  
Primary human oral 
keratinocytes 
(Acheampong 
et al., 2005) 
Productive infection (p24 over 6 days culture) with 
polyamines (spermine and spermidine in 
concentration similar to human semen) and 
dNTPs. 
Epithelial cell lines from 
salivary gland: HSY, HSG 
(Moore et al., 
2002) 
Cell-associated virus transmission to epithelial cells 
(from PBMC, CEM  T-cell line and monocytes by 
p24).  
Primary human gingival 
keratinocytes and 
adenoid epithelial cells 
(Moore et al., 
2003) 
Cell-free R5, but not cell-associated HIV-1, infected 
gingival keratinocytes (p24). Gp160 anti-sera 
blocked infection. Infected keratinocytes released 
infectious virus that could infect PBMC via a cell-
free mechanism. 
Cell-free (X4) and cell-associated (R5) productively 
infected adenoid epithelial cells. 
Human palatine tonsil (Maher et al., 
2005) 
Cell-associated infection of primary tonsil epithelial 
cells by HIV-1 infected lympohcytes (p24 
immunohistochemistry increased over time) 
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Cell type Reference Binding, productive infection, transfer of 
infectious virus  
Human palatine tonsil 
stratified squamous 
epithelium and cryptal 
epithelium  
(Kumar et al., 
2006) 
Surface epithelial cells did not support infection 
(p24) 
OKF6/TERT-2 cell line (Vacharaksa 
et al., 2008) 
Integrated HIV-1 DNA. However, abortive 
replication: multiply spliced and unspliced HIV 
mRNAs not detected. 
Transfer to PBMC or MOLT4 cells.  
Human buccal (TR146), 
pharyngeal (FaDu) 
epithelial cell lines, vulval 
(A431) 






Binding detected by flow and transfer of live virus 
to susceptible reporter cells.  
No DNA integration. No productive infection. 
Productive infection achieved only when endocytic 
pathway used for entry with a VSV-G envelope.   
 
within the epithelial cells but simply HIV-1 that is captured on the surface of the 
epithelium during initial exposure and released on contact with susceptible cells. 
 
1.7.4 Transfer to permissive cells 
 Many studies have described the ability of oral and vaginal epithelium to transfer 
HIV-1 to susceptible, CD4 expressing cell types (Asin et al., 2004; Asin et al., 2003; 
Bobardt et al., 2007; Giacaman et al., 2008; Han et al., 2000; Liu et al., 2003; Maher et 
al., 2005; Moore et al., 2003; Vacharaksa et al., 2008; Wu et al., 2003). However, as 
discussed above, this is not necessarily reflective of productive infection within the 
epithelial cell (Dezzutti et al., 2001; Wu et al., 2003). 
For oral and pharyngeal epithelial cells many studies have been published. Liu et 
al. (2003) incubated normal human oral keratinocytes (NHOK) with HIV-1 Ba-L (R5) and 
NL4.3 (X4), washed and then incubated the cells with peripheral blood lymphocytes 
(PBL) that subsequently became productively infected (Liu et al., 2003). Transmission of 
HIV-1 from salivary gland epithelial lines, keratinocytes and adenoid epithelial cells to 
PBMC and CEM T-cell line and monocytes has also been reported (Moore et al., 2002; 
Moore et al., 2003). Maher et al. (2005) used tissue explants derived from 
tonsillectomies in order to study HIV-1 interacting with the tonsil epithelium and resident 
immune cells. Firstly, they showed HIV-1 infected T-cells bound to the surface of the 
epithelium and caused p24 accumulation in explants by immunohistochemistry. Basal 
epithelial cells were positive for p24, suggesting transmigration of HIV-1 infected cells or 
transcytosis of the virus across the epithelium (Maher et al., 2005). Vacharaksa et al. 
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(2008) used tonsil keratinocytes from donors and OKF6/TERT-2 cells to trans-infect 
PBMCs. In fact, the OKF6/TERT-2 cells transferred at least five-fold more HIV-1 than 
donor tissues as demonstrated by p24 ELISA of the PBMCs (Vacharaksa et al., 2008). 
Thus, despite there being a low apparent in vivo transmission rate (Campo et al., 2006), 
these studies show that oral and pharyngeal transmission to susceptible cells may occur. 
Consistent with evidence of the susceptibility of oral and tonsil epithelium, other 
in vivo data supports the possibility of oral HIV-1 transmission. Not only do oral epithelial 
cells of HIV-infected patients have HIV-1 DNA integrated into their genomes (Rodriguez-
Inigo et al., 2005), but also, non-traumatic exposure of tonsil tissue to SIV and oral 
exposure to cell-free SIV caused systemic infection in macaques (Baba et al., 1996; 
Stahl-Hennig et al., 1999). Taken together, these findings demonstrate that epithelial 
cells of the oral cavity might be productively infected with HIV-1 by cell-borne virus in the 
absence of CD4 and potentially serve as mediators of systemic infection if they can 
sequester infectious virions.  
In contrast to the oral cavity, the vagina is an accepted susceptible milieu for HIV-
1 transmission. Studies with vaginal epithelium have also demonstrated transfer of HIV-1 
to susceptible cells by capturing or allowing transmigration of infectious virus. In the late 
nineties, primary PBMCs from HIV-1 positive patients were shown to transmit virus 
across many epithelial lines to infect mononuclear cells on the basolateral side of the 
epithelium (Bomsel, 1997). While human primary urogenital epithelial cells could not be 
infected with cell-free HIV-1 they were capable of sequestering virus and transmitting it 
to PBMCs in co-culture (Dezzutti et al., 2001). Carreno et al. (2002) demonstrated with 
HEC-1A cells that R5 HIV-1 transcytosis was enhanced under pro-inflammatory 
conditions (Carreno et al., 2002). Furthermore, it was shown that an ectocervical genital 
epithelial cell line sequestered and transmitted HIV-1 to H9 CD4+  T cells or PBMC (Wu 
et al., 2003). Finally, the ability of HIV-1 to retain infectivity after transcytosis across a 
tight monolayer of primary genital epithelial cells was confirmed by activation of 
luciferase activity in TZM-bl cells by basally collected medium (Bobardt et al., 2007). 
However, one study opposes this view of HIV-1 transmission across the mucosa, since 
recently HIV-1 was found not to cross the vaginal mucosa within 4 h using a model of a 
reconstituted human epithelium (Bouschbacher et al., 2008). However, epithelium 
associated sequestered virus may have a longer infectious potential than 4 h (Wu et al., 
2003). 
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1.7.5 Epithelial responses to HIV-1 
1.7.5.1  Host cell recognition of pathogens 
The innate immune system is the first line of defense against invading 
microorganisms. Host cell responses to viral, bacterial and fungal microbiota is 
predominantly mediated by pattern recognition receptors (PRRs), which are well 
recognised as microbial sensors (Mogensen, 2009). PRRs are triggered by pathogen-
associated molecular patterns (PAMPs) expressed by bacteria, viruses and fungi and are 
comprised of different families. The most recognised include toll-like receptors (TLRs), 
NOD (nucleotide oligomerization domain)-like receptors (NLRs), the retinoid-inducible 
gene (RIG)-like receptors (RLRs),  C-type lectins (CTLs) and the immunoreceptor 
tyrosine-based activation (or inhibitory) motifs)-containing receptors (ITAM/ITIM) 
(Mogensen, 2009). The main PRRs associated with viral sensing are the RLRs, 
predominantly RIG-1 and melanoma differentiation-associated protein 5 (MDA5) in the 
cytoplasm and TLRs at the cell surface (McCartney and Colonna, 2009) (TLR3, TLR7/8 
and TLR9). Viruses are usually recognized by innate cells such as epithelial cells, tissue        
macrophages, and dendritic cells (DCs) or Langerhans cells that patrol the        
epithelium through their nucleic acid, dsDNA or ssRNA.  Recognition of viruses induces 
the production of type I interferons, TNFα and other cytokines (Reuter et al., 2012). The 
production of cytokines signals to neighbouring cells to increase their innate antiviral 
defences (Reuter et al., 2012). Innate recognition of viruses also allows the activation 
and instruction of the adaptive immune response: dendritic cells are potent inducers of T 
cell responses (Carrington et al., 2012). After the virus is captured by DCs, these cells 
migrate to the local lymph node to process the virus for antigen presentation to T cells, 
which results in the initiation of Th1 cell proliferation.  Once initiated within the lymph 
nodes, effector Th1 cells travel to the site of infection and eliminate the virus infection 
when possible (Flint et al. 2009).  
 
1.7.5.2  PRR-mediated signalling and HIV-1 
PRR-mediated signalling for bacteria and fungi  predominantly involves activation 
of TLRs and the recruitment of signalling adapters, which ultimately leads to the 
activation of transcription factors: via the nuclear factor of kappa light polypeptide gene 
enhancer in B-cells (NF-ΚB), a pathway active in almost all cell types and mitogen-
activated protein kinase (MAPK) pathways (p38, JNK (c-Jun N-terminal kinases) and 
ERK1/2 (extracellular-signal-regulated kinases) and the induction of 
immune/inflammatory effector (cytokine) responses (Moyes et al., 2010). Single stranded 
RNA viruses activate especially RIG-1 or TLR7/8 in myeloid cells. They then activate 
signalling through the adaptor molecule myeloid differentiation primary response gene 
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(MyD88) via interferon regulatory factor 3 (IRF3), IRF7, NF-ΚB and MAPK leading to the 
production of inflammatory cytokines and Type I interferons (McCartney and Colonna, 
2009). 
Whilst progress has been made in deciphering viral- and HIV-1-mediated 
signalling  in myeloid cells (Doehle et al., 2009), much less is known in epithelial cells. 
The majority of epithelial cell work has been bacterial-based and identifies NF-ΚB and 
MAPK as the main pathways activated (Moyes et al., 2010). In addition, our unpublished 
studies using agonists of TLR3, TLR7/8, showed activation of these aforementioned and 
IRF3 pathways. Limited data exists regarding HIV-1 activation of epithelial cells, 
therefore we picked a few candidate pathways to explore. Serious gaps exist in our 
understanding of HIV-1-epithelial interactions with the immune system and how these 
might affect establishing a primary infection and /or the progression of HIV-1 disease. 
 
 
Figure 1-6: Simplified signalling pathways involved in innate immunity with a focus on 
transcription factors that may have a role to play in epithelial responses to HIV-1. In blue, 
the intracellular portion of NF-ΚB pathway is illustrated. In orange, the three main MAPK pathways 
are shown and in green, TLR sensors for single stranded RNA viruses are pictured. P represents 
phosphorylation. 
 
1.7.6 Epithelial responses to HIV-1 and its components 
Given that the predominant route of HIV-1 infection is through mucosal surfaces 
and that HIV-1 has been shown to interact with epithelial tissues, it is surprising how little 
information is available with regard to how epithelial cells respond to HIV-1. Treatment of 
epithelial cells with HIV-1 gp120 has been shown to alter cellular responses (Del Corno 
et al., 2005; Kapasi et al., 2002; Martinelli et al., 2007; Shan et al., 2007; Singhal et al., 
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1999). In kidney glomerular epithelium, gp120 increases proliferation at low levels but 
increases apoptosis and decreases growth at higher concentrations (Singhal et al., 
1999). Expression of the transcription factors c-Jun and c-Fos (which are one of many 
transcription factors that can form the activating protein-1 (AP-1) transcription factor 
complex), was increased upon treatment with high concentrations of gp120 (Singhal et 
al., 1999).  Following up, apoptosis induced by gp120 in these cells was shown to be 
dependent on phosphorylation of the MAPK p38 and CD4 expression (Kapasi et al., 
2002). Given that the AP-1 transcription factor complex is activated via the MAPK 
pathway, this implicates the MAPK pathway in epithelial responses to HIV gp120. 
It is known that the intestinal epithelium in HIV-1 infected individuals can become 
dysfunctional allowing bacteria to infiltrate across or invade through the single cell 
columnar epithelium of the intestine (Epple et al., 2009a; Epple et al., 2009b). Given this, 
investigators wished to determine whether similar dysfunction was affecting the vaginal 
epithelium (Nazli et al., 2010). Using electrical transepithelial resistance (TER) and dye, 
authors showed a decrease in the strength of the tight junctions in epithelial monolayers 
and decrease in tight junction protein expression (Nazli et al., 2010). Gp120 treatment 
alone was shown to be sufficient to reduce TER measurement in primary endometrial 
epithelium and an intestinal epithelial line (Nazli et al., 2010). Finally, the authors showed 
the cytokines TNF-α, IL-6 , IL-10, IL-1β were significantly increased in apical medium of 
ADA (R5) HIV-1 exposed primary endometrial epithelium (Nazli et al., 2010). More 
recently, human mannose receptor (hMR) has been implicated in gp120 binding to 
vaginal protein lysates and the vaginal epithelial line Vk2/E6E7 since they could be 
competed out in a dose dependant manner with mannan and by blocking with a hMR 
antibody (Fanibunda et al., 2011). Gp120 treatment of the cells resulted in significant 
increase of MMP-9 (Fanibunda et al., 2011), an enzyme that degrades tight junctions, 
perhaps explaining the mechanism of the relaxation of TER (Nazli et al., 2010). These 
lines of evidence strongly suggest that the epithelial cells were sensing HIV-1 and were 
altering their gene expression, morphology and cytokine expression in response to the 
virus supernatant. 
More recently, cyclooxygenase-2 (COX-2) has been shown to be up-regulated in 
response to Toll-Like receptor (TLR) ligands and TNF-α in human vaginal epithelial cells 
and ectocervical biopsies (Joseph et al., 2012). This is relevant because COX-2 is an 
inflammatory enzyme that drives expression of prostaglandin E2, that in turn can drive 
the expression of the HIV-LTR (Dumais et al., 2002). Therefore, inflammation in the 
genital tract can lead to changes in gene expression in the genital epithelium, leading to 
inflammatory signalling from genital epithelium to HIV-1 infected cells, triggering HIV-1 
gene expression.  
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Another publication further characterised a model of heterosexual contact leading 
to HIV-1 infection. Primary endometrial epithelial cells were shown to respond 
differentially to HIV-1 infected sperm from men in the acute and chronic phases of 
infection (Kafka et al., 2012). HIV-1 infected seminal plasma contains more cytokines, 
chemokines and TGF-β that appear to be different depending on whether the 
provenance was from an acute phase or a chronic phase patient (Kafka et al., 2012). IL-
1α and TNF-α are increased from endometrial epithelium in response to acute phase 
seminal plasma while IL-6 is increased in response to uninfected seminal plasma (Kafka 
et al., 2012). Finally they showed that NF-κB (positive) and TGF-β (negative) pathways 
had immunomodulatory roles in responses to uninfected and chronically infected seminal 
plasma, respectively (Kafka et al., 2012), although the role these pathways play in 
responses to seminal plasma from acute infected individuals was not addressed.  
Another approach to determine epithelial cell responses to HIV-1 is to assess 
global signalling changes using whole genome expression arrays. However, there is a 
paucity of microarray data for oral and vaginal epithelial cells. One publication from 
Acheampong et al. (2005) examined primary oral keratinocytes treated with HIV-1 
gp120, Nef and HIV-1 Tat and characterised the cells by utilizing a cDNA expression 
human apoptosis array. These treatments were all found to induce substantial apoptosis 
at a concentration of 10ng/ml through the TNF/TNF-R Fas/Fas ligand pathways 
(Acheampong et al., 2005). Although limited to one study, the attainment of such 
information indicates that comparisons of microarray data from oral and vaginal epithelial 
cells in response to HIV-1 may identify common signalling pathways and gene profiles 
important in HIV-1 responses and thus provide a better understanding of HIV-1-epithelial 
interactions. 
Nevertheless, questions remain, including: does HIV-1 activate oral and vaginal 
epithelial cells and does this promote transmission? Do HIV-1-epithelial interactions lead 
to cytokine production or a cellular response that would activate or attract immune cells, 
thus enhancing infection? Mounting evidence suggests that vaginal and cervical 
epithelium serves more than just an inert structural barrier since their secretions abound 
with anti-microbial peptides and modulators of innate immunity (Cole et al., 2008). 
 
1.8  HIV-1 and co-infections  
In the last few years much research attention has been given to co-pathogens 
and their effect on HIV-1 infection in the vaginal milieu. Sexually transmitted infections 
significantly increase the probability of HIV-1 transmission since they not only increase 
viral shedding in infected individuals, but also increase susceptibility of individuals who 
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are HIV negative (Galvin and Cohen, 2004; Klotman et al., 2008; Mabey, 2000). This can 
be due to the epithelial barrier being physically breached by microorganisms, by 
inflammation and/or by attracting immune cells to the mucosa. 
N. gonorrhoeae was shown to induce the expression of human β-defensin-5 and 
6, which may recruit susceptible immune cells to the surface (site of infection) where 
they will be exposed to HIV-1 captured by the vaginal epithelium (Klotman et al., 2008). 
Endometrial epithelial cells were used to study co-infecting bacteria using TLR ligands or 
N. gonorrhoeae and viral pathogens herpes simplex virus type 1 or 2 (HSV-1/2), and 
their effect on the expression of the HIV-LTR using a reporter T cell line as a model of 
HIV-1 genome activation (Ferreira et al., 2011). The genital epithelial cells were briefly 
exposed to the aforementioned stimuli, extensively washed and their supernatants were 
collected to study their effect on HIV-LTR activation. Supernatants collected from GECs 
previously incubated with HSV-1/2, N. gonorrhoeae, and TLR ligands gave off apical 
cytokine signals (IL-6, IL-8, MCP-1, TNF-α) and induced HIV-LTR reporter gene 
expression (Ferreira et al., 2011). Thus, inflammation brought about by co-pathogens in 
the vaginal milieu appears to have an effect on HIV-1 by altering gene expression and 
inflammatory mediators of epithelial cells. 
In addition, oral microbiota may promote HIV-1 disease and/or reactivation. The 
presence of the periodontal pathogen Porphyromonas gingivalis correlates with 
increased CCR5 expression on the surface of oral and tonsil epithelial cells, thereby 
promoting receptor-mediated recognition and binding of HIV-1 and possible transfer to 
susceptible immune cells (Giacaman et al., 2008). Also, bacterial extracts from oral 
pathogens Fusobacterium nucleatum and P. gingivalis were shown to induce the release 
of inflammatory signals from an oral epithelial cell line and gingival fibroblasts that could 
lead to HIV-1 reactivation (Gonzalez et al., 2010). However, bacterial extracts, although 
perhaps easy to work with, are less physiologically relevant than stimulus by whole 
bacteria. In addition, F. nucleatum and P. gingivalis were shown to activate NF-κB and 
increase cytokine expression (Milward et al., 2007), therefore potentially having an 
additive effect in promoting HIV-1 infection in the oral cavity, since NF-κB has been 
implicated in response to HIV in other cell types (Giri et al., 2006). Thus, the human 
microbiota may stimulate inflammation that in turn may promote activation of HIV-1 gene 
expression and the exposure of susceptible immune cells to the virus in the mucosa. The 
oral microbiota, e.g. Candida albicans may also bind to HIV-1 directly (Gruber et al., 
2003) and potentially protect HIV-1 from being cleared by the flow of saliva and mucosal 
secretions, thereby further facilitating transfer of infectious virus to permissive host cells. 
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1.8.1  Candida and HIV-1 infection 
Candida infections occur in approximately 50% of HIV infected and 90% of AIDS 
patients (Phelan et al., 1987). It is often the first clinical sign presenting in patients that 
have chronic HIV-1 infection (Flint and American Society for Microbiology., 2009). The 
close relationship between Candida and HIV-1 infection was recently verified in an 
epidemiological study, which found an association of Candida infections with HIV 
acquisition at two clinics in Zimbabwe and Uganda (van de Wijgert et al., 2008).  
Human mucosal surfaces normally have a commensal relationship with 
C.albicans but this depends on the maintenance of a varied population of normal 
microbial flora and the maintenance of tissue integrity by a healthy immune system 
(Henriques et al., 2006). The progression of Candida infection involves the perturbation 
of the mucosal microenvironment to allow adherence of the yeast form, leading to hyphal 
formation and eventually hyphal elongation to invade the mucosal barrier, in severely 
immunocompromised individuals this is followed by growth and dissemination through 
the blood system to cause a systemic infection (Henriques, et al 2006). 
Many factors govern Candida virulence. Firstly, three families of hydrolases exist: 
secreted aspartyl proteinases (Sap), secreted lipases (Lip), phospholipase B (Plb). 
These contribute to the provision of nutrients and dissolve tissues to promote fungal 
penetration of host barriers (Brown et al., 2007; Henriques et al., 2006; Schaller et al., 
2005). In addition, adhesins such as the Als family and Hwp1, both responsible for 
attachment to epithelial cells and promoting hyphal morphogenesis, contribute to 
Candida’s interface with the host (Brown et al., 2007; Hoyer, 2001). 
Like other mucosal pathogens, C. albicans may also activate epithelial responses 
to induce inflammation, which may subsequently affect HIV-1 progression. Recently, our 
group identified that in oral epithelium C. albicans triggers an initial NF-κB and MAPK 
response based on recognition of common polysaccharides present in the cell (chitin, β-
glucan, mannan), followed by a second, stronger MAPK activation event that is 
dependent on fungal burdens and the formation of hyphae (Moyes et al., 2010). In 
vaginal epithelium, the initial MAPK activation is slightly delayed but the second phase is 
common to both epithelial sites (Moyes et al., 2011). These are similar pathways to 
those implicated in HIV-1 infection in immune cells (Giri et al., 2006). In addition, C. 
albicans induces the expression of COX-2 in HeLa cells via TLRs (Deva et al., 2003), 
which is an enzyme that processes prostaglandins and leads to mucosal inflammation 
(Joseph et al., 2012). Thus, C. albicans specifically increases inflammation and affects 
signalling pathways and loss of epithelial barrier function in similar ways to HIV-1. 
Therefore, their effects may be additive and promote HIV-1 infection. This would 
correlate with epidemiological data, which showed that women with vaginal Candida 
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infections were more likely to acquire HIV-1 especially if the Candida infection was 
present at the time of HIV-1 detection or at the previous visit (van de Wijgert et al., 
2008). However, the authors failed to find a relationship between disrupted vaginal flora 
and immune activation but acknowledge that monitoring pro-inflammatory cytokines may 
have been more rigorous than the cytology they performed (van de Wijgert et al., 2008). 
Most of the studies on Candida and its direct interaction with HIV-1 originate from 
the Wurzner group from 1997 to the present. The binding of the HIV-1 envelope to C. 
albicans using two competition assays suggested that gp41 was involved in this binding 
event (Wurzner et al., 1997). The following study showed that HIV-1 envelope (gp160) 
bound to the fungal surface and increased Candida adhesion to HIV-1 infected cells. 
gp160 binding also decreased phagocytosis of Candida and increased the production of 
the Sap from Candida (Gruber et al., 1998). The authors followed this by claiming that 
HIV-1 Tat was able to induce hyphal growth (Gruber et al., 2001). Subsequently, HIV-1 
gp41 was shown to bind to different Candida species (C. albicans, C. dubliniensis and C. 
tropicalis).  Glycoprotein gp41 was able to modulate C. albicans adhesion to HIV-1 
infected T cells as well as uninfected epithelial and endothelial cells (Gruber et al., 2003). 
Most recently, the group claimed to have identified an HIV-1 interacting protein in 
C.albicans: Hgt1p (Lesiak-Markowicz et al., 2011). However, the evidence provided for 
Hgt1p-HIV-1 binding is tenuous, since binding to whole virus particles was not verified. 
Instead, the authors demonstrated gp160 binding was reduced by ~30% to a Δhgt1 null 
mutant. However, the Δhgt1 mutant was not able to form hyphae like the parent and 
revertant strains (Lesiak-Markowicz et al., 2011), so if the yeast form of C. albicans binds 
the gp41 portion of gp160 less avidly than hyphae (Gruber et al., 2003), then this could 
account for the reduction in binding to gp160. 
 Work on another human RNA retrovirus, human T-lymphotrophic virus (HTLV),  
has shown that this virus forms a biofilm: a carbohydrate covered, glycosylated “cocoon”. 
This disguise, both enhances infectious capacity by allowing the virus to bind host cells, 
improves transmission between cells within the host and increases immune evasion 
(Pais-Correia et al., 2010; Thoulouze and Alcover, 2011). This virus shares similarities 
with HIV-1 in that it is composed of two single-stranded RNA genomes and that it 
originated in primates. Although work with HIV-1 in this field has not yet been published 
to our knowledge, there is now a significant level of interest in this area as evidenced by 
presentations on this topic at the HIV symposium held at the Barts and the London (July 
4th 2010). Thus, it is possible that given the highly glycosylated nature of gp120, HIV-1 
may adhere to biofilms laid down on mucosal surfaces by the host microbiota, including 
the carbohydrate/polysaccharide moieties of Candida species. HIV-1 may form a biofilm 
of its own since 50% of the molecular mass of HIV-1 gp120 is constituted of N-linked 
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glycans (Allan et al., 1985; Checkley et al., 2011) with a small addition of O-linked 
glycans (Bernstein et al., 1994). Notably, gp120 harbours 20-35 N-linked glycosylation 
sites and gp41 harbours 3-5 N-linked glycosylation sites (Checkley et al., 2011). Candida 
also has an abundance of glycosylation sites for attachment of N-linked and O-linked 
glycans. Mutants defective in N- and O- glycosylation have been developed to assess 
yeast cell-cell interactions (Bates et al., 2006; Bates et al., 2005; Munro et al., 2005). 
Therefore, it is possible that HIV-1 may interact with C. albicans via these glycosylation 
moieties.  
 
1.9 Project Aims 
Given the ambiguous literature on the interactions of HIV-1 with oral and vaginal 
epithelial cells and Candida, this project aimed to determine whether HIV-1 binds, enters 
and integrates into oral epithelial cells, whether productive infection ensues, and whether 
sequestered infectious virus can be transferred to permissive cells. We also investigated 
which epithelial signalling pathways HIV-1 activates and how HIV-1 modulates epithelial 
cells on a global scale. Finally, we investigated the ability of HIV-1 and Candida to 
directly interact with each other, and whether this mucosal fungal pathogen was able to 
sequester and transfer infectious virus to permissive cells. To undertake these 
investigations, we utilized epithelial cell lines representative of oral and vaginal sites that 
are rarely investigated with regard to epithelial HIV-1 transmission but are one of the first 
cell types that are likely to come into contact with HIV-1. These were buccal (TR146), 
oro-pharyngeal (FaDu) and vulvovaginal (A431) epithelial cells, all of stratified squamous 




Figure 1-7: Simplified model of HIV life cycle to be tested in this thesis work. We wished to 
assay binding, integration of HIV-1 and infectious virus release. HIV-1 particle taken from (Sierra 
et al., 2005). 
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The specific project aims, outlined in Figure 1.7, were: 
1. To characterise epithelial models of oral, oro-pharyngeal and vaginal epithelial 
cells for RNA and protein expression of HIV-1 receptors, co-receptors and 
binding factors. 
2. To determine whether HIV-1 binds to epithelial cells. 
3. To ascertain whether integration (as a surrogate for infection) occurs upon HIV-1 
exposure to epithelial cells. 
4. To assess whether HIV-1 is transferred from epithelial cells to susceptible 
reporter cells. 
5. To determine which cytokine, intracellular signalling or global gene expression 
changes occurred in epithelial cells in response to HIV-1 exposure. 
6. To characterise the interaction events that occur between HIV-1 and Candida 
and whether C. albicans is able to transfer virus to susceptible cells. 
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Chapter 2 Materials and Methods 
2.1 Cell lines, culture and reagents 
Human oral buccal (TR146), oro-pharyngeal (FaDu), and vulvo-vaginal (A431) 
epithelial carcinoma cell lines and renal epithelial (293T) cells were obtained from the 
American Type Culture Collection (ATCC).  
TR146 cells are a human buccal carcinoma cell line originally isolated from a 
neck metastasis (Rupniak et al., 1985). These cells form undifferentiated, non-
keratinized stratified epithelium that share many functional and morphological 
characteristics of normal buccal mucosa. FaDu cells are a pharyngeal cell carcinoma line 
(Rangan, 1972).  A431 (also designated A-431) cells are human epidermoid carcinoma 
of vulval origin (Giard et al., 1973). All three cell lines are commonly used in infection 
studies and we have utilised the TR146 and A431 cell line extensively in our previous 
studies (Moyes et al., 2011; Moyes et al., 2012; Moyes et al., 2010; Murciano et al., 
2011).  
The following reagents were obtained through the AIDS Research and Reference 
Reagent Program (ARRRP), Division of AIDS, NIAID, NIH: TZM-bl cells (catalogue no. 
8129), PM1 cells (no. 3038), C8166 (no. 404) and JLTRG-R5 (no. 11586). 
TZM-bl are a HeLa derived reporter cell line used for HIV-1 infection studies 
(Derdeyn et al., 2000). HeLa cells originated from what was diagnosed as an epidermoid 
carcinoma (Scherer et al., 1953) but were later thought to be adenocarcinoma of the 
cervix (Jones et al., 1971). The clone originally named JC53-BL expresses CXCR4 and 
was engineered to express CD4 and CCR5 (Platt et al., 1998). The cells were further 
modified to incorporate reporter cassettes expressing luciferase and β-galactosidase 
under the control of an HIV-1 long terminal repeat (LTR: the retroviral promoter 
sequence) where expression of the reporter is triggered by the production of HIV-1 tat 
(Derdeyn et al., 2000). 
Three cell lines were used for virus propagation. C8166 are human umbilical cord 
blood T lymphocytes (Salahuddin et al., 1983). NP2-R5 cells are human glioma cells 
expressing CD4 and CCR5 (Soda et al., 1999). JLTRG-R5 cells are a Jurkat T cell-
based reporter cell line expressing CD4 and both HIV-1 co-receptors, CXCR4 and 
CCR5, and are derived as a spontaneously occurring sub-clone of JLTRG cells 
(Ochsenbauer-Jambor et al., 2006). 
TR146, FaDu, A431, TZM-bl and 293T are all adherent cells maintained in 
Dulbecco's Modified Eagle Medium (DMEM, 4.5 g/l glucose and L-glutamine) (PAA 
laboratories) supplemented with 10% foetal calf serum (FCS) and 1% 
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Penicillin/Streptomycin (P/S) (DMEM 10). They were passaged every 2-3 days. TR146, 
293T and FaDu grew rapidly and were split 1:6 to 1:8. On the other hand, A431 and 
TZM-bl cells grew at a slower rate and were split 1:3 or 1:4. 
NP2-R5 cells were additionally supplemented with 1 mg/mL of G418 (Invitrogen) 
and 1 µg/mL of puromycin (Invitrogen) in DMEM supplemented with 10% FCS and 1% 
P/S. They were passaged every 3-4 days at split 1:4. 
C8166, JLTRG-R5 and PM-1 cell are suspension cells and were maintained in 
Roswell Park Memorial Institute medium (RPMI) supplemented with 10% FCS and 1% 
P/S. They were passaged every 3-4 days at split 1:10. 
2.2 Plasmid isolation 
Plasmids were used in transfections to generate infectious viruses (see section 
2.3.1) Plasmids were transformed into Escherichia coli DH5α competent cells. Typically 
100-200 ng of plasmid DNA was incubated with freshly thawed cells for 25-30 min, 
incubated for 30 s at 42°C, then fed with 950 μg Lysogeny broth (LB) (10 g/L Tryptone, 5 
g/L yeast extract, 10 g NaCl/L in H2O and immediately autoclaved). The tube was then 
incubated with shaking at 37°C for 1 h and then streaked onto an LB agar (same as LB 
with 15 g/L agar added) plate with appropriate selection antibody (typically Ampicillin: 50 
mg-75 mg/L). The plate was then incubated at 16 h in 37°C. 
For HIV molecular clones, an E. coli DH5α colony was selected from the plate, 
inoculated to LB ampicillin medium and grown for 8 h with shaking at 37°C. Then the 
liquid medium was spread and dried to an LB ampicillin agar plate and incubated at 37°C 
and the E. coli DH5α cells grown to confluence. Cells were scraped using a sterile loop 
and the DNA isolated by NucleoSpin® Plasmid miniprep kit (Macherey-Nagel). This 
would typically yield about several μg of DNA. 
If more DNA was required the E. coli DH5α colony from the plate was grown in 
250 mL LB ampicillin (50 mg-75 mg/L) liquid medium and incubated with shaking for 16 
h. The DNA was harvested the following day using the EndoFree Plasmid Maxi Kit 
(Qiagen). 
2.3 Virus growth  
2.3.1 Virus growth by transfection 
The following reagents were obtained through the ARRRP: HIV-1 molecular 
clones pYU2 (R5-utilizing, catalogue no.1350) and pLAI.2 (X4-utilizing, catalogue no. 
2532), HIV-gpt (gp160 deficient HIV molecular clone catalogue no. 1067), pYK-JRCSF 
(R5-utilizing, catalogue no. 2708), pNL4.3 (or NL4-3, an X4-utilizing, catalogue no. 114). 
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Briefly, 293T cells were seeded at 95% confluency in a 10 cm3 dish. The following day 
cells were transfected with 5 µg of the infectious molecular clone pLAI.2 (X4) or pYU2 
(R5) or pJRCSF (R5) or 10 µg HIV-gpt used per transfection using the polyanionic 
transfection reagent Jet PEI (10 µL JetPEI per 5 µg DNA with 250 µL of included NaCl 
solution) (Polyplus Transfection). After 24 h, the media was replaced and at 48, 72 and 
96 h post-transfection virion-containing culture supernatants were harvested and filtrated 
through a 0.45 µm pore size membrane and stored in aliquots at -80C until required for 
plaque assay (section 2.3.3). 
2.3.2 Virus growth by passaging through susceptible cells 
High titer virus stock (initially made by the above transfection protocol) in DMEM 
10 was thawed, and about 1 ml was added to 1-2x106 cells (see below) in small volume 
for 1-3 h then transfered to a T75 flask. For YU2-R5 virus, the infection was started with 
NP2-R5 cells and for LAI-X4 virus, C8166 suspension cells were used. For control 
conditions, cultures were started with the same number of NP2-R5 or C8166 cells but 
without the addition of virus. Once cytopathic effects (CPE) were visible, more cells were 
added (JLTRG-R5 for YU2 or C8166 for LAI) to the virus and control conditioned 
medium stocks, and the stocks were monitored daily for acidification of the medium and 
proportion of the cells displaying CPE in the virus stock. The stocks were fed with 
medium (DMEM 10) until no more CPE was observed accumulating (usually 1-2 weeks). 
The virus stocks were frozen in equal aliquots with equal amounts of cells. When 
required, a small aliquot was thawed, clarified by centrifugation at 15000rpm for 10 min 
assayed by plaque assay (section 2.3.3). Aliquots with an approximated titer were 
thawed, clarified and used as required. On use, virus stocks were retitrated. This method 
yielded ten-fold higher titer (approximately 1x105 to 1x106 infectious units per mL)viruses 
as compared to transfection and was more cost effective. 
2.3.3 Virus quantification  
Infectious virus stock (LAI-X4, YU2-R5, JRCSF and NL4.3) titers were 
determined by plaque assay. Briefly, TZM-bl cells (1 × 104 cells/well) were cultured 
overnight (96-well plates) and incubated with eight replicates of ten serial dilutions (0.5 
log) of virus stock in a total of 50 μL DMEM 10 per well. After 16 h, 50 μL of DMEM 10 
was added to each well. After 48 h, virus supernatant was removed and the cells were 
fixed with 0.05% glutaraldehyde for 10 min at room temperature and washed twice with 
phosphate-buffered saline (PBS). Expression of β-galactosidase was determined by 
staining cells with X-Gal stain [1 mg/mL X-Gal in 5 mM KFe4(CN6) 3H2O, 5 mM 
KFe3(CN6) 3H2O, and 1 mM MgCl2]  and incubating culture plates at 37°C for 1 h. Virus 
infectivity was estimated as plaque forming units (PFU) per mL. 
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Since this plaque assay was not effective for quantification of HIV-gpt, p24 ELISA 
(ZeptoMetrix Corporation, Franklin, MA, USA) was used according to the manufacturer’s 
instructions (by Carlo Scala alongside his samples) to estimate concentration and 
extrapolated to multiplicity of infection (MOI) using a few viruses whose MOI was known. 
2.4 HIV-1 receptor expression 
2.4.1 HIV-1 receptor surface protein expression by flow cytometry 
TZM-bl, NP2-X4, NP2-R5, TR146 and FaDu resting cells were washed with PBS 
and incubated with 0.02% (W/V) EDTA for 5-30 min. Detached cells were washed 
thoroughly with PBS supplemented with 1% BSA and 0.01% azide (wash buffer), and 
resuspended at 1 × 106 cells in 1 mL wash buffer. To identify surface expressed HIV-1 
receptors and co-receptors, 100 μL of cells were incubated at room temperature for 1 h 
with mouse anti-human CD4 (1:4 catalogue no.724), CCR5 (1:20, catalogue no. 4090), 
CXCR4 (1:80, catalogue no. 4083), monoclonal antibodies (all obtained from the 
ARRRP), DC-SIGN (1:100, Biolegend), GalCer (1:200, anti-galactocerebroside, 
Millipore) or heparan sulfate proteoglycan (1:200, Millipore), and ICAM-1 (a kind gift from 
Annapurna Vyakarnam) monoclonal antibodies. Primary antibodies were detected with 
goat anti-mouse IgG conjugated with fluorescein isothiocyanate (FITC) (Jackson 
ImmunoResearch) except the ICAM-1 which was directly conjugated with phycoerythrin 
(PE). After thorough washing, cells were fixed in 200 L 4% formaldehyde and the 
percentage of FITC-expressing cells was determined by flow cytometry. 
2.4.2 HIV-1 receptor gene expression by real-time PCR 
RNA was isolated from resting TZM-bl, TR146, FaDu and A431 cells using 
GenElute Mammalian Total RNA Miniprep Kit (Sigma) or Nucleospin II kit (Macherey 
Nagel), followed by treatment with Turbo DNAse free (Ambion) according to the 
manufacturer’s instructions. All samples were confirmed DNA free prior to analysis. 
cDNA was synthesized from 1 g of RNA using HIV Reverse Transcriptase (Ambion) 
according to the manufacturer’s instructions. Primers were obtained from RTPrimerDB 
(http://medgen.ugent.be/rtprimerdb/) (Lefever et al 2008) and PrimerBank 
(http://pga.mgh.harvard.edu/primerbank) (Spandidos, 2010). Gene expression of CD4, 
CCR5, CXCR4, DC-SIGN, SDC-1 (syndecan-1) and SDC-4 (syndecan-4) was calculated 
by quantitative real-time PCR using SYBR Green JumpStart Taq Ready Mix (Sigma) 
with 4 pmol primers and 1 μL cDNA in 10 μL reactions on the Corbett Research Rotor-
Gene 6000 (Qiagen) using the following cycling parameters: 95°C for 3 min; followed by 
95°C for 3 s, annealing for 10 s and extension for 20-30 s for 40 cycles at the 
temperatures listed in Table 2-2. Data was analysed with Corbett Research Rotor-Gene  
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Table 2-2: qPCR cycling conditions 
Primer Initial Denaturation  Cycling times 
(40 cycles) 
  
CCR5, β-actin 95C 3min 95C 3s 58C 10s 75C 30s (Read at 75C ) 
SDC1, CD4 95C 3min 95C 3s 60C 10s 75C 20s (Read at 75C ) 
SDC4, ICAM-1 95C 3min 95C 3s 58C 10s 72C 20s Read at 80C  5s 
CXCR4, DC-SIGN 95C 3min 95C 3s 60C 10s 75C 30s Read at 80C  5s 
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6000 Series Software 1.7 using the two standard curve method with β-actin used as the 
normalizer gene. 
2.4.2.1 HIV-1 receptor expression by real-time PCR on C. albicans exposed 
epithelial lines 
1 x 106 cells were seeded to 6-well tissue culture plates and inoculated with 2 x 
104 yeast cells in 1 ml volume DMEM 1% P/S. After 24 h the cells were washed, and 
RNA isolated as detailed in the previous section. 
2.4.3 Flow cytometry for HIV gp120 detection at the surface of epithelial cells 
Prior to the method being definitely established, many antibodies from the 
ARRRP were screenedto determine if they could be used to monitor the presence of 
gp120 envelope of whole virus or p24 on the cell surface. Antibodies against gp120 
assayed included catalogue numbers: 810, 2640, 7369, 2343, 1476, 7371 (see Appendix 
C for their properties) as well as those we ultimately used: 7626 (F425 B4e8) and 7624 
(F425 A1g8). Antibodies against p24 assayed for flow cytometry included catalogue 
numbers: 6521, 1238, 530, 4121, 6457. None were used in flow cytometry. Those 
selected were chosen because the presence of HIV-1 could be detected by flow 
cytometry (by an increase in percent fluorescence) on epithelial cells. Once it was 
established that HIV-1 gp120 could be detected on the surface by flow cytometry, the 
blocking and washing conditions were then optimized. 
ARRRP # 
Name  





IgG1,κ CD4i epitope of 
gp120; binding 
enhanced by sCD4 
yes Pantophlet et al., 2007,  
Bell et al., 2008 
7626 
F425 B4e8 
IgG2,κ Base of V3 loop of 
gp120 
yes Pantophlet et al., 2007,  
Bell et al., 2008 
 
5 x 104 target cells were infected with 5 infectious units per cell (MOI of 5) of 
either YU2-R5 virus or LAI-X4 virus. The cells were incubated for 18 h at 4C, then 
washed with PBS three times before being blocked in PBS 10% BSA for 10 min at room 
temperature. Cells were then scraped from the plate and stained for 30 min at 4C with 
NIH HIV-1 gp120 monoclonal antibody (F425 B4e8) or a second monoclonal where 
indicated (F425 A1g8) at a 1/200 dilution in PBS/10% BSA. These monoclonals were 
obtained through the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH and were made available by Dr. Marshall Posner and Dr. Lisa 
Cavacini. 
After labelling, the cells were washed three times with PBS and then stained with 
CyTM5-conjugated AffinityPure Goat Anti-Human IgG secondary antibody (Jackson 
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ImmunoResearch Laboratories, INC.) at a dilution of 1/400 in PBS/10% BSA and 
incubated at 4C for 30 min. The cells were washed three times with PBS, resuspended 
in 4% formaldehyde, and subjected to flow cytometry analysis on FACSCanto machine 
using the FACSDiva software. The FCS file data was then analysed using WinMDI. 
CyTM5 fluorescence was read on APC channel. Percentages were calculated as 
increased in CyTM5 shift from the scatter plot of uninfected primary and secondary 
stained cells.  
2.4.4 Trypsin sensitivity and flow cytometry 
TZM-bl, TR146 and FaDu cells (5 x 104) were infected with YU2-R5 or LAI-X4 
virus at an MOI of 5, or no virus overnight at 4C. Cells were washed three times with 
PBS and then trypsinised for 5 min at 37C (control cells were left without trypsin). 
Trypsin was inactivated with DMEM 10 and washed with PBS. All cells were blocked in 
PBS/10% BSA for 10 min at room temperature. Cells were gently removed by scraping, 
centrifuged and labelled with NIH HIV-1 gp120 monoclonal antibody F425 B4e8 (1:200) 
and then Cy5-conjugated AffinityPure goat anti-human IgG secondary (1:400) (Jackson 
ImmunoResearch) in blocking buffer, each for 30 min at 4C. Cells were washed three 
times with PBS, resuspended in 4% formaldehyde and subjected to flow cytometry. 
Binding percentages were calculated as increased Cy5 shift of the infected and stained 
cells from infected secondary alone stained cells. 
2.5 Western Blotting 
2.5.1 Detection of p24 and signalling proteins 
TR146 and A431 cells were seeded at 5 x 105 cells per well, grown overnight, 
and then serum starved using serum free DMEM with 1% P/S for 24 h. Cells were then 
infected with YU2-R5 or LAI-X4 virus at an MOI of 5. After 2 h incubation at 37oC (or 24 h 
for p24 binding Westerns) the cells were washed three times to remove unattached 
virus. Cells were harvested in 150 L 1 x RIPA buffer [50 mM Tris/HCl (pH 7.4), 150 mM 
NaCl, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS, supplemented with 
Halt complete protease inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitors 
(Perbio Science), placed on ice for 30 min, scraped, clarified by centrifugation for 10 min 
at 14,000rpm, and stored at -80C until required. Total protein lysates (mammalian) were 
normalized for protein content using the bicinchoninic acid (BCA) assay (Pierce) and 
separated using 12% SDS-PAGE gels. 10-20 μg of total protein was loaded per sample 
per well. 10% Dithiothreitol (DTT) and Thermo Scientific Pierce Sample Loading Buffer 
(4X), a non-reducing lithium dodecyl sulfate sample loading buffer (LDS), were added 
and the sample heated at 80°C for 10 min prior to loading. After gel electrophoresis 
(usually 120 V for 1 h), proteins were transferred to PVDF membranes (100V for 90 min) 
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and probed with the monoclonal antibodies listed in Table 2-3 to detect activation 
(phosphorylation) of epithelial signalling proteins. Primary antibodies were detected with 
the appropriate secondary IgG horseradish peroxidase (HRP)-conjugated antibody 
(Jackson ImmunoResearch) before developing using Immobilon-ECL (Millipore). -actin 
was used as a loading control and p24 to detect presence of virus. The Western blot 
method was optimized in the laboratory by Arinder Kohli (p24) and David Moyes (other 
antibodies) (Moyes et al., 2010). 







Specificity Catalogue number, 
company 
p24 55 for p55, 38 for 
p38, 24 for p24 
Anti-Mouse Epitope not 
mapped 




57 phospho p54, 
46.5 phospho 
p46 
Anti-Rabbit Phosphorylation at 
Threonine 183 and 
tyrosine 185 








42, 44 Anti-Rabbit Thr202/204 4370, Cell Signalling 
Technology 
Phospho-IB- 30-40 Anti-Rabbit Ser 32 2859, Cell Signalling 
Technology 




42 Anti-Mouse N-terminal 2/3  
possibly near 50-70 
1501, Chemicon MAB 
 
2.5.2  Detection of HIV-1 p24 on fungal species. 
The fungal species used in this study and fungal growth conditions are listed in 
section 2.11 below. 1 x 105 fungal cells from a culture grown overnight with shaking at 
30°C were aliquoted into a 1.5 mL tube and resuspended with DMEM 10 and 1% P/S 
with or without virus as indicated (either YU2-R5, LAI-X4, JRCSF-R5 or NL4.3-X4 at MOI 
of approximately 1, confirmed by retitration alongside experimental samples in 1 mL total 
volume). Cells were incubated at 37°C with a gently shaking platform for 2 h or 24 h as 
indicated. The fungal cells were washed three times with cold PBS and the fungal cell 
pellets resuspended in 10 μL Laemmli’s loading dye containing DTT. The samples were 
then boiled for 10 min at 80°C, 15 μL per well were loaded and separated using 12% 
SDS-PAGE gels. Proteins were transferred to PVDF membranes, probed with anti-HIV-1 
gag monoclonal antibody recognizing p24 and p55 isoforms (ARRRP catalogue no. 
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6457) and a secondary anti-mouse IgG horseradish peroxidase (HRP)-conjugated 
antibody (Jackson ImmunoResearch), before developing, using Immobilon-ECL 
(Millipore). 
 
2.6 Cell damage assay 
Epithelial cell damage was determined at 24 h by measuring lactate 
dehydrogenase (LDH) activity in the culture supernatant as described previously (Moyes 
et al., 2010; Murciano et al., 2011). This was performed using the Cytox 96 
nonradioactive cytotoxicity assay kit (Promega) according to the manufacturer’s protocol 
and using a recombinant porcine LDH (Sigma-Aldrich) to generate a standard curve. 
Sample values were then extrapolated from this standard curve (Murciano et al., 2011). 
 
2.7 Integrated HIV-1 PCR Assays 
2.7.1 Alu-LTR two-step PCR 
To determine whether HIV-1 DNA was able to integrate into epithelial cells, a 
nested PCR was performed initially with HIV-1 and human Alu-specific primers as 
previously described (Brussel and Sonigo, 2003, 2004). TR146, FaDu and PM-1 
(control) cells were seeded at 5 x 105 cells per well and the following day infected with 
YU2 (R5) or LAI (X4) virus at an MOI of 0.2. After overnight incubation at 37oC, unbound 
virus was removed by washing and total DNA was isolated using the GeneElute DNA 
Extraction kit (Sigma) according to manufacturer’s instructions. A 2 L aliquot of DNA 
was used in first round PCR to amplify Alu-LTR sequences using 10 pmol forward primer 
L-M667 (5’- ATG CCA CGT AAG CGA AAC TCT GGC TAA CTA GGG AAC CCA CTG-
3’) and 30 pmol of Alu-1 (5’- TCC CAG CTA CTG GGG AGG CTG AGG-3’) and Alu-2 
(5’- GCC TCC CAA AGT GCT GGG ATT ACA G-3’) reverse primers in a 20 L total 
volume containing 1 x PCR buffer, 100 µM dNTP’s, 1.5 mM MgSO4, 2.5 U Taq 
polymerase (New England Biolabs). Cycle parameters were as follows: 95°C for 8 min; 
followed by 95°C for 10 s, 60°C for 10 s, 72°C for 170 s for 12 cycles. A 1 L aliquot of 
the first round product was used in the subsequent nested PCR, comprising 30 pmol of 
forward primer T (5’- ATG CCA CGT AAG CGA AAC T -3’) and reverse primer AA55M 
(5’- GCT AGA GAT TTT CCA CAC TGA CTA A-3’), in a 10 µL reaction containing 1 x 
SYBR Green JumpStart Taq Ready Mix (Sigma). Cycle conditions were as follows: 95°C 
for 8 min; followed by 95°C for 10 s, 60°C for 10 s, 72°C for 9 s for 40 cycles. PCR 
products were resolved on 2% agarose gels stained with ethidium bromide. This method 
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was optimized by Arinder Kohli, and was futher tested and proven to be prone to false 
positives in Chapter 5 (5.3.1). 
Where indicated two drugs from ARRRP were used to inhibit integration by pre-
treatment for 4 h at 37°C prior to incubation with infectious HIV-1: AZT (no 3485) 500 μM 
diluted in 10% FCS, 1% P/S medium and Integrase Inhibitor (118-D-24 or 4-[3-
(azidomethyl)phenyl]-2-hydroxy-4-oxo-2-butenoic acid, no 9957) 25 µM in SFM. 
 
2.7.2 Primer-Probe PCR assay 
The primer-probe assay was based on the protocol described by Mbisa et al 
(2009). 1 x 105 TR146, A431, FaDu and either C8166 or NP2-R5 were plated and 
infected or incubated the following day with indicated viral MOI (1-144). Virus stocks 
were pre-treated with RNAse-free DNAse (Roche, Welwyn Garden City, UK) at 37C for 
1 h in 1x buffer, with an equivalent volume of untreated (not DNAse treated) controls. 
The virus stock that was left untreated was then heat inactivated 60-65C for 1 h. This 
heat inactivated virus is unable to infect cells and acts as a control giving a measure of 
the level of DNA contamination in the system. Cells were incubated with DNAse-treated 
and heat inactivated virus stocks at the stated MOI for 48 h with addition of medium if the 
medium was acidifying. The cells were washed three times with PBS and DNA harvested 
with GenElute™ Mammalian Genomic DNA Miniprep Kit (Sigma, Poole, UK) according 
to the manufacturer’s instructions except the samples were treated with Proteinase K for 
longer (20 min). DNA samples were digested with DpnI enzyme (New England Biolabs, 
Hitchin, UK) (1 unit to 1x buffer 4) to degrade any plasmid DNA contaminant (the 
enzyme has a short recognition site and cuts to produce blunt fragments and is blocked 
by CpG methylation in mammalian DNA but not by dam methylation in E. coli) for 2 h 
with 20 min heat inactivation at 80C. DNA was then quantified by Nanodrop and 50 ng 
or 100 ng of cellular DNA was used in real time PCR (all samples from the same cell line 
were compared at same DNA concentration) using primers 0.2 M MH535 forward (5’-
AACTAGGGAACCCACTGCTTAAG-3’) and 0.8 M reverse SB704 (5’-
TGCTGGGATTACAGGCGTGAG-3’) with 0.2 M probe P-HUS-SS1 (5’FAM-
TAGTGTGTGCCCGTCTGTTGTGTGAC-TAMRA-3’) (Mbisa et al. 2009) with Sigma 
JumpStart™ Taq ReadyMix™ (Poole, UK) in 10 μL reactions. Samples were denatured for 
10 min followed by cycling conditions 94 C for 15 s, 60C for 30 s and 72C for 60 s for 
60 cycles of amplification in a Corbett Rotor-Gene machine. DNAse treated virus 
exposed samples were compared with heat inactivated virus-exposed samples amplified 
from an equal concentration of starting template. A positive integration event is 
demonstrated when a lower Ct value is observed in the DNAse treated virus sample 
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when compared with the heat inactivated virus. A negative integration event occurred 
when the DNAse treated virus-exposed sample showed either no amplification or a 
higher Ct value than the heat inactivated virus-exposed sample. This method was used 
to verify whether epithelial integration of HIV occured in section 5.3.2.  
 
2.8 Virus transfer from epithelial cells to TZM-bl 
FaDu, TR146, A431 and TZM-bl cells were seeded at 1 x 105 cells and the 
following day infected with YU2 (R5) or LAI (X4) virus at an MOI of 0.2. After 16-18h 
incubation at 37oC the cells were thoroughly washed three times (PBS) to remove any 
unbound virus. Controls included incubation of cell lines without the addition of virus. 
TZM-bl cells (3 x 105) were then overlaid onto the epithelial cells and the plates 
incubated for a further 48 h at 37oC. Cells were fixed and stained for β-galactosidase 
expression with X-Gal stain. Individual wells were photographed by light microscopy at 
200 X magnification. 
 
2.9 Cytokine induction by gp120/140 by Luminex assay  
TR146 and A431 cells were grown to confluence and then serum starved in serum-
free medium (SFM) with 1% P/S for 2 h prior to stimulation with HIV-1 envelope 
recombinant glycoproteins gp120 BAL-R5 that binds CD4 (no 4961, expression construct 
by Dr. Marvin Reitz), recombinant full-length glycosylated CN54-X4 Clade C produced in 
insect cells using the baculovirus expression system. The protein is produced in as a 
fusion with maltose binding protein. It also contains a C-terminal His tag. (no 7749, 
Morikawa et al.,1990) (both from ARRRP) and mammalian glycosylated oligomeric 
gp140s UG21-X4 (Jeffs et al., 2004, 2006) and ZM96 Clade C (Cat no ARP696 from 
Programme EVA Centre for AIDS Reagents, provided by Polymun GmbH) all at a 
concentration of 1 μg/mL in SFM. No cellular toxicity was obvious from microscopic 
examination. Untreated wells were also serum starved in SFM. After 24 h, supernatants 
were collected and quantified by Luminex multiplex bead assay according to the 
manufacturer’s instructions (Luminex assay by Celia Murciano). The trimeric gp140 
glycosylated proteins (UG21 and ZM96) were produced by mammalian cell transfection 
or stably expressing lines rather than in bacteria or insect cells (like gp120 BAL and CN-
54). UG21 was a kind gift from Dr Simon Jeffs (Imperial College London).  
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2.10 Global gene profiling by microarray analysis 
5 x 105 cells were exposed to HIV-1 YU2-R5 and LAI-X4 for an 8 h stimulation. The 
cells were washed with PBS and total RNA isolated using the GenElute total mammalian 
RNA miniprep kit (Sigma, UK). The following was performed by Chengguo Shen, a 
postdoctoral scientist and bioinformatician in the lab. Genomic DNA contamination was 
removed from the RNA sample using the Turbo DNase free kit (Ambion, UK). RNA was 
amplified using the MessageAmp Premier RNA Amplification Kit (Ambion, UK) then 
hybridized onto U133a 2.0 gene chips (Affymetrix, UK) after fragmentation. Chips were 
scanned (Affymetrix GeneChip Scanner 3000) and checked using Affymetrix Command 
Console (AGCC) software suite. This data was statistically analysed using Partek 
Genomics Suite (version 6.4, Partek, USA). The data was then assessed by myself. 
Gene lists representing up and down regulated genes were compared using the Venn 
diagram program Venny (Oliveros, 2007) and submitted to the Database for Annotation, 
Visualisation and Integrated Discovery (DAVID) (Huang da et al., 2009) and examined 
for gene ontology.  
 
2.11 Fungal culture and quantification 
The fungal wild-type strains used in this study were C. albicans SC5314 (Gillum et 
al., 1984), C. albicans 529L (in-house clinical isolate), C. dubliniensis (CD36), C. 
tropicalis (ATCC 750), C. glabrata (ATCC 2001), C. guilliermondii (in-house clinical 
isolate), C. krusei (clinical isolate (Jayatilake et al., 2008)) and S. cerevisiae (NCPF 
3139). This represents a selection of strains of Candida species with one non-Candida 
fungal species. The C. albicans null mutant strains used in this study were yeast locked 
Δeed1 (Zakikhany et al., 2007), pseudohyphal  Δtup1 (Braun and Johnson, 1997), and 
hyphal Δnrg1 (Murad et al., 2001), as well as Δpmr1 (Bates et al., 2005), Δoch1 (Bates et 
al., 2006) and Δmnt1/2 (Munro et al., 2005), which are mutant in genes governing N- and 
O- glycosylation of Candida surface proteins.  The parent strain of these mutants was C. 
albicans CAI4, which had the Ura3 gene replaced using the plasmid CIp10 (Murad et al., 
2000), C. albicans CAI4 is a derivative strain of C. albicans SC5314. Particulate β-glucan 
was a kind gift from David Williams, University of Tennessee. Chitin was crab chitin 
(Sigma). 
Fungal cultures were grown overnight at 30°C in 5 ml YPD (1% yeast extract, 2% 
peptone, 2% dextrose) with 5 μl of a previous culture or from a frozen bead stock kept at 
-80°C. A 1 mL aliquot of the culture was centrifuged for 1 min at 14,500-15,000 rpm and 
resuspend in 1 mL filter sterilized PBS and washed twice. Using a spectrophotometer, a 
1:100 dilution of the resuspended culture was measured at OD 600 nm to determine the 
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colony forming units (CFU)/mL using a standard curve previously established in the 
group. Then the fungal cells were diluted accordingly to obtain a concentration of 1 x 105 
yeast/mL for the assay.  
 
2.11.1 HIV-1 transfer from fungal cells to TZM-bl reporter cells 
105 fungal cells from an overnight culture at 30°C were aliquoted into a 1.5 mL 
tube and resuspended with DMEM 10 with or without virus, as indicated (either YU2-R5 
or LAI-X4 at MOI of 1, in 1 mL total volume). Samples were incubated overnight at 37°C 
on a gently shaking platform to allow for the virus to bind to the fungal cells. Meanwhile, 
TZM-bl cells (1 × 104 cells/well) were also seeded overnight (96-well plates). The fungal 
cells were washed three times with cold PBS and the pellets resuspended in 600 μL (per 
sample tube) of DMEM 10 with addition of 34 μL Fungizone/mL or 34 μL 250 μg/mL 
Amphotericin B (final concentration 0.136 μg/ml) (PAA laboratories) to inhibit fungal 
growth and the killing of TZM-bl indicator cells by the fungus. The resuspended fungal 
pellets were then incubated with the TZM-bl cells. After 18-24 h incubation at 37°C, the 
cells were fed with 50 μL of fresh medium containing Amphotericin B as described 
above. After a further 48 h, virus supernatant was removed and the cells were fixed with 
0.05% glutaraldehyde for 10 min at room temperature and washed twice with PBS. 
Expression of β-galactosidase was determined by staining cells with X-Gal stain, as 
described in section 2.3.3,  and incubating culture plates at 37°C for 1 h. Virus transfer 
was counted in HIV-1 yeast exposed wells and compared to control wells incubated with 
yeast not exposed to HIV-1.  
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Chapter 3 Expression of HIV-1 related receptors in oral and 
vaginal epithelial cells 
3.1 Introduction 
The initial step of HIV-1 infection of any host cell is surface receptor binding. 
Classical binding of HIV-1 to permissive host cells is the sequential interaction of the viral 
envelope protein gp120 with the cellular CD4 receptor and then a fusion co-receptor. For 
macrophages and T cells these fusion co-receptors are the chemokine receptors CCR5 
(R5-trophic virus) or CXCR4 (X4-trophic virus), respectively (Pierson and Doms, 2003). 
Together, these receptors (CD4, CCR5/CXCR4) are termed canonical HIV-1 receptors. 
Despite these receptor dependencies, HIV-1 gp120 may also bind CD4- cells such as 
spermatozoa (Baccetti et al., 1994), fibroblasts (Tateno et al., 1989) and 
oligodendrocytes (Harouse et al., 1991). Therefore, it is clear that HIV-1 utilizes several 
alternative receptor mechanisms for binding host cells that appear to be independent of 
the CD4/CCR5 and CD4/CXCR4 mechanism. These alternative, non-canonical host 
receptors include DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin) (Geijtenbeek et al., 2000), ICAM-1 (intercellular adhesion 
molecule-1) (Paquette et al., 1998), GalCer (galactosylceramide) (Alfsen and Bomsel, 
2002; Delezay et al., 1997; Harouse et al., 1991; Yahi et al., 1995), and heparan 
sulphate proteoglycans (HSPGs) such as syndecan-1 and -4 (Bobardt et al., 2003; 
Hamon et al., 2004; Urbinati et al., 2009; Wu et al., 2003) (see Chapter 1, literature 
review, sections 1.5, and Tables 1.2, 2.1 for details).  
The vast majority of reports indicate that oral and vaginal epithelial cells do not 
express or express very little CD4 (Bobardt et al., 2007; Dezzutti et al., 2001; Kumar et 
al., 2006; Liu et al., 2003; Quinones-Mateu et al., 2003; Vacharaksa et al., 2008) and 
express CCR5 and CXCR4 at either undetectable or very low levels (Bobardt et al., 
2007; Giacaman et al., 2007; Liu et al., 2003; Vacharaksa et al., 2008). However, since 
HIV-1 is known to bind epithelial cells from these mucosal sites (Dezzutti et al., 2001; 
Tugizov et al., 2011; Wu et al., 2003), it is thought HIV-1 gp120 also utilizes several 
alternative receptor mechanisms for binding epithelial cells at these mucosal sites. 
These include GalCer and HSPGs, which are commonly expressed on epithelial cells 
and are thought to promote HIV-1 binding (Bobardt et al., 2007; Wu et al., 2003). 
In this chapter we aimed to determine the expression of canonical HIV-1 receptors 
(CD4, CCR5 and CXCR4) along with non-canonical HIV-1 receptors (DC-SIGN, HSPG’s, 
ICAM-1 and GalCer) in three epithelial cell lines representing oral (TR146 (Rupniak et 
al., 1985) and FaDu (Rangan, 1972)) and vaginal (vulval - A431 (Giard et al., 1973) 
mucosal sites. This was performed to determine whether the presence of these HIV-1 
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receptors correlated with the ability of HIV-1 to bind (Chapter 4) and subsequently infect 
(Chapter 5) these epithelial sites, as this may provide clues as to why oral transmission 
of HIV-1 is a rare event in comparison with vaginal transmission. We utilized epithelial 
cell lines representative of two oral sites that have not previously been investigated with 
regard to oral HIV transmission but are one of the first cell types that come into contact 
with HIV-1 in the oral cavity: buccal (TR146) and oro-pharyngeal (FaDu) epithelial cells, 
both of stratified squamous cell origin. Comparison of these three cell lines also allowed 
for convenient and direct comparisons to be made with regard to receptor expression. 
We demonstrate that there are small but definitive differences in HIV-1 related receptor 
expression between oral and vaginal epithelial cells, which may result in differential 
ability of HIV-1 to bind these mucosal sites (Chapter 4 and 5). 
 
3.2 Methods 
3.2.1 mRNA expression 
Methods are detailed in section 2.4.2. Briefly, RNA was isolated from the same 
number of plated resting cells. RNA was treated with DNAse and converted to cDNA 
using HIV reverse transcriptase and then assayed with primers in Table 2-1 (for CD4, 
CXCR4, CCR5, DC-SIGN, SDC-1, SDC-4, ICAM-1 and β-actin) under cycling conditions 
in Table 2-2 in a Sybr green mastermix by realtime PCR. 
3.2.2 Flow cytometry for surface protein expression 
Methods are as detailed in section 2.4.1. Briefly cells were detached with mild 
EDTA-treatment, washed and stained with antibodies against CD4, CXCR4, CCR5, DC-
SIGN, HSPGs, ICAM-1 and GalCer and washed and analysed by flow cytometry. 
 
3.3 Results 
The expression of epithelial cell receptors that bind HIV-1 gp120 can be 
determined at the mRNA and protein levels. In this study, we utilized quantitative reverse 
transcription PCR (qRT-PCR) to assess mRNA expression and flow cytometry to assess 
protein levels of CD4, CCR5, CXCR4, DC-SIGN, HSPG’s (syndecan-1-4), ICAM-1 and 
GalCer. It should be noted that GalCer is a glycosphingolipid (non-protein moiety) and 
could not be investigated by mRNA expression.  
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3.3.1 Establishment of a qRT-PCR protocol to assess mRNA expression of HIV-1 
related receptors 
Prior to determining the mRNA expression levels of HIV-1 related receptors in 
epithelial cells, preliminary experiments were first undertaken to optimize the qRT-PCR 
protocol. A number of forward and reverse primer sets and cycling times were tested for 
each target gene (CD4, CCR5, CXCR4, DC-SIGN, SDC-1, SDC-4 and ICAM-1) and 
various parameters were assessed including the dynamic range (5-log dilution series 
with a slope of  approximately –3.3 ±10%), R2 value (a statistical term that indicates how 
good one value is at predicting another; an R2 value >0.95 provides good confidence in 
correlating two values and a value >0.99 provides excellent confidence), precision (low 
standard deviation ≤0.250) and sensitivity (capable of effectively amplifying low copy 
numbers of starting template). Based on these assessment parameters, the optimal 
primer sets were chosen for detecting gene expression of the target genes. For all primer 
sequences and cycling conditions tested please refer to Chapter 2 (Materials and 
Methods, Section 2.4.2, Tables 2.1 and 2.2 respectively). 
3.3.1.1 Gene expression of HIV-1 related receptors in oral and vaginal epithelium 
Once the conditions for the qRT-PCR protocol were optimised, we proceeded with 
determining the expression of CD4, CCR5, CXCR4, DC-SIGN, SDC-1, SDC-4 and 
ICAM-1 in the oral (TR146, FaDu) and vaginal (A431) epithelial cell lines. This was 
performed in resting epithelial cells to determine the basal gene expression levels of 
these receptors, as under normal conditions (e.g. natural infection with HIV-1) epithelial 
cells are in the resting state when exposed to HIV-1. TZM-bl cells were included as a 
positive control, which are a HeLa-derived cell line (Derdeyn et al., 2000) that have been 
engineered to express CD4, CCR5 and CXCR4 (Platt et al., 1998). 
To determine basal gene expression levels of these receptors, the total RNA was 
isolated from resting TR146, FaDu and A431 epithelial cells (see Chapter 2, Materials 
and Methods, section 2.4.2) and CD4, CCR5, CXCR4, DC-SIGN, SDC-1, SDC-4 and 
ICAM-1 gene expression determined using the optimised qRT-PCR protocol. The data 
are shown in Table 3.1 and are representative of between 5 and 10 independent 
experiments, each performed in technical triplicates with the average value for each 
technical triplicate presented.  
The arbitrary copy number for each target gene is compared with -actin, a 
housekeeping gene, used as a control, which was given an arbitrary mRNA copy number 
of 10000. Outlier quantified values more than two standard deviations from the mean 
were excluded from analysis (E). For direct comparisons between cell lines, the average 
arbitrary mRNA copy number for each gene is also presented in Fig 3.1. 
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Table 3-1: SyBrGreen qRT-PCR detection of HIV-1 related receptor genes in oral (TR146, 





Canonical HIV receptors HIV binding factors 























TZM-bl-1 10000 2640 E 420 8 3100 E 4000 
TZM-bl-2 10000 2040 1870 220 0 1300 E 3400 
TZM-bl-3 10000 2090 7460 1120 0 900 28 600 
TZM-bl-4 10000 1450 6670 430 0 820 31 700 
TZM-bl-5 10000 E 3700 690 0 1320 34 1100 
Average 10000 2055 4925 576 2 1488 31 1960 
+/- SD 0 486 2253 347 4 929 3 1613 
TR146-1 10000 E E E 0 2500 E 2600 
TR146-2 10000 0 0 1 0 E E 2900 
TR146-3 10000 38 0 1 0 910 1 1659 
TR146-4 10000 0 0 0 17 2011 0 5874 
TR146-5 10000 0 0 0 0 1692 0 1306 
TR146-6 10000 0 0 0 0 1093 0 2901 
TR146-7 10000 2 0 0 0 1915 0 1001 
TR146-8 10000 0 0 0 0 2164 0 2838 
TR146-9 10000 21 0 0 0 842 0 2115 
TR146-10 10000 74 0  2 1846 0 554 
Average 10000 15 0 0 2 1664 0 2350 
+/- SD 0 26 0 1 5 585 0 1578 
FaDu-1 10000 0 0 10 E E 100 1400 
FaDu-2 10000 0 10 24 E E 600 0 
FaDu-3 10000 0 0 20 0 2020 100 1400 
FaDu-4 10000 0 0 20 5 2080 100 1700 
FaDu-5 10000 0 0 10 0 1040 200 1500 
Average 10000 0 2 17 2 1713 220 1500 
+/- SD 0 0 4 9 3 584 217 141 
A431-1 10000 E 0 0 E E 100 2500 
A431-2 10000 E 0 1 E 2300 100 700 
A431-3 10000 177 0 0 0 3728 125 127 
A431-4 10000 16 0 0 0 8766 299 851 
A431-5 10000 353 0 0 4 6361 249 302 
A431-6 10000 66 E 0 11 2675 57 237 
A431-7 10000 268 0 0 1 6103 213 639 
Average 10000 179 0 0 3 4989 163 765 
+/- SD 0 139 0 0 5 2513 90 810 
a
  Data are representative of between 5 – 10 independent experiments 
b




  Arbitrary mRNA copy number of target genes relative to β-actin.  
SDC-1, syndecan-1; SDC-4, syndecan-4. 
E: eliminated from analysis due to greater than 2 standard deviations from the mean. 
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Figure 3-1: Averages mRNA transcript levels (number of copies) of HIV-related receptors in 
TR146, FaDu, A431 and TZM-bl cell lines, relative to 10000 copies-actin. TR146 are shown 
in blue, FaDu in red, A431 in green, TZM-bl in purple. 
The data presented in Table 3.1 and Figure 3.1 shows both similarities and 
differences in gene expression of HIV-1 related receptors between the two oral epithelial 
cell lines and between the oral and vaginal cell lines. With regard to the oral epithelial 
cell lines, both TR146 and FaDu cells expressed undetectable or very low levels of the 
canonical HIV-1 receptors CD4, CCR5 and CXCR4. Although FaDu cells appear to 
express greater levels of CXCR4 than TR146 cells, expression is very low compared 
with the control TZM-bl cells. Likewise, although TR146 cells appear to express greater 
levels of CD4 than FaDu cells, CD4 expression in TR146 cells is variable and, when 
detected, is present in very low amounts. Both TR146 and FaDu cells express similar 
(high) levels of the non-canonical receptors SDC-1 and ICAM-1, with neither cell type 
expressing detectable amounts of DC-SIGN. The main difference between the two oral 
epithelial cell lines is that FaDu cells express greater levels of SDC-4 compared with 
TR146 cells. 
Like TR146 and FaDu oral epithelial cells, A431 vaginal epithelial cells expressed 
undetectable or extremely low amounts of CCR5, CXCR4 and DC-SIGN. Interestingly 
though, unlike TR146 and FaDu oral cells, A431 vaginal cells expressed CD4 mRNA, 
albeit at levels lower than the positive control TZM-bl cell line. A431 cells also expressed 
slightly elevated levels of SDC-1 and reduced levels of ICAM-1 compared with TR146 
and FaDu cells, and similar levels of SDC-4 as FaDu cells, which was absent in TR146 
cells. 
To summarize, gene expression studies indicate that resting oral epithelial cells 
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However, unlike buccal (TR146) oral epithelial cells, pharyngeal (FaDu) cells additionally 
express SDC-4. Notably, vaginal (A431) epithelial cells express CD4 at low levels and 
SDC-4 at similar levels as pharyngeal (FaDu) epithelial cells. Finally, SDC-1 and ICAM-1 
are generally highly expressed in all epithelial cell types and DC-SIGN is undetectable. 
3.3.2 Establishment of a flow cytometry protocol to assess surface expression of 
HIV-1 related receptors 
The gene expression studies were useful in providing indicative information of 
which HIV-1 related receptors were expressed in resting epithelial cells. However, gene 
expression levels may not correlate with expression of these receptors on the epithelial 
cell surface, which is where HIV-1 would initially bind to epithelial cells during natural 
exposure to the virus. Therefore, it was important to verify whether gene expression 
levels correlated with surface protein expression of these receptors. To determine this 
we used flow cytometry to detect CD4, CCR5, CXCR4, DC-SIGN, HSPGs and ICAM-1 
on the surface of TR146, FaDu and A431 epithelial cells, and compared this with the 
positive control TZM-bl cell line. We also investigated the surface expression of GalCer 
as this glycosphingolipid moiety could not be investigated by gene expression. It should 
also be noted that the antibody used to determine surface expression of HSPG’s 
detected all four syndecans (1-4), rather than just syndecan-1 and -4 as assessed in the 
gene expression studies. This was because we wanted to ensure that we could detect 
general HSPG expression on the epithelial cell surface as opposed to just specific 
HSPG’s. 
Prior to determining the expression of HIV-1 related receptors on the surface of 
epithelial cells, preliminary experiments were first undertaken to optimize the flow 
cytometry protocols. Section 2.4.1 shows which antibodies and respective dilutions were 
optimal to detect the expression of HIV-1 related receptors on the surface of epithelial 
cells. 
3.3.2.1 Protein expression of HIV-1 related receptors in oral and vaginal 
epithelium 
Once the flow cytometry protocol was optimized, we proceeded with determining 
the surface expression of the HIV-1 related receptors in resting TR146, FaDu and A431 
epithelial cells. To achieve this, epithelial cells were isolated from monolayer cultures 
and labelled with antibodies specific to each target receptor (Chapter 2, section 2.4.1) 
and detected with a FITC-labeled secondary antibody (section 2.4.1) except for ICAM-1 
antibody that was directly conjugated to PE. Table 3.2 and Figure 3.2 represent the 
same data set and depict the surface protein expression of HIV-1 related receptors on 
TR146, FaDu and A431 epithelial cells in comparison to the positive control TZM-bl cells. 
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In most cases the data are representative of two independent experiments, each 
performed in technical duplicates with the average value for each technical duplicate 
presented. The data was obtained in addition to and as verification of data included in 
Kohli et al (2012, submitted manuscript). 
Table 3-2: Surface protein expression of HIV related receptors on epithelial cells  
 


















TZM-bl 56 (9.4) 40  (7) 93 (3.5) 0.3 (0.1) 6.2 (3.2) 0(1.3) 96 (1.4) 
TR146 1.2 (3.1) 13b 5.8 b 0.1 (0.9) 28 (24) 4.9 (4.5) 99 (0.3) 
FADU 0.7 (0.6) 2 b 2.5 b 0.2 (0.4) 18 (5.8) 2.5 (0.2) 62 (15) 
A431 1.3 (3.7) 11 b 8 b 0.2 (0.4) 36 (13) 37 (16) 90 (6.7) 
a
  HSPGs; antibody detecting syndecans 1-4. 
b  
Represents singleton data points, thus no SD is shown. All other data sets are representative of 




Figure 3-2: Percent surface protein expression of HIV-1 related receptors in TR146, FaDu, 
A431 and TZM-bl, cell lines as determined by flow cytometry using monoclonal primary 
antibodies for listed cell surface moieties. Primary antibodies were detected with goat anti-mouse 
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IgG conjugated with fluorescein isothiocyanate (FITC). The only directly conjugated ab was 
ICAM-1 to PE. 
Both TR146 and FaDu oral cells expressed undetectable or low levels of CD4, 
CCR5 and CXCR4 on the surface, which supports the gene expression data. Although a 
greater number of TR146 cells appeared to express CCR5 than FaDu cells (13% versus 
2%, respectively), expression was still low compared with the positive control TZM-bl 
cells (40%). A high percentage of TR146 and FaDu cells expressed ICAM-1 (99% versus 
62%, respectively), but neither cell type expressed detectable amounts of DC-SIGN, 
again correlating well with the gene expression data. However, both TR146 and FaDu 
cells appeared to express minimal amounts of HSPGs, which was in contrast to the gene 
expression data that indicated the presence of SDC-1 mRNA for TR146 and both SDC-1 
and -4 mRNA for FaDu cells. Given that the HSPG antibody detects syndecans 1-4, this 
was an unexpected result. This would suggest that although SDC-1 and SDC-4 are 
expressed at the mRNA level, they may not to be translated into surface protein 
expression. Finally, a similar percentage of TR146 and FaDu cells expressed the 
glycosphingolipid GalCer (28% versus 18%, respectively). Together, our data suggest 
that there were no major differences between buccal and oro-pharyngeal epithelial cells 
with regard to surface expression of the target HIV-1 receptors. Both cell types 
expressed undetectable/very low levels of the canonical HIV-1 receptors (CD4, CCR5 
and CXCR4) but greater amounts of the non-canonical HIV-1 receptors (ICAM-1 and 
GalCer).  
Like TR146 and FaDu oral epithelial cells, A431 vaginal epithelial cells expressed 
undetectable or very low amounts of CD4, CCR5, CXCR4 and DC-SIGN. This correlates 
with the gene expression data except for CD4, which was shown to be expressed by 
A431 cells, albeit at low levels. This would suggest that although CD4 is expressed at 
the mRNA level in vaginal epithelial cells, it appears not to be translated into surface 
protein expression (i.e. similar to HSPG’s (SDC-1 and SDC-4) for oral epithelial cells). A 
similar percentage of A431 cells also expressed ICAM-1 (90%) and GalCer (36%) as the 
two oral epithelial cell lines. The only major difference between the vaginal and oral 
epithelial cells was that HSPG’s were expressed on the surface of a good percentage of 
A431 cells (37%) but only minimally on TR146 (4.9%) and FaDu (2.5%) oral cells. 
To summarize, surface protein expression studies indicate that resting oral and 
vaginal epithelial cells do not express significant levels of the canonical HIV receptors 
CD4, CCR5 or CXCR4, or the non-canonical receptor DC-SIGN. However, oral and 
vaginal epithelial cells do express surface ICAM-1 and GalCer, with vaginal cells 
additionally expressing surface HSPG’s.  
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3.4 Discussion 
The majority of HIV-1 infections worldwide are acquired via mucosal surfaces, 
predominantly across the female or male genital tracts (Hladik and McElrath, 2008). In 
contrast, HIV-1 transmission through the oral mucosa is thought to be uncommon 
(Cohen, 2008; Jotwani et al., 2004). However, studies in primates indicate that oral 
transmission is a possible occurrence since non-traumatic oral exposure to SIV results in 
regional dissemination followed by systemic infection (Baba et al., 1996; Joag et al., 
1997; Milush et al., 2004). Given that both genital and oral mucosae are lined by 
epithelial cells, this raises the possibility that in addition to representing a barrier to HIV-1 
transmission at one level, epithelial cells may also be a conduit for viral entry. This is 
particularly important given the occurrence of viral transmission during heterosexual 
intercourse, during oro-genital contact in adults, and in nursing infants. In this regard, 
binding of HIV-1 to epithelial cells could be an essential first step in subsequent viral 
transmission across the mucosae. 
HIV-1 has been shown to utilize many surface receptors to bind to host cells 
including the classical receptors CD4, CCR5 and CXCR4 as well as the alternative 
receptors DC-SIGN, HSPG’s, ICAM-1 and GalCer (Cook et al., 1994; Fantini et al., 1993; 
Fortin et al., 1998; Geijtenbeek et al., 2000; Paquette et al., 1998; Saidi et al., 2007; Tan 
et al., 1993; Yahi et al., 1995). Therefore, in this chapter we aimed to determine the 
expression of CD4, CCR5, CXCR4, DC-SIGN, HSPG’s, ICAM-1 and GalCer in three 
epithelial cell lines representing oral buccal (TR146), oro-pharyngeal (FaDu) and vaginal 
(vulval - A431) mucosal sites. This was performed to determine whether these HIV-1 
related receptors were differentially expressed at these body sites, which may provide 
clues as to why oral transmission of HIV-1 is considered a rare event in comparison with 
vaginal transmission. We demonstrate that there are small but definitive differences in 
HIV-1 related receptor expression between oral and vaginal epithelial cell lines that may, 
if true for primary epithelia, ultimately result in the differential ability of HIV-1 to bind 
and/or subsequently infect these mucosal sites, which was investigated in Chapters 4 
and 5. 
 
3.4.1 Expression of canonical HIV-1 receptors in oral epithelial cells 
Both the gene and protein expression studies indicated that resting TR146 and 
FaDu oral epithelial cells express generally undetectable levels of CD4 and very low 
levels of CCR5 and CXCR4 (Tables 3.1, 3.2 and Figures 3.1, 3.2). Although these cell 
lines have not previously been used in HIV-1 studies, a number of studies using 
epithelial cells isolated from various sites within the oral cavity have been undertaken. 
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Our data are in line with the majority of these studies, which also indicate a general lack 
or low level expression of CD4, CCR5 and CXCR4 (Chapter 1, Literature review, Section 
1.6.1, Tables 1.1 and 1.2) (Giacaman et al., 2008; Kumar et al., 2006; Liu et al., 2003; 
Quinones-Mateu et al., 2003; Vacharaksa et al., 2008). However, several other studies 
have demonstrated the presence of CD4, CCR5 and CXCR4 in oral epithelial cells 
(Moore et al., 2002; Moore et al., 2003; Tugizov et al., 2011). 
Moore et al. demonstrated that two salivary gland epithelial cell lines expressed 
CXCR4 mRNA, one expressed CCR5 mRNA, but both were negative for CD4 mRNA, 
and that this correlated with surface protein expression (Moore et al., 2002). The same 
authors also demonstrated CCR5 and CXCR4 mRNA expression in two keratinocyte and 
two adenoid epithelial cell lines, with one adenoid cell line expressing CD4 mRNA, which 
again correlated with protein expression except surface CD4 was not detected (Moore et 
al., 2003). In addition, Giacaman et al (2007) showed that immortalized TERT-2 cells 
(human oral keratinocyte line) expressed CXCR4 and to a lesser extent CCR5 mRNA 
and surface protein, whereas another study  demonstrated weak expression of CD4, 
CCR5 and CXCR4 mRNA in seven gingival keratinocytes biopsies and five palatine 
tonsil epithelial samples (all primary cells) by microarray analysis (Moutsopoulos et al., 
2007). However, the unit for the expression level was not provided in the latter paper, 
making the expression data difficult to evaluate. Other studies only investigated surface 
protein expression of CD4, CCR5 and CXCR4. These studies also demonstrated the 
general absence of surface CD4 concomitant with the absence or low level expression of 
CCR5 and CXCR4 in primary oral keratinocytes, immortalized TERT2 cells and 
adult/foetal tongue and tonsillar epithelium (Liu et al., 2003; Tugizov et al., 2011; 
Vacharaksa et al., 2008).  
In summary, our data are in line with the published literature and we conclude 
that CD4, CCR5 and CXCR4 are absent or expressed at very low levels in oral epithelial 
cell lines. Given that CD4, CCR5 and CXCR4 are required for efficient viral infection of 
immune cells (macrophages and T-cells (Alkhatib et al., 1996; Berson et al., 1996; 
Klatzmann et al., 1986), this suggests that oral epithelial cells are unlikely to support 
productive HIV-1 infection (see Chapter 5). 
 
3.4.2 Expression of non-canonical HIV-1 receptors in oral epithelial cells 
Gene expression studies indicated that SDC-4 was preferentially expressed in 
pharyngeal (FaDu) but not buccal (TR146) epithelial cells, and that SDC-1 and ICAM-1 
were highly expressed in both oral epithelial cell types (Table 3.1, Figure 3.1). Protein 
studies demonstrated surface expression of ICAM-1 and GalCer but that HSPG 
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expression (SDC1-4) was surprisingly very low. Notably, FaDu cells expressed higher 
levels of ICAM-1 and GalCer compared with TR146 cells. DC-SIGN was generally 
undetectable by mRNA or protein (Table 3.1, 3.2, Figures 3.1, 3.2).  
Our data are generally in line with the current literature demonstrating the 
presence of GalCer and HSPGs in oral epithelial cells (Chapter 1, Literature review, 
Section 1.6.1.2, Table 1.2). The most common non-canonical HIV-1 receptor analysed is 
GalCer, which has been detected in nearly all epithelial cell types when investigated, 
including salivary gland epithelial lines, primary gingival keratinocytes and adult/foetal 
tongue and tonsil epithelium (Liu et al., 2003; Moore et al., 2002; Moore et al., 2003; 
Tugizov et al., 2011). However, one study in immortalized TERT-2 cells showed little 
(<1%) GalCer on the surface (Vacharaksa et al., 2008), which opposes the above 
studies and our findings. The Vacharaksa et al (2008) study also demonstrated high 
levels of surface HSPGs (91% ± 20%), which again contrasted with our data (4.9% ± 
4.5% for TR146, and 2.5% ± 0.2% for FaDu) and that of Tugizov et al (2011) (35-40 %) 
who investigated adult tongue epithelium, both of which demonstrated lower expression 
levels of surface HSPGs. This suggests that the TERT-2 cells may not be representative 
of epithelial cells within the oral cavity with regard to surface GalCer and HSPG 
expression, which may affect their relevance for HIV-1 infection studies of oral epithelial 
cells. Only one study has investigated DC-SIGN expression in oral epithelial cells, in a 
palatine tonsil explant, and was undetectable (Vacharaksa et al., 2008). We are unaware 
of any HIV-1 related studies investigating mRNA or protein levels of ICAM-1 in oral 
epithelial cells. 
  In summary, we conclude that oral epithelial cells express GalCer and ICAM-1, 
but limited amounts of HSPGs and an absence of DC-SIGN. Also, in the case of HSPGs 
(SDC-1 and SDC-4) mRNA expression may not translate into surface protein expression. 
It appears that epithelial cells from different sites within the oral cavity express variable 
levels of non-canonical HIV-1 related receptors and indicates that if HIV-1 binds to 
epithelial cells (see Chapter 4), it is most likely via non-canonical HIV-1 related receptors 
rather than CD4, CCR5 and CXCR4. 
 
3.4.3 Expression of canonical and non-canonical HIV-1 receptors in vaginal 
epithelial cells 
Like oral epithelial cells, vaginal (A431) epithelial cells expressed minimal levels 
of CD4, CCR5, CXCR4 and DC-SIGN, but higher levels of ICAM-1 and GalCer. As in the 
case of HSPGs in oral epithelial cells, CD4 mRNA expression in vaginal epithelial cells 
appears not to be translated into surface protein expression. The main difference 
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between the two cell types was that vaginal cells expressed higher levels of surface 
HSPG’s, unlike oral epithelial cells. 
Although no studies could be found relating to gene expression of the HIV-1 
related receptors in vaginal epithelial cells, several studies have investigated surface 
expression of these receptors in female genital tract epithelium (Chapter 1, Literature 
review, Section 1.6.1.2, Table 1.2). Asin et al (2003) examined two uterine (ECC1, RL95-
2) and an endometrial (HEC-1A) epithelial line, which expressed CD4, CXCR4 and low 
levels of GalCer (Asin et al., 2003). Saϊdi et al (2007) also studied the HEC-1A line and 
found it to express high levels of CXCR4 and GalCer, with the GalCer finding contrary to 
that of the previous study (Saidi et al., 2007). Tugizov et al (2011) also detected high 
levels of GalCer on HEC-1A cells, but only moderate expression of HSPGs and low 
expression of CXCR4 and CCR5 expression, with CD4 being undetectable. Very few 
studies have investigated HIV-1 receptor expression in primary vaginal epithelial cells. 
Bobardt et al (2007) studied primary vaginal epithelial cells from four donors and 
demonstrated very low surface expression of CD4, CXCR4, CCR5 and GalCer but high 
levels of HSPGs, including SDC-1 and SDC-2. However, since only average mean 
fluorescence values were shown with no standard deviations, it is difficult to evaluate 
inter-sample variation in expression in this study. Most recently, in a cervical biopsy 
sample Tugizov et al (2011) detected moderate levels of surface CXCR4, CCR5 and 
HSPGs but low levels of GalCer, with no detectable CD4. These published studies 
suggest that vaginal epithelial cells generally express GalCer and HSPGs at 
high/moderate levels, low amounts of CXCR4 and CCR5 and low/undetectable levels of 
CD4, and that vaginal cell lines generally express higher levels of these receptors than 
primary vaginal epithelial cells. As with oral epithelial cells, we are unaware of any HIV-1 
related studies investigating mRNA or protein levels of ICAM-1 in vaginal epithelial cells. 
Notably, A431 express less than ICAM-1 than the two oral epithelial cell lines, potentially 
indicating less tight intercellular adherence in this monolayer culture. However, the 
downstream biological effect of this observation with regard to HIV-1 infection is 
unknown. 
In summary, our data are in line with the published literature and demonstrate 
that vaginal epithelial cell lines express minimal levels of CD4, CXCR4, CCR5 and DC-
SIGN but increased levels of GalCer, HSPG’s and ICAM-1. Furthermore, the increased 
amount of surface GalCer and HSPG’s in vaginal epithelial cell lines as compared with 
oral epithelial cells may indicate that vaginal epithelial cells potentially have a greater 
capacity to bind HIV-1 via non-canonical HIV-1 related receptors than oral epithelial 
cells. This hypothesis was tested in Chapter 4. 
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3.4.4 General discussion 
In this chapter we used real-time qRT-PCR and flow cytometry to determine 
mRNA and protein expression of HIV-1 related receptors in oral and vaginal epithelial 
cell lines. Most gene expression studies predominantly use semi-quantitative methods 
based on intensities of RT-PCR products. In this study we used real-time RT-PCR, which 
provides a more robust and quantitative measure of gene expression than most current 
studies in the literature. An additional strength of our approach is that all total RNA 
samples were first reverse transcribed together in equal concentrations prior to 
performing qPCR, which limits the variability that could be introduced by changes in 
efficiency between these two PCR steps. Therefore, in comparison with the published 
studies we are confident that data accurately reflect HIV-1 related receptor gene 
expression in epithelial cells. The flow cytometry protocols are in line with current 
approaches investigating surface protein expression of HIV-1 related receptors and our 
data adds support and substance to the current literature in this area. 
It should be noted that we have used cell lines as models of normal human oral 
and vaginal tissues. The assumption made is that the tumour lines used approximate 
normal human tissues. However, many would argue that tumour cell lines are not 
representative of normal mucosal sites (Yadev et al., 2011; Moharamzadeh et al., 2012) 
and that any patterns observed in cell lines must be verified in primary cells. Tumour cell 
lines are much easier to obtain and culture and we did not have ethical approval for the 
collection of primary female genital tract epithelium. Confirmation of the findings in 
primary tissues would have been highly desirable but was deemed beyond the scope of 
this thesis. 
We note that SDC-2 (syndecan-2) and SDC-3 (syndecan-3) gene expression was 
not assayed by qRT-PCR alongside SDC-1 and SDC-4. This was because in the same 
study that suggested SDC-4 forms complexes with CXCR4 on primary lymphocytes and 
macrophages, oligomerized and glycanated SDC-2 (in contrast to SDC-4) could not be 
co-immunoprecipitated with CXCR4 (Hamon et al., 2004). Also, while SDC-3 has been 
suggested to mediate HIV-1 attachment in dendritic cells (de Witte et al., 2007), SDC-3 
is very weakly expressed in human primary (genital) epithelial cells (Bobardt et al., 2007) 
and a role in HIV-1 attachment to epithelium has not been demonstrated. Given that our 
flow cytometry studies utilized an antibody that detected all four syndecans (SDC-1-4), 
we deemed it unnecessary to assess SDC-2 and SDC-3 mRNA levels by qRT-PCR. 
While gene and surface protein expression data correlated well, this was not 
always the case (e.g. SDC-1 and SDC-4 mRNA expression in TR146 and FaDu cells but 
low HSPG surface protein expression, and presence of CD4 mRNA transcripts in A431 
vaginal cells but undetectable surface protein). However, it is well known that expression 
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of mRNA transcripts do not always reflect protein levels or that this provides any 
indication that the protein will be functional (Bustin et al., 2009). Given that our studies 
utilized cell lines, mRNA and surface protein expression levels were sometimes 
assessed at different passage number or different times of isolation. Eliminating this 
disparity may have perhaps minimized any differences in mRNA and protein detection. 
We also stress that any differences between our data and those described in the 
literature may be partly explained by the type of epithelial cell used. For example, the 
FaDu epithelial cell line used in this study is derived from squamous epithelium of 
pharyngeal origin, whereas the adenoid studies (pharyngeal tonsil) in the literature are 
based on pseudostratified columnar epithelium. Since differences in epithelial origin may 
contribute to the variations in gene and surface protein expression of HIV-1 related 
receptors, this may complicate direct data comparisons between studies. Finally, it is 
recognised that our data are based on cell lines and that expression of HIV-1 related 
receptors may be different in primary buccal and pharyngeal squamous epithelial cells. 
This is particularly relevant given the heterogenious nature of most human populations 
and was recently highlighted in a study that showed variability in HIV-1 receptor 
expression across several tonsillar tissue sections isolated from different individuals 
(Kumar et al., 2006). Therefore, variability in expression patterns of HIV-1 related 
receptors between individuals may alter the ability of HIV-1 to bind epithelial cells during 
natural exposure to the virus in vivo. This may result in some individuals becoming more 
susceptible to HIV-1 attachment and subsequent infection than others. 
 
3.5 General conclusions 
In this chapter we set out to determine the levels of mRNA and surface protein 
expression for the HIV-1 receptor CD4, its co-receptors CXCR4 and CCR5, as well as 
several other alternate HIV-1 receptors and binding factors (DC-SIGN, HSPG’s, GalCer 
and ICAM-1) in epithelial lines that we use as models of mucosal epithelia. We have 
quantified the expression for these HIV-1 related receptors in three epithelial cell lines 
and show that oral and vaginal epithelial cell lines express minimal levels of CD4, CCR5, 
CXCR4 and DC-SIGN, but higher levels of GalCer and ICAM-1. Vaginal epithelial cell 
lines additionally express increased levels of HSPG’s on their surface.  These small 
differences in HIV-1 related receptor expression between oral and vaginal epithelial cells 
may result in the differential ability of HIV-1 to bind and/or subsequently infect these 
mucosal sites. This was investigated in Chapter 4 (HIV-1 binding) and Chapter 5 (HIV-1 
infection).Additional verification in primary normal cells would be desirable but was 
beyond the scope of the thesis.   
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Chapter 4 Binding of HIV-1 to oral and vaginal epithelial cells 
 
4.1  Introduction 
In the previous chapter, the mRNA gene expression and flow cytometry for surface 
receptor expression data suggested that there is potential for HIV-1 to bind to oral and 
vaginal epithelium according to our models. Although TR146 (buccal), FaDu 
(pharyngeal) and A431 (vaginal) cells express low surface levels of the HIV-1 receptor 
CD4 and co-receptors CCR5 and CXCR4, they do express the alternative HIV-1 receptor 
GalCer and HIV-1 binding factors HSPGs and ICAM-1. Therefore, all three epithelial cell 
lines possess molecules on their surface that have been documented to bind HIV-1. 
Although the evidence for direct interactions between HIV-1 and epithelial cells is often 
conflictory, there is a solid body of literature to suggest that HIV-1 directly binds epithelial 
cells. 
Kage et al (1998) demonstrated that latex microparticles coated with gp120 were 
internalised by gingival epithelial cells, suggesting direct interaction with the virus particle 
envelope (Kage et al., 1998). More recently, Rodriguez-Inigo (2005) used in situ 
hybridization of oral biopsies from HIV-1 positive patients to co-localize viral RNA with 
oral keratinocytes, which is also suggestive of direct interaction (Rodriguez-Inigo et al., 
2005). Two studies used GFP-vpr labeled HIV-1 to visualize HIV-1 in contact with 
epithelium. In 2009, Nittayananta et al. exposed differentiated oral epithelial organotypic 
cultures to GFP-labeled HIV-1 and observed the virus penetrating up to 15 μm into the 
model, although most GFP-positive particles remained on the apical surface 
(Nittayananta et al., 2009). Tugizov et al. (2011) demonstrated similar results with adult 
tonsil biopsies, but due to low magnification it is difficult to observe direct interaction 
between the epithelial cell membranes and virus particles. Two additional electron 
microscopy studies also showed that HIV-1 infected peripheral blood mononuclear cell 
(PBMC) interact with intestinal (Alfsen et al., 2005) and foreskin (Ganor et al., 2010) 
epithelial cells but, again, in both studies it was difficult to visualize distinct virus particles 
attached to the epithelial surface. Thus, at the physical level there is strong, suggestive 
evidence of direct interactions between HIV-1 and epithelial cells but it has been difficult 
to visualize individual virus particles bound on the cellular level. 
Other studies have explored inhibition of HIV-1 infection using antibodies and 
interfering molecules to understand which molecules are required for binding to 
epithelium. Antibodies against CD4 blocked infection of some colonic epithelial lines but 
not HT29 (Fantini et al., 1991; Omary et al., 1991). In addition, peptide portions of 
GalCer interfered with binding of gp120 to GalCer decreased HIV infection by 50% (Yahi 
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et al., 1995). Next, heparin was shown to be able to compete 90% of RF (X4) HIV 
binding, while heparanatase also reduced association with uterine epithelium (Wu et al., 
2003). Binding of HIV to primary vaginal epithelial cells was shown to be independent of 
CD4, CXCR4 and CCR5 using inhibitors and neutralising antibodies (Bobardt et al., 
2007). Endometrial cells stripped of HSPG mostly abolished their interaction with X4 and 
R5 HIV versus controls (Saidi et al., 2007). In addition mannose receptors were 
implicated in HIV transcytosis since fucose, N-acetylglucosamine and mannosylated-
residues inhibited the, interaction of HIV with epithelium (Saidi et al., 2007). Thus, 
alternative HIV binding molecules have been shown by interference studies to be 
responsible for HIV binding to epithelium. 
 Therefore, in this chapter we aimed to demonstrate whether HIV-1 R5 and X4 
directly bind to oral and vaginal epithelial cell lines in vitro. This was investigated using 
two separate methods: detection of whole virus binding to epithelial cells by analysis of 
HIV-1 envelope gp120 protein by flow cytometry and presence of the HIV-1 capsid p24 
by Western blot. We detected the presence of gp120 envelope on the surface of 
individual epithelial cells using two primary monoclonal antibodies and that this 
interaction was sensitive to trypsin. However, trypsin digestion did not completely abolish 
virus binding (our ability to detect gp120), suggesting that HIV-1 binds to oral and vaginal 
epithelial cell lines via both protein and non-protein surface moieties. In addition, protein 
extracts from HIV-1 exposed oral and vaginal epithelial cells also tested positive for HIV-
1 p24 by Western blotting. In conclusion, our data suggest that oral and vaginal epithelial 
cell lines have the ability to directly bind and capture HIV-1.  
 
4.2  Methods 
4.2.1 Detection of HIV-1 gp120 by flow cytometry 
The methods used are detailed in Chapter 2.4.3, briefly TR146, FaDu, A431 and TZM-bl 
cells were incubated with cell free YU2 (R5) or LAI (X4) infectious virus overnight (16 h) 
at 4°C and thoroughly washed with PBS. Surface gp120 was detected using F425 B4e8 
and F425 A1g8 (Pantophlet et al., 2007, Bell et al., 2008), followed by detection with a 
Cy5-labeled secondary antibody.  
4.2.2 Interference of detection of HIV-1 gp120 with trypsin digestion 
The methods are described in detail in 2.4.4. Briefly the cell lines were exposed to HIV 
as described in the previous section but after washing, trypsin treatment for 5 min at 
37°C was used to see if it would reduce our ability to detect cell surface bound gp120 
(with F425 B4e8) (Pantophlet et al., 2007, Bell et al., 2008),  by flow cytometry. 
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4.2.3 Western blot for p24 capsid on epithelial cells extracts 
Epithelial cells were exposed to HIV-1 R5 (YU2) and X4 (LAI) viruses for 24 h at 37oC 
(Chapter 2, section 2.5.1 detection of p24), washed extensively with PBS and lysed for 
protein extraction. Samples were analysed by Western blot by probing for HIV capsid 
p24 using HIV-1 p24 Gag Monoclonal (#24-2) (from ARRRP) (Simon et al., 1997).  
 
4.3 Results  
4.3.1 Whole virus binding to epithelial cells: detection of HIV-1 gp120 by flow 
cytometry 
In preliminary experiments, to investigate whether epithelial cells were able to bind 
and capture HIV-1 we tested a number of assay systems. Initially, a series of p24 
antibodies (data not shown) and gp120 antibodies were used to determine whether a 
reliable cellular ELISA assay could be developed. However, the ELISA system we tried 
to develop (Abcam goat antibody to gp120 biotin conjugated, 53937) demonstrated high 
background staining of oral and vaginal epithelial cells making it impossible to distinguish 
virally exposed cells from untreated cells with confidence (data not shown).  
Therefore, we next developed a flow cytometry assay for the detection of HIV-1 
gp120 on the surface of epithelial cells. Two human monoclonal antibodies obtained 
from the NIH AIDS reagent program proved useful for the establishment of this assay: 
F425 B4e8 (ARRRP no. 7626) and F425 A1g8 (ARRRP no. 7624) provided by Dr. 
Marshall Posner and Dr. Lisa Cavacini (Pantophlet et al., 2007; Bell et al., 2008). The 
main reason for their selection was because they had broadly neutralizing characteristics 
(therefore would recognize many gp120s) and that a dilution was specified for flow 
cytometry applications on the data sheet, although other antibodies were initially 
assayed alongside these (see section 2.4.3 and Appendix C). 
 TR146, FaDu, A431 and TZM-bl cells were incubated with cell free YU2 (R5) or 
LAI (X4) virus overnight (16 h) at 4°C. The reduced incubation temperature enabled the 
direct visualization of surface bound HIV-1 in all cell types. Surface gp120 was detected 
using F425 B4e8 (see Figure 4.1 for representative experiment, Figure 4.2 for average of 
2-3 experiments) and F425 A1g8 (Figure 4.3), followed by detection with a Cy5-labeled 
secondary antibody. Outlying data points (greater that 3 standard deviations from the 
mean) were eliminated from the analysis. 
In Fig 4.1, the first column represents the unstained (no antibody) cell control for 
each of the cell lines. Gates were added (polygon shape) using the WinMDI program to 
encompass the unstained cells and this was taken to be 0% cells shifted towards Cy5 
positive. The second column represents cells stained with primary and secondary 
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antibody (without HIV-1 addition), a second cell control for non-specific staining. The 
third and fourth columns represent gp120 detection of epithelial cells exposed to HIV-1 
YU2 (R5) and HIV-1 LAI (X4), respectively. The percentage displayed on these plots 
represents the percent Cy5-fluorescence shift to the right versus the unstained cell 
control. However, to obtain a net number for percent of cells with bound HIV-1 on the 
surface, percentages for stained, untreated cells were subtracted from the percentages 
of virally exposed cells. Data are from 2-3 experiments are represented in Fig 4.2. 
 
Figure 4-1: Detection of immobilized gp120 on the cell surface of oral and vaginal epithelial 
cells by flow cytometry.  Oral (TR146, FaDu), vaginal (A431) and control (TZM-bl) cells were 
incubated overnight (16 h) at 4°C with infectious R5 and X4 HIV-1, washed, and epithelial 
surface-bound gp120 detected using human monoclonal antibody F425 B4e8 and a Cy5-labeled 
secondary antibody. The plots show a Cy5 fluorescence shift to the right (read on APC channel) 
after viral incubation. Percentages represent the proportion of cells shifted to higher fluorescence 
when compared with the cell control. Data are representative of three independent experiments. 
This assay shows that both R5 and X4 gp120 can be detected on the surface of 
TR146, FaDu and A431 cells, demonstrating direct binding of infectious virus to oral and 
vaginal epithelial cells. With regard to the oral epithelial cell lines, FaDu cells appeared to 
capture both R5 and X4 virus more efficiently than TR146 cells: 27-32% versus 4-7%, 
respectively. Notably, A431 vaginal cells exhibited similar (low level) HIV-1 binding ability 
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as TR146 cells (2-7%). It should be noted that X4 virus can be detected to a slightly 
higher degree than R5 virus on the surface of all three epithelial cell lines despite the 
MOI prior to incubation being estimated to be equivalent. However, these differences are 
marginal. Interestingly, in the case of the positive control susceptible TZM-bl cells, R5 




Figure 4-2: Detection of net immobilized gp120 on the cell surface by flow cytometry using 
a Cy5-labeled secondary to detect the human monoclonal antibody against HIV-1 gp120 
F425 B4e8. Percentages are calculated by subtracting the Cy5 percentage for HIV untreated and 
antibody stained cells from the percent of cells shifted towards higher Cy5 fluorescence for HIV 
treated cells. The graph represents an average of 2-3 experiments. 
 
To determine the reproducibility of the findings, data were repeated using a 
second gp120 primary monoclonal antibody (F425 A1g8; ARRRP no.7624). The data are 
presented in Figure 4.3 and reveals a globally similar percent HIV-1 binding profile as 
F425 B4e8 antibody (Fig 4.2). However, differences were observed between the two 
antibodies, which might be because F425 A1g8 recognises a different epitope on gp120 
than F425 B4e8. First, HIV-1 YU2 R5 exhibits slighter higher binding to FaDu cells than 
HIV-1 LAI X4 (although this is a singleton data point) and, second, both R5 and X4 virus 
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Figure 4-3: Detection of net immobilized gp120 on the cell surface by flow cytometry using 
a Cy5-labeled secondary to detect the human monoclonal antibody against HIV-1 gp120 
F425 A1g8. Percentages are calculated by subtracting the Cy5 percentage for stained, untreated 
cells from the percent of cells shifted towards Cy5 for HIV treated cells minus the.  The graph 
represents an average of 1-3 experiments.        Represents singleton data point. 
 
In conclusion, the flow cytometry data indicates that there is generally low level 
HIV-1 binding to oral and vaginal epithelial cells. However, both R5 and X4 virus appear 
to bind pharyngeal epithelial cells (FaDu) more efficiently than buccal epithelial cells 
(TR146). 
 
4.3.2 HIV-1 binding to oral and vaginal epithelial cells is partially trypsin sensitive 
Since HIV-1 was capable of binding to epithelial cells, we wished to determine 
the nature of the interaction further. Trypsin treatment could provide information on 
whether the interaction between gp120 and epithelial cells was mediated by a trypsin-
sensitive protein moiety or a non-protein surface moiety such as GalCer or the N-linked 
glycans (accounting for half the molecular mass of gp120 according (Allan et al., 1985).  
TZM-bl, TR146 and FaDu cells were infected with either YU2 (R5) or LAI (X4) 
virus at an MOI of 5 overnight at 4C. Cells were then treated with trypsin-EDTA for 5 
min at 37C before being blocked in PBS/10% BSA at room temperature. Any remaining 
HIV-1 bound to epithelial cells was detected using the HIV-1 gp120 monoclonal antibody 
F425 B4e8 by flow cytometry as described above (see Chapter 2 , section 2.1.7.1 for full 
details). These experiments were performed on three separate occasions using two 
batches of F425 B4e8 antibody. Both batches provided similar data and a representative 
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Trypsin treatment of virally exposed cells greatly reduced the ability to detect 
gp120 on all epithelial cell types as well as TZM-bl positive control cells. With TR146 
cells, HIV-1 R5 binding was reduced by 78% after trypsin treatment, whereas HIV-1 X4 
binding was more resistant and was only reduced by 32%. Notably, R5 binding was 
almost abolished in FaDu cells (greater than 95%) whereas X4 binding was reduced by 
70%. Vaginal A431 cells demonstrated similar data to the oral TR146 cell line, with 75% 
reduction in R5 binding and only 15% reduction in X4 binding. Finally, the susceptible 
control TZM-bl reporter cells demonstrated 71% reduction in both R5 binding and X4 
binding (62% to 12%) but notably over 10% of the originally detected virus remains 
detectible on surface of TZM-bl cells. 
 
 
Figure 4-4: Reduction of detection of gp120 on the surface of virally exposed epithelial 
lines, treated with trypsin (versus untreated), by flow cytometry using a Cy5-labeled 
secondary to detect the human monoclonal antibody against HIV-1 gp120 F425 B4e8. Top 
panel represents percent positive versus secondary alone stained cells and trypsin treated 
exposed cells versus secondary alone, trypsin treated cells. The bottom panel percentage 
reductions are calculated by subtracting the Cy5 secondary alone stained virally exposed cells 
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one representative experiment of 3 independent experiments with a new batch of anti-gp120 
antibody (compared to Figures 4-1 to 4-3). R5: YU2-R5 virus. X4: LAI-X4 virus.  
 
4.3.3 Detection of HIV-1 p24 on virally exposed epithelial samples  
The flow cytometry data demonstrated that HIV-1 R5 and X4 virus was able to 
bind oral and vaginal epithelial cells. We wished to verify this data so a second assay 
was developed to detect the presence of the HIV-1 capsid protein p24 on the surface of 
epithelium after virus binding by Western blot.  
In this experiment epithelial cells were exposed to HIV-1 R5 (YU2) and X4 (LAI) 
viruses for 24 h at 37oC (Chapter 2, section 2.1.8.1 for Western Blot for binding protocol). 
The exposed cells were washed extensively with PBS and lysed for protein extraction. 
Samples were analysed by Western blot by probing for HIV capsid p24 Gag monoclonal 
(Simon et al., 1997). 
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Figure 4-5: Western blot for p24 HIV-1 nucleocapsid using Gag monoclonal on epithelial 
virally exposed protein lysates. Top panel from Kohli et al 2012 (submitted manuscripts) 
performed by Arinder Kohli where TZM-bl is a positive control for virus binding. C represents 
untreated cell control. R5: YU2-R5, X4: LAI-X4. Bottom panel is own repeat. Antibody detects 
major band at 24kD indicated by arrow. 
  HIV-1 p24 capsid can be detected on or in the surface of FaDu, TR146 and A431 
cells (Figure 4.4). Cells exposed to both viral trophisms tested positive for p24. Given 
that the stock concentrations of the viruses varied, a concerted effort was made to infect 
the epithelial cells with the same MOI across the viral subtypes. However, despite this, it 
is possible that the differences in intensity of p24 detection may be due to slight 
differences in virus MOI.   
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4.4 Discussion:  
The objective of this chapter was to determine whether HIV-1  binds to oral and 
vaginal epithelial cell lines. To achieve this, two separate assays were developed to 
monitor HIV-1 presence on the surface of epithelium. The first assay detected surface 
HIV-1 gp120 on epithelial cell lines using two human monoclonal antibodies by flow 
cytometry and the second assay detected the presence of the capsid p24 by Western 
blot. The data conclusively demonstrates that HIV-1 R5 and X4 trophic viruses are able 
to directly bind oral and vaginal epithelial cells. 
First, flow cytometry was utilised to detect HIV-1 bound to the surface of epithelial 
cells using two monoclonal antibodies: F425-B4e8 and F425-A1g8. F425-B4e8 was 
isolated from an HIV-1-infected individual (Bell et al., 2008) and recognizes the crown/tip 
of V3 variable loop on the gp120 subunit (via IleP309 and ArgP315). This region is critical 
for viral infectivity of permissive cells (Bell et al., 2008) and F425-B4e8 has been shown 
to be broadly neutralizing for HIV-1: of 40 primary HIV-1 isolates, F425-B4e8 neutralized 
half of clade B (n=16), one clade C (n=11) and one third of clade D (n=6) viruses 
(Pantophlet et al., 2007).  The origin or epitope binding region of the second antibody, 
F425-A1g8, is unknown and no information was present on the NIH AIDS Reagent data 
sheet or in the PubMed database. However, its nomenclature implies that this antibody 
was probably isolated from the same study that isolated F425-B4e8 (Bell et al., 2008). 
F425-A1g8 is unlikely to be neutralizing since it is not reported in the literature. 
Data with both antibodies suggest that R5 and X4 viruses bind to all epithelial cell 
types (Figs 4.2 and 4.3). However, using F425-B4e8, more HIV-YU2 (R5-trophic) virus 
(~60%) bound to the susceptible TZM-bl cells (positive control) compared with HIV- LAI 
(X4-trophic) (~23%), despite there being higher surface expression of CXCR4 on the 
surface of these cells (Chapter 3). This large difference in R5 versus X4 binding was not 
observed using the F425-A1g8 monoclonal antibody (both bound ~60%). This suggests 
that the epitopes detected in the V3 loop region of gp120 by F425-B4e8 and F425-A1g8 
are different, with the F425-B4e8 epitope being partially obscured when X4 binds to 
CD4/CXCR4 on TZM-bl cells and the F425-A1g8 epitope remaining available for binding. 
Importantly, given that this difference in R5 and X4 binding with F425-B4e8 is not 
observed with TR146, FaDu or A431 cells, this indicates that X4 (and probably R5 virus) 
binding to epithelial cells utilises gp120 regions that are different to those regions used to 
bind permissive cells. 
The F425-B4e8 antibody (and F425-A1g8) used in flow cytometry has a 
significant amount of background staining that is non-specific to HIV gp120 on the 
epithelial cell lines as shown in Figure 4.1 in the second column from the left where cells 
are primary and secondary stained for gp120 with no HIV. Given that the antibody 
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showed high background staining in flow cytometry and by ELISA (data not shown), the 
data must be interpreted with caution. Perhaps future experiments could explore further 
methods of blocking prior to antibody staining such as using purified human polyclonal Ig 
or inactivated human serum. Furthermore, additional antibodies could be tested that 
could provide a reduced level of non-specific fluorescence. Antibodies not directed 
against the V3 loop of gp120 should be tested.  Only using antibodies directed to this 
epitope, that is masked until after CD4 binding (Checkley et al., 2011), may only allow 
the detection of a gp120 subset in a specific conformation open conformation.  As far as 
we are aware, the conformation of gp120 in complex with all alternate receptors is not 
known and we cannot be certain that we are detecting all the gp120 on the epithelial 
surface. Furthermore, gp120 and p24 can be shed by infected cells (to the viral 
supernatant) and may not be part of whole virus particles, therefor some of what we 
observe may be just these two proteins (not associated with infectious virions). Ideally, 
electron microscopy would be used to visualise virus particles in contact with epithelium. 
This would also allow one to distinguish internalised versus external particles. 
The flow cytometry R5 and X4 virus binding data was supported by Western blot 
data demonstrating detection of the p24 nucleocapsid after exposure of HIV-1 to 
epithelial cells. However, unlike the flow cytometry data, Western blots are not 
quantitative and only provide a qualitative measure of R5 and X4 binding to epithelial 
cells i.e. differences in binding capacity are not reliably revealed. Irrespective, both 
qualitative (Western) and quantitative (flow cytometry) approaches demonstrate that R5 
and X4 virus bind oral and vaginal epithelial cells. 
The quantitative flow cytometry data suggest that R5 and X4 virus are able to 
bind pharyngeal (FaDu) cells (~30%) better than buccal (TR146) and vaginal (A431) 
cells (~5%) (Fig 4.2 and 4.3). This was an unexpected finding but the trypsin digest 
experiments potentially provide some explanation into the nature of HIV-1 binding to the 
different epithelial cell types (Fig. 4.4). First, that HIV-1 binds to epithelial cells in both a 
trypsin-sensitive and -insensitive manner, suggesting that virus binding is mediated by 
protein and non-protein moieties. Second, the predominant mechanism of R5 binding is 
protein-mediated (since binding is reduced by at least 75% for all epithelial cell types and 
abolished in FaDu cells after trypsin treatment) and the predominant mechanism of X4 
binding is non-protein mediated (since binding is generally more resistant to trypsin 
treatment, except for FaDu cells). Indeed, the majority of X4 binding to buccal and 
vaginal cells appears to be mediated via non-protein moieties or is internalized and 
detected. Fourth, intriguingly, that the mechanism of binding of HIV-1 to buccal and 
vaginal cells appears more similar than that between buccal and pharyngeal cells (both 
oral), in terms of trypsin sensitivity for R5 virus and trypsin resistance for X4 virus. One 
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could argue that if R5 and X4 virus utilised the same surface moieties to bind buccal, 
pharyngeal and vaginal epithelial cells, then an equal level of sensitivity to trypsin 
treatment should have been observed. Since this was not the case, it is possible that 
HIV-1 R5 and X4 utilise predominantly non-protein moieties (such as GalCer or 
carbohydrate/lectin-based molecules (Alfsen and Bomsel, 2002)) to bind to pharyngeal 
cells but protein moieties (such as HSPGs (Alfsen et al., 2005) or ICAM-1 (Paquette et 
al., 1998)) to bind to buccal and vaginal epithelial cells. However, this hypothesis would 
need to be fully explored by receptor blocking experiments using monclonals against 
GalCer, HSPGs (or heparanitase to remove HSPGs) and ICAM-1, then exposing the 
epithelium to HIV, washing and then detecting gp120 by flow cytometry. This could aid in 
identifying the surface moiety responsible for HIV interaction with epithelial lines. 
Given the low density of envelope spikes on the surface of HIV-1, perhaps the 
detection of gp120 data post tryspinisation could be noise or reflects a conformational 
change that is caused by trypsing treatment in either gp120 or another protein in the 
epithelial membrane. 
A search of the literature indicates that our flow cytometry approach to evaluate 
HIV-1 binding to the surface of epithelium appears relatively unique. Therefore, our data 
must be put into context with similar studies investigating the interaction of epithelium 
with HIV-1 using other methods. Kage et al. (1998) showed by light microscopy that 
microparticles coated with gp120 were taken up by primary gingival epithelium, 
suggesting a binding and internalization mechanism. Our method on the other hand 
directly visualizes the virus particles using gp120 envelope protein as a marker on the 
epithelial surface since we do not permeabilize the cells prior to flow cytometry. Thus, 
the two studies show different processes. Other studies use p24 ELISA of protein extract 
samples (Saidi 2007, Alfsen 2005) in order to detect virus binding, but the ELISA method 
does not distinguish between surface viral binding or degradation of the virus after 
internalization and digestion. Finally, Nittayananta, et al (2009) used confocal 
microscopy of fluorescently labeled HIV-1 particles on differentiated oral epithelial 
models and observed that the majority of virus particles bound to the apical surface of 
the epithelial tissue with a few particles transcytosing, suggesting HIV-1 binding and 
potential transmigration across the epithelium. Although we did not utilize reconstituted 
multi-layer epithelial models, our approach detecting gp120 on epithelial monolayers also 
demonstrates evidence of HIV-1 binding to the surface of oral and vaginal epithelial cells.  
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4.5  Conclusion  
The aim of this chapter was to determine whether HIV-1 binds to oral and vaginal 
epithelial lines. To achieve this we developed a flow cytometry assay with two separate 
monoclonal antibodies to detect surface bound gp120 and a Western blot assay 
detecting p24 capsid. Both approaches demonstrated direct (but low level) binding of 
HIV-1 R5 and X4 to oral and vaginal epithelial cell lines. Trypsin digest experiments 
revealed that the predominant binding mechanism of R5 virus to all epithelial cell types 
and for X4 virus to pharyngeal epithelial cells is via protein moieties, whereas the 
predominant binding mechanism of X4 virus to buccal (TR146) and vaginal (A431) 
epithelial cells is via non-protein moieties. However, it should be noted that HIV-1 binding 
to epithelial cells may be via protein moieties that are trypsin-insensitive. The direct 
interaction between HIV-1 and epithelial cells raises the possibility that HIV-1 may be 
internalized and its genome integrated into the epithelial DNA to support productive viral 
infection. This was addressed in Chapter 5. 
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Chapter 5 HIV integration 
5.1 Introduction 
In chapter 3, we demonstrated that oral and vaginal epithelial cell lines do not or 
very poorly express CD4, CCR5 and CXCR4 on the cell surface but, rather, they express 
non-canonical HIV-1 receptors including GalCer and HSPG’s. Chapter 4 demonstrated 
that R5 and X4 virus are capable of binding to both epithelial cell types. Therefore, we 
hypothesised that HIV-1 binding may result in viral uptake and integration of the viral 
genome into epithelial cell DNA, potentially establishing a productive viral infection. This 
chapter investigates whether R5 and X4 virus integrates into oral and vaginal epithelial 
DNA.  
HIV-1 integration was chosen as the step to monitor in order to monitor whether 
epithelial cells are productively infected. When HIV-1 infects a cell, the virus must enter 
the cell either by fusing with the plasma membrane through interaction with CD4 and its 
co-receptors (reviewed in (Checkley et al., 2011) and (Turner and Summers, 1999)) or 
alternate non-canonical receptors  (Alfsen et al., 2005; Vacharaksa et al., 2008), or by 
internalisation via the endocytic pathway (Miyauchi et al., 2009). The virus then uncoats 
and a viral reverse transcriptase transcribes the plus stranded RNA to double stranded 
DNA in multiple steps classified as early, intermediate and late events that can be 
monitored by PCR (Mbisa et al., 2009). Not every reverse transcription event leads to 
integration and dead end products of linear or circular viral DNAs 1-LTR and 2-LTR-
circle products may be created (Mbisa et al 2009). Integration occurs at the end of the 
early phase of HIV-1 infection (Turner and Summers, 1999) and once a host cell has an 
integrated copy of the viral genome its DNA coding material has been altered 
permanently. This final step of viral genome integration into the epithelial cell DNA was, 
therefore, chosen to assess HIV-1 infection. 
In the literature, many published papers use the method described by Brussel et al. 
(Brussel and Sonigo, 2003, 2004) to show HIV-1 integration in human cells (Garvey et 
al., 2008; Goffinet et al., 2007; Nishimura et al., 2009; Vacharaksa et al., 2008). This is a 
two-step nested PCR method where repetitive Alu sequences in the human genome are 
utilized to enrich for integrated HIV-1 LTR sequences in cellular DNA, followed by an 
HIV-1 specific second round of amplification, yielding a measure of HIV-1 integration 
(Brussel and Sonigo, 2003).  
The only directly relevant study to our own work was performed by Vacharaksa et 
al (2008) who used the Brussel et al method (2003) to show that HIV-1 may directly 
integrate into the genome of the OKF6/TERT-2 (floor of mouth) oral epithelial cell line 
without establishing a productive infection. However, it is hard to understand why a 
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provirus that is efficiently integrated in the cellular chromosome is unable to drive viral 
gene expression and subsequently a productive infection. It appears that rather than 
DNAse-treating their virus stocks to remove plasmid/non-integrated HIV-1 DNA 
contamination (as in Brussel et al 2003, 2004), Vacharaksa et al (2008) instead 
performed nuclear extraction of cellular DNA to eliminate possible contamination from 
virus producer cells and plasmid. To our knowledge, this is the only study to use this 
method to eliminate viral DNA contamination. Using this approach, Vacharaksa et al 
(2008) showed that after 3-72 h incubation of OKF6/TERT-2 cells with the virus, 
integrated HIV-1 LTR was detected by visualising an amplicon using agarose gel 
electrophoresis. Using the same protocol, the authors also showed that viral integration 
was stable for three subcultures of the OKF6/TERT-2 cells (Vacharaksa et al 2008).  
Other studies have claimed productive viral infection of epithelial cells by 
reporting p24 accumulation in epithelial culture medium (Han et al., 2000; Liu et al., 
2003; Pang et al., 2000) or by demonstrating that trypsin-treated epithelial cells can 
transfer infectious virus to permissive cells (Giacaman et al., 2008; Vacharaksa et al., 
2008). However, in Chapter 4 we found that trypsin treatment does not remove all virus 
from the epithelial cell surface and that p24 can be detected on the epithelial cell surface 
after viral exposure. Therefore, the claims of the above studies may not be the result of 
productive viral infection from within the epithelial cell but simply HIV-1 that remains 
bound on the epithelial surface during initial exposure. 
For this study, we first utilised the Brussel method (2003, 2004) to investigate 
HIV-1 integration into epithelial cell DNA. However, this did not yield perfectly additive 
fluorescence curves for the two-step Alu-LTR HIV-1 PCR with increasing integrated 
copies at increasing numbers of infected cells. Therefore, we modified and optimized the 
protocol, with an unchanged first round enrichment followed by second amplification step 
performed using reagents and cycling times for qPCR. However, the final amplicon 
products were detected by agarose gel electrophoresis as in Vacharaksa et al. (2008) 
(Chapter 2, section 2.7.1). Irrespective of our optimising protocols, we still found that this 
two-step Alu-LTR PCR method to determine HIV-1 integration was liable to 
contamination by plasmid/non-integrated viral DNA. Therefore, the Brussel method was 
abandoned and replaced with a more reproducible and specific primer-probe qPCR 
design method (Chapter 2, section 2.7.2), which was adopted for this study. We also 
tried to produce infectious HIV from the epithelial lines but despite 5-10% transfection 
efficiency with GFP plasmid of A431 and TR146, we were unable to make any 
measurable titre virus using an infectious  virus vector system (data not shown) which is 
consistent with the cells not being able to harbour productive infection.  
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The main aim of this chapter was to determine whether positive integration 
occurred in buccal oral epithelial cells (TR146) and to verify this data in oro-pharyngeal 
(FaDu) and vaginal (A431) epithelial cells. However, after extensive investigation we 
found no evidence of HIV-1 integration in oral, oro-pharyngeal or vaginal epithelial lines. 
5.2 Methods 
Methods are as detailed in Chapter 2, section 2.7.1, for the Alu-LTR-based 
nested-PCR assay. Briefly, HIV-1 (either DNAse treated virus stocks or not) exposed 
epithelial cells were lysed for DNA and were used in first round PCR to amplify Alu-LTR 
sequences. Then an aliquot of these “enriched” products was used for the second round 
of amplification within the HIV-LTR. 
Methods for the definitive primer-probe assay for HIV-1 integration are detailed in 
Chapter 2, section 2.7.2. Briefly, virus stocks were DNAse-treated prior to infection of 
epithelial cells and compared with matched heat-inactivated viruses from the same 
stocks. Using a primer-probe assay, epithelial cell lines were tested after 48 h incubation 
with HIV-1 R5 and X4 to allow sufficient time for infection to occur. After thorough 
washing, cellular DNA samples were isolated and DpnI treated to eliminated plasmid 
DNA contamination prior to PCR amplification with a specific primer probe design. 
Table 5-1: Recommendations for optimising qPCR methods 
1. Use previously described primers for a given gene, using established conditions, but this 
may need optimization. 
2. Use an on-line tool for primer design such as OligoArchitect™ (Sigma-aldrich). Contact 
Sigma-aldrich (UK specialist Dr Tania Nolan) and/or attend a workshop or course on 
primer design and qPCR.  Refer to Nolan et al (2006). 
3. BLAST search the primers to ensure they will not amplify other undesired products.  
4. Avoid runs of nucleotides of more than 4 bp long.  
5. Design primers 19-22bp in length that are approximately equal in GC versus AT content. 
Using a 3’ GC-clamp (3-4 G and/or Cs) will promote primer binding to the template. 
6. Be aware of intron-exon boundaries and splice variants of amplified gene of interest. 
7. Verify that the primers amplify the predicted length amplicon around 100-200bp (not 
several bands) in a conventional PCR reaction. The ideal size is about 150 bp. 
8. Choose an appropriate detection chemistry for your purpose: Sybr green can be easy 
since it is incorporated into the amplification product (and the assays are inexpensive) but 
a primer-probe design can be more specific to your template of interest. 
9. If no amplicon is detected, reduce or increase the annealing temperature, vary the 
elongation temperature or the fluorescence acquisition read temperature. Also optimize 
MgCl2 concentrations and primer concentrations 
10. If many peaks are observed for fluorescence alter Sybr cycling conditions.. 
11. Use known amount of template in a duplicate or triplicate dilution series to verify that the 
Ct (at log phase) increases with greater DNA concentration (especially important if trying 
to quantify gene of interest).  
12. Ensure the template is of high quality (e.g. not degraded). 
13. The goal is to have a PCR reaction where the baseline is flat, the threshold is set in the 
log portion of the amplification curve, and that the curves of increasing DNA concentration 
are parallel in log phase. Plot Ct versus quantity and a linear curve should be obtained of 
the form y= mx+b.  Ensure the slope of curve (m) is close to -3 to -3.9 and that r
2
 is close 
to 1.  
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5.3 Results 
5.3.1 Integrated  HIV-1 detection by Alu-LTR-based nested-PCR assay 
Brussel et al (2003) described a method to detect integrated HIV-1 in human cells 
whereby two outward facing Alu-sequence specific primers are included with an HIV-1 
LTR DNA specific primer (Figure 5.1a, R region) in the first round PCR for twelve cycles. 
Alu sequences are widespread throughout the human genome with an average distance 
between elements of approximately 4 kb (Britten et al., 1988). Since the viral integration 
event can occur anywhere in the epithelial genome, it is likely to be in close proximity to 
an Alu sequence, hence these repetitive sequences are used to enrich for HIV-1 
integration into human DNA in the first round of PCR. The second PCR step is nested, 
using HIV-1-specific sequences with primers targeting Lambda T and another HIV-1 LTR 
specific primer (Figure 5.1b, U5 region) for 24 cycles. This generates a small product 
that can be used to determine HIV-1 integration (Brussel and Sonigo, 2003, 2004). 
 
 
Figure 5-1: Integrated HIV-1 detection by Alu-LTR-based on a two step nested-PCR assay 
design (taken from Brussel et al 2004).  Host DNA is enriched using two outward facing primers 
complimentary to human Alu sequences in conjunction with HIV-1 LTR specific primer, L-M667. 
The second round is a nested PCR that specifically amplifies HIV-1 specific sequences from 
Lambda T to U5 within the LTR region. The limit of detection is 10 copies per sample (Brussel et 
al 2003). 
This assay was initially utilized to detect integrated HIV-1 in oral and vaginal 
epithelial cell lines (Figure 5.2). TZM-bl cells were not used for this assay since these 
cells test positive for integrated HIV-1 (our observation in Figure 5.3b). This is because 
they were constructed to express β-galactosidase under the control of the HIV-1 LTR 
(Wu X. et al., unpublished data (Derdeyn et al., 2000). Therefore, PM-1 cells were used 
as a positive control for infection. Initially, virus stocks were not DNAse-treated since we 
generated stocks by propagating the virus through susceptible suspension cells. 
a) 
b) 
Human  Human DNA 
HIV DNA 
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Mistakenly, we assumed that the ability of virus producer cells to contaminate the PCR 
with their integrated HIV-1 DNA would not be an issue after extensive washing of the 
virally exposed epithelial cells prior to DNA extraction. Figure 5.2 shows a representative 
result with HIV-1 exposed epithelial lines from this experiment. The TR146 and FaDu 
cells appear to have integrated copies of HIV-1 when exposed to R5 (YU2) and X4 (LAI) 




 round integrated PCR detection for epithelial lines exposed to HIV-1 using 
the Alu-LTR primers (Brussel et al 2003, 2004). R5 is YU2, X4 is LAI. C refers to an untreated 
cell control. +ve: 8E5/LAV CEM-derived human T-cells, containing a single integrated copy of the 
HIV genome per cell. –ve: no-template control. Ladder, far right. From Kohli et al 2012, submitted. 
 
 Given that these initial studies appeared to demonstrate that HIV-1 was able to 
integrate into the epithelial cell DNA, we attempted to confirm and qualify the data 
further. First, we investigated whether viral integration was dependent on the presence of 
the envelope protein by using an envelope-deficient virus (HIV-gpt) or this same virus 
complemented with gp160 of YU2 (Chapter 2, section 2.1.3.1) . Second, we determined 
whether viral integration could be inhibited by reverse transcriptase (AZT) or integrase 
inhibitor (118-D-24 or 4-[3-(azidomethyl)phenyl]-2-hydroxy-4-oxo-2-butenoic acid). Both 
drugs should prevent HIV-1 integration and were used as negative controls. Finally, we 
investigated whether incubation of epithelial cells with small amounts of plasmid HIV-1 
molecular clone DNA resulted in detection of integration. The data from these additional 
studies demonstrated fundamental flaws in the reliability and consistency of this assay 
system, which can be observed when analysing the Alu-LTR 2nd round PCR amplification 
data for A431, FaDu and TR146 cells in Figure 5.3. 
For example, in Figure 5.3A and B, A431 YU2 (R5) incubated with AZT treatement 
(lane 5) or integrase inhibitor (lane 8) tested positive for viral integration while LAI (X4) 
tested negative (lanes 6 and 9 respectively). Similar confusing data is shown for FaDu 
cells, YU2-AZT tests positive (A, lane16) and LAI incubated with integrase inhibitor tests 
positive for integration (B, lane 20). For TR146 the data is equally confounding: they test 
positive for integration with YU2 in the presence of AZT (Fig. 5.3B, lane 31). For all 
these, one would expect no integration events in the presence of AZT or integrase 
inhibitor if integration was due to virus infection of the cells. In addition, data were 
inconsistent as demonstrated by positive integration events for LAI virus in TR146 and 
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FaDu cells in Fig 5.2 but no detectable integration for LAI in either cell type in Fig 5.3 
(lanes 15 and 30). Finally, the addition of 1 ng viral plasmid DNA alone, followed by 
extensive washing, also resulted in erroneous detection of positive integration events 
(contamination) in TR146, FaDu and A431 cells (lanes 10, 21, 34). Together, these 
experiments demonstrate that the positive integration events we observed are very likely 
due to contaminating plasmid rather than viable virus infecting and integrating its 
genome into the epithelial DNA. We determined that the reason for this was the lack of 
DNAse treatment of our original virus stocks. Finally, it should be noted that the use of 
TZM-bl cells in this experiment as a positive control was inappropriate since, due to their 
construction, they always test positive for integrated HIV-1, an error identified post-
experiment (see untreated, lane 26). 
  





Figure 5-3:  Detection of integrated HIV-1 DNA in TR146, FaDu and A431 epithelial cells 
using Alu-LTR PCR. Cells were grown in monolayers, exposed to the described conditions and 
genomic DNA isolated.  A two-step nested PCR was performed using primers and protocols 
described by Brussel et al (2003, 2004) and the second round of PCR amplification is shown.  
HIV-gpt with no gp160, HIV-gpt complemented HIV-gpt with YU2 envelope, YU2 (R5) HIV-1,  LAI 
(X4) HIV-1, pre-incubation with AZT followed by YU2, pre-incubation with AZT followed by LAI, 
pre-incubation with integrase inhibitor, pre-incubation with integrase inhibitor and YU2, pre-
incubation with integrase inhibitor and LAI, no virus but only 1 ng plasmid DNA. 
 
 Given the apparent importance of DNAse treatment for assessing integration of 
HIV-1 DNA, we decided to DNAse treat the virus stocks prior to experimentation to 
determine whether this treatment would be sufficient to remove the false positive data 
and to provide reproducibility to the Brussel assay (Brussel and Sonigo, 2003). On this 
occasion, we used susceptible PM-1 cells rather than TZM-bl cells as a positive control. 
Additionally, we only performed the experiment with LAI (X4) (as a representative virus) 
since large quantities of high-titre YU2 (R5) stocks were difficult to produce. PM-1 cells 
20  21  22  23   24   25        26  27   28  29  30        31   32  33  34  35 36 37 38 
1     2    3     4    5     6     7     8    9   10   11   12  13   14  15  16  17   18  19 
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were exposed to (i) LAI (X4) with and without DNAse treatment and (ii) different 
concentrations of plasmid DNA (1 ng and 1 g) with and without DNAse treatment, and 
integration events determined. Figure 5.4 shows the 2nd round PCR amplification data for 
the Alu-LTR assay (Brussel et al 2003, 2004). PM-1 cells incubated with LAI (X4) after 
two types of DNAse treatment (DNAse with and without its own buffer) did not appear to 
have integrated HIV-1 DNA (lanes 1 and 2), whereas untreated (no DNase) virally 
exposed PM-1 cells tested positive (lanes 3). The former data set was not expected as 
the DNase-treated LAI (X4), being a viable whole virus, should integrate into the dual 
trophic permissive PM-1 cells. Notably, PM-1 cells exposed to 1 ng or 1 μg of plasmid 
DNA tested positive for integration only when not DNase-treated (lanes 4 and 5 versus 
6). It should be noted that a very faint amplification product was observed for 1 μg of 
plasmid DNA after DNAse treatment (lane 7) but this probably reflects the presence of 
insufficient amount of DNase to remove all the plasmid. Thus, these data demonstrate 
that the Brussel assay as we carried it out appears exquisitely sensitive to plasmid 
contamination and that DNase treatment is essential to prevent false positive integration 
events. However, it also highlights a lack of confidence in this assay since the DNase-
treated LAI (X4) should integrate into the permissive PM-1 cells. 
 
Figure 5-4: Second round integrated Alu-LTR PCR for HIV-1 integration with PM-1 cells 
incubated under various conditions. For brief methods see legend to Figure 5.3.  LAI X4 virus 
DNAse treated with or without its own buffer, untreated LAI, PM-1 cells exposed to 1 ng or 1 g 
plasmid DNA with and without DNase treatment, and untreated cells. Also included in controls are 
1
st
 round PCR no template control, 1 ng or 1 g plasmid DNA, and a no template control for the 
2
nd
 round PCR. 
 
To confirm our hypothesis, we additionally analysed the amplicon product amplified 
from the first round of PCR (Figure 5.5.). It was clear that the first round enriching step 
150bp 
1       2     3       4     5      6      7     8      9    10    11    12   
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was amplifying plasmid DNA at both the 1 ng level (showing amplification of a specific 
150 bp LTR region) -second lane from right and more so at the 1 μg level, where it 
appears the whole circular plasmid has been amplified (top of gel-far right lane). In 
summary, these investigations indicated that the Brussel assay was susceptible to 
providing false positive data for viral integration as a result of plasmid contamination that 
could not confidently be resolved solely by DNAse treatment. Therefore, we abandoned 
this PCR assay in search of a more precise and reliable assay based on quantitative 
PCR. 
 
Figure 5-5: First round Alu-LTR PCR of PM-1 samples. For brief methods see legend to Figure 
5.3. LAI X4 virus DNAse treated with or without its own buffer, untreated LAI, PM-1 cells exposed 
to 1 ng or 1 g plasmid DNA with and without DNase treatment, and untreated cells.  Controls are 
1 ng or 1 g plasmid DNA. 
 
5.3.2  Primer-probe assay for HIV-1 integration 
The assay described by Brussel et al (2003, 2004), which has been used in many 
published papers including Vacharaksa et al (2008), proved to be unreliable in our 
hands. Therefore, we searched for a different approach to investigate HIV-1 integration 
into epithelial cell DNA and subsequently found an elegant protocol described by Mbisa 
et al (2009) using qPCR. In this protocol, the forward primer binds to the U5 region of the 
150bp 
whole circular plasmid 
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HIV-1 LTR, the reverse primer binds to the Alu repeat sequence in the host genome, and 
the internal FAM-TAMRA labeled probe binds in between these regions (but also binds 
the U5 region of the HIV-1 LTR) (Figure 5.6). The specific utilisation of the U5 specific 
FAM-TAMRA probe also adds specificity to qPCR assay. During PCR, this assay 
amplifies the majority of the HIV-1 LTR together with some host genomic material, and a 
PCR product can only be amplified if the HIV-1 LTR has integrated into the host genome. 
In qPCR the DNA polymerase adds nucleotides to the primers and when it reaches 
the region bound by the probe in the annealing phase of the PCR cycle, the probe is 
displaced and degraded by the polymerase’s exonuclease activity. Probe degradation 
leads to the separation of the fluorescent label (FAM) from its quencher (TAMRA), 
allowing the fluorescence to be emitted and recorded by the qPCR machine’s detector 
(Mbisa et al 2009). Since the goal of the assay was solely to ascertain whether or not the 
epithelial lines comprised an integrated copy of HIV-1, it was deemed unnecessary to 
make the standard curve for quantitative assessment of the number of integrated copies 
as described in Mbisa (et al 2009). 
 
Figure 5-6: Primer-probe qPCR assay for detection of integrated HIV-1 DNA. Protocol 
adapted from Mbisa et al  (2009). Reverse primer for Alu region was used in conjunction with an 
HIV-1 LTR, U5 specific primer, and U5 specific FAM-TAMRA probe. 
 
 Three major steps were taken to ensure that this assay was precise and would 
detect only positive integration events. First, to eliminate issues of contamination from 
plasmid or DNA from virus producer cells, virus stocks were treated with DNAse prior to 
incubation with epithelial lines. Second, cells were carefully but extensively washed with 
PBS after viral incubation and the isolated genomic cellular DNAs were digested with 
DpnI, which only digests methylated plasmid DNA and not epithelial cellular DNA. Lastly, 
Mbisa et al (2009) describe the use of a heat-inactivated virus control to be assayed 
alongside the test samples. Thus, the same virus stock that was DNAse treated and 
incubated with cells was heat-inactivated for 1 h for 60°C and amplified alongside the 
test sample. Heat-inactivated virus that is unable to gain entry to cells gives a 
quantitative measure of any remaining contaminating DNA in the system. In qPCR, a 
positive integration event will result in a lower Ct value (amplifies sooner) in the DNAse-
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treated virus sample when compared to the heat-inactivated virus. Absence of 
integration is demonstrated when the sample exposed to DNAse-treated virus shows a 
lack of amplification or a higher Ct (amplifies later) value than the sample exposed to 
heat-inactivated virus. 
Initially this qPCR assay was tested with PM-1 and C8166 cells, which are 
susceptible to R5 and X4 virus, respectively, and the raw data shown in Figure 5.7. 
Incubation of PM-1 cells (Figure 5.7a) with DNAse-treated YU2-R5 virus (red)  and 
plasmid DNA (blue) did not amplify an integrated product while PM-1 cells incubated with 
untreated heat-inactivated virus did amplify an integrated product (pale green). In a 
second graph from the same experiment, we investigated C8166 and PM-1 cells with X4 
virus (Fig. 5.7b). The fluorescence plot shows a product for integrated HIV-1 with the 
DNAse-treated virus in PM-1 (purple) and C8166 (blue) cells. For both cell types, the 
curve has a higher Ct value in the DNAse-treated than the heat-inactivated virus treated 
cells (green). This confirms that this qPCR assay can reliably detect integrated X4 HIV in 
control cell lines (PM-1 and C8166). However, it also suggests that the PM-1 cells may 
not be the ideal cell type to assess HIV-1 R5 integration. Thus, in future assays we 
utilized the NP2-R5 cell line (that expresses CCR5 under drug selection) as a positive 
control in assessments of HIV-1 R5 integration.  
Once the assay was established, we used the Alu-LTR primer-probe assay to 
verify whether HIV-1 YU2-R5 and LAI-X4 can integrate into TR146, FaDu and A431 
epithelial cell lines after 48 h of incubation. Initial experiments indicated that no 
integration of DNAse-treated HIV-1 was observed in the epithelial lines at an MOI of 1 
(data not shown). We then decided to increase the MOI (7.6) in order to test whether this 
would allow detection of viral integration into the epithelial genome. We initially 
performed this experiment with the YU2-R5 virus. Figure 5.8 shows the fluorescent 
traces for epithelial cell lines incubated with DNAse-treated YU2-R5, heat inactivated 
YU2-R5, and a combination of DNAse-treated and heat-inactivated YU2-R5 (the latter 
being an additional control that we expected to have a reduced signal versus the two 
former conditions). It is clear that A431 (Fig 5.8a), FaDu (Fig 5.8b) and TR146 (Fig 5.8c) 
cells exposed to DNAse-treated and heat-inactivated viruses do not amplify the 
integrated HIV-1 product. On the other hand, the control NP2-R5 susceptible cells do 
contain integrated HIV-1 because the DNAse-treated virus amplifies at approximately 30 
cycles (Fig 5.8d, beige line). In conclusion, HIV-1 YU2-R5 does not appear to integrate 
into the host genome when epithelial cells are incubated with approximately eight virus 
particles per cell.  
 
  







Figure 5-7 : Fluorescence traces for primer-probe Alu-LTR assay to detect HIV-1 
integration. (a) PM-1 cells with YU2-R5 virus MOI 1 incubated for 48 h.  Red line: DNAse treated 
YU2 on PM-1 cells. Blue line: 1 ng plasmid DNA incubated on cells. Pale green: untreated and 
heat inactivated virus incubated with cells. Peach: no template control. (b) C8166 and PM-1 cells 
with LAI-X4 virus MOI 1 for 48 h. Pale blue line: C8166 cells with DNAse treated X4. Teal line: 
C8166 untreated and heat inactivated X4. Purple line: PM-1 DNAse treated X4. Pink line: 
untreated X4 and heat inactivated PM-1. Peach line: no template control. 
 
 









Figure 5-8: Fluorescence traces for primer-probe Alu-LTR assay to detect YU2 (R5) virus 
integration. Experiments were performed at an MOI of 7.6 and assayed after 48 h incubation. (a) 





- 96 - 
heat inactivated R5. Purple: untreated cell control. (b) FaDu cells. Pink line: DNAse treated R5. 
Blue line: DNAse and heat inactivated R5. Teal line: heat inactivated R5. Peach line: untreated 
cell control. (c) TR146 cells. Green line: DNAse treated R5. Pink line: DNAse and heat inactivated 
R5.  Black line: heat inactivated R5. Pale blue line: untreated cell control. (d) NP2-R5 cells. Beige 
line: DNAse treated R5. Pale green: DNAse and heat inactivated R5. Sky blue: heat inactivated 
R5. Blue: untreated cell control. 
 
 We then proceeded to determine whether HIV-1 LAI-X4 was able to integrate into 
the genome of A431 and TR146 epithelial cells. TR146 cells were used as a 
representative cell line from the oral cavity (FaDu cells were not tested for this 
experiment). We observed a similar integration pattern with LAI-X4 as we did with YU2-
R5. The experiment was performed at two MOIs; first at an MOI of 10 (Figure 5.9 for 
epithelial DNA PCR fluorescent traces and Table 5.1) and also at an MOI of 146 (Table 
5.1:  >100). Figure 5.9a shows that an integrated product is not detected from the DNA 
of A431 cells incubated with DNAse-treated LAI-X4 (red line) while the heat-inactivated 
virus treated cellular DNA (blue), the control for contamination, does amplify. Identical 
data were obtained for TR146 cells, with only the control for DNA contamination (teal 
line: heat-inactivated virus) amplifying a product in the Alu-LTR primer-probe integrated 
HIV-1 PCR (Figure 5.9b). We next increased the MOI to >100 in order to further 
demonstrate the lack of viral integration even when virus is in excess. Again, no PCR 
product was amplified from DNA of TR146 or A431 epithelial cells exposed to DNAse-
treated virus (Table 5.1). 
In summary, the Alu-LTR primer probe assay detects integrated DNA in control 
susceptible cells lines but does not support the hypothesis that epithelial lines exposed 
to HIV-1 become infected. 
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Figure 5-9: Fluorescence traces for primer-probe Alu-LTR assay to detect LAI (X4) virus 
integration. Experiments were performed at an MOI of 10 and assayed after 48 h incubation. (a) 
A431 cells. Red line: DNAse treated X4. Pale green: DNAse treated X4 and heat inactivated. 
Dark blue: heat inactivated virus. Purple line: untreated A431. (b) TR146 cells. Pink line: DNAse 
treated virus. Teal line: heat inactivated virus. Blue line: DNAse treated and heat inactivated. 
Peach line: untreated TR146. 
 
Table 5-2: Detection of integrated HIV-1 in epithelial cell lines after 48h 
Cell line R5-YU2 (MOI:7.6) X4-LAI (MOI:10) X4-LAI (MOI  >100) 
FaDu ND Not included ND 
TR146 ND ND ND 
A431 ND ND ND 
C8166 n/a + (Ct = 32.7) + (Ct = 33.5) 
NP2-R5 + (Ct = 28.8) n/a n/a 
ND, not detected (Ct value greater than 60) 
n/a not included in experiment 
 
5.4 Discussion 
  Viral integration into the host genome is an essential step for the subsequent 
production of infectious new virions. Therefore, the objective of this chapter was to 
a) 
b) 
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determine whether HIV-1 integrates into the genome of oral and vaginal epithelial cells. 
To achieve this, a two-step PCR and primer-probe qPCR assays were developed to 
monitor HIV-1 LTR integration using an Alu-LTR detection system. Using a sensitive and 
reliable primer-probe assay for integration we find no evidence that HIV integrates into 
the epithelial genome. 
5.4.1 Two step Alu-LTR integrated HIV-1 DNA PCR 
Using the Alu-LTR primers described by Brussel et al (2004) and an agarose gel 
readout system, integrated HIV-1 DNA appeared to be detected in the epithelial genome. 
However, when this PCR assay was tested rigorously it became apparent that the assay 
was susceptible to contamination by virus producer cell DNA and plasmid DNA. This was 
confirmed when DNAse treatment of the virus abrogated the ability to detect integrated 
HIV-1 DNA. Furthermore, the addition of AZT (reverse transcriptase) and integrase 
inhibitors did not prevent detection of viral integration in the absence of DNAse 
treatment. Therefore, we pursued a modified two-step nested PCR for the detection of 
integrated HIV-1 but similar results were obtained. Taken together, the data demonstrate 
that the two PCR based assay system was unreliable and was not showing true viral 
integration events. 
Our data are in contrast to Vacharaksa et al (2008) who published data using the 
primers from this assay to show that oral epithelial OKF6/TERT-2 cells contained 
integrated HIV-1 DNA, which was stable for three generations. However, the method 
used by Vacharaksa differs from that of Brussel et al (2003, 2004). Firstly, the virus 
stocks were not treated with DNAse prior to infection of the OKF6/TERT-2 cells and, 
secondly, the DNA nuclear extracts were used to avoid contamination when testing for 
viral integration (Vacharaksa et al 2008). They showed that heat-inactivated HIV-1 (70°C 
for 3 h), AZT and Colchicine (inhibits microtubule polymerization, cytoskeletal 
rearrangement and mitosis) pretreated cells did not amplify a 150 bp product for 
integrated HIV-1, thereby concluding that HIV-1 integrates into the epithelial genome. 
However, these data are suspect as the AZT and Colchicine treated cells and no 
template control all amplified a ‘smear’ approximately the same size as the 150 bp size 
product, which should not be present. It should be emphasised that nuclear extraction 
without DNAse treatment of virus stocks may not have been sufficient to remove 
potential DNA contamination, and thus the use of nuclear extracts and heat-inactivated 
controls in the Vacharaksa et al (2008) study may not have been sufficient to prevent 
false positives for viral integration. The key experiment that these authors did not 
perform was to expose epithelial cells to different concentrations of viral plasmid, then 
nuclear extract epithelial cell DNA and perform the nested PCR to detect for viral 
integration. However, it should be noted that the differences between our study and that 
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of Vacharaksa et al (2008) might also reflect a difference in the properties of the cell 
lines used in this study (TR146, FaDu, A431) versus OKF6/TERT-2 cells. Thus, it is 
plausible that the OKF6/TERT-2 cells (floor of the mouth) are more susceptible to HIV-1 
infection and display HIV-1 integration into their genome unlike TR146, FaDu, A431 
cells. 
Given the false positive data we obtained for HIV-1 integration using the two-step 
Alu-LTR PCR assay we concluded that it would be desirable to test for HIV-1 integration 
by a more specific and reproducible assay, namely the primer-probe Alu-LTR 
quantitative PCR assay. 
5.4.2 Primer-probe Alu-LTR qPCR assay 
We first established that the primer-probe Alu-LTR quantitative PCR assay 
(Mbisa et al 2009) was reliable, specific and sensitive. This was achieved by 
incorporating three aspects to the protocol: (i) DNAse treatment of virus stocks to 
eliminate issues of contamination from plasmid or DNA from virus producer cells; (ii) 
digestion of epithelial DNA (post-infection) with DpnI, which only digests plasmid DNA 
and not epithelial DNA; and (iii) inclusion of a heat-inactivated virus control, which is 
unable to gain entry to cells and thus provides a quantitative measure of contaminating 
DNA in the system. 
The primer probe Alu-LTR assay is straightforward and does not appear to be 
susceptible to contamination by plasmid DNA when the appropriate precautions are 
taken (see above). Fluorescence is emitted only when the probe is degraded by the 
exonuclease activity of the polymerase and, therefore, the assay is specific and 
reproducible. Using this assay we found no evidence for integration of R5 or X4 HIV-1 
viruses after 48 h infection of oral (TR146, FaDu) or vaginal (A431) epithelial cells, even 
when testing high MOIs (up to 140 for X4 virus) that would be unlikely to occur during a 
natural exposure/infection episode. The only potential drawback of this assay could be 
the limit of detection. Mbisa et al used 100-500 ng of DNA per 50 l qPCR reaction while 
we used either 50 or 100 ng in a 10 l qPCR reaction, which is within the same order of 
magnitude for the reaction DNA concentration. However, if viral integration into the 
epithelial genome is a rare event and occurs at very low levels, it is possible that this 
assay may not be sensitive enough to detect the integration event.  
5.5 Conclusion 
The aim of this chapter was to determine whether HIV-1 was able to integrate 
into the genome of oral and vaginal epithelial cells.  Initially a two-step nested Alu-LTR 
PCR designed by Brussel et al (2003, 2003) was used but this assay was found to be 
unreliable and vulnerable to contamination. To eliminate contamination, we used several 
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methods including DNAse treatment of virus stocks prior to incubation with epithelium 
and DpnI treatment of extracted cellular DNA samples post-exposure to virus. By utilizing 
a more specific primer-probe qPCR assay to monitor HIV-1 integration (Mbisa et al 
2009), we found no evidence for R5 or X4 viral integration into oral or vaginal epithelial 
cells, even when the virus titre was increased to >100 virus particles per epithelial cell. 
We conclude that although studied epithelial lines appear to express HIV-1 binding 
factors (Chapter 3) and HIV-1 is able to directly bind epithelium (Chapter 4), the virus is 
unable to integrate into the epithelial genome. Therefore, it is highly unlikely that 
epithelial cells become productively infected. However, this does not exclude the 
possibility that captured virus on the surface of epithelial cells could be transferred to 
other susceptible/permissive cells that may be present in the sub-mucosa. This 
hypothesis was examined in the next chapter (Chapter 6).  
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Chapter 6 Epithelial transfer of infectious virus to susceptible 
reporter cells 
6.1 Introduction 
In previous chapters HIV-1 was shown to bind to TR146, FaDu and A431 
epithelial lines (Chapter 4) but failed to integrate into the epithelial genome (Chapter 5). 
Thus, the question arose as to whether HIV-1 remained infectious post-capture by 
epithelium and in a conformation that was transmissible to susceptible cells, permitting 
infection. Therefore, the aim of this chapter was to determine whether HIV-1 exposed 
oral, oro-pharyngeal and vaginal epithelial cells were able to transfer infectious virus to 
susceptible TZM-bl reporter cells. 
 Many studies have described the ability of oral and vaginal epithelium to transfer 
HIV-1 to susceptible, CD4 expressing, cell types (Asin et al., 2004; Asin et al., 2003; 
Bobardt et al., 2007; Bomsel, 1997; Carreno et al., 2002; Giacaman et al., 2008; Liu et 
al., 2003; Maher et al., 2005; Vacharaksa et al., 2008; Wu et al., 2003). For oral and 
pharyngeal epithelial sites only four studies appear to have been published. Liu et al 
(2003) incubated normal human oral keratinocytes (NHOK) with HIV-1 Ba-L and NL4.3, 
washed and then incubated them overnight with peripheral blood lymphocytes (PBL). 
The PBL were then washed, separated from the epithelium and grown for 11 days and 
shown to be p24 positive by ELISA and were therefore infected (Liu et al., 2003). In 
2005, Maher et al used tissue explants derived from tonsillectomies in order to study 
HIV-1 interacting with the tonsil epithelium and resident immune cells. Firstly, they 
showed HIV-1 infected H9 T lymphocytes bound to the surface of the epithelium and 
caused p24 accumulation in epithelial explants by immunohistochemistry. They also 
detected that basal epithelial cells were positive for p24, suggesting transmigration of 
HIV-1 infected cells or transcytosis of the virus across the epithelium (Maher et al., 
2005).  Using time lapse confocal microscopy they showed that HIV-1 infected 
lymphocytes migrated through the epithelium (Maher et al., 2005), thus demonstrating a 
mechanism by which transmission might occur at the pharyngeal tonsil surface. In 2008, 
Vacharaksa et al used tonsil keratinocytes from donors and OKF6/TERT-2 (TERT-2) 
cells to trans-infect peripheral blood mononuclear cells (PBMCs) after washing. In fact, 
the TERT-2 cells transferred at least five fold more HIV-1 than donor tissues as 
demonstrated by p24 ELISA of the PBMCs (Vacharaksa et al., 2008). Giacaman et al 
(2008) followed up soon after and showed that TERT-2 cells pre-stimulated with 
Porphyromonas gingivalis exhibited a greater ability to transfer HIV-1 to TZM-bl than 
unstimulated virally exposed TERT-2 cells (Giacaman et al., 2008). Thus, despite there 
being a low apparent in vivo transmission rate (Campo et al., 2006), these studies show 
that in vitro, oral and pharyngeal transmission to susceptible cells may occur. 
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Studies with female genital tract epithelium have also demonstrated its ability to 
transfer HIV-1 to susceptible cells by capturing or allowing transmigration of infectious 
virus. In the late nineties, primary PBLs from HIV-1 positive patients were shown to 
transmit virus across many epithelial lines I407 (intestinal), HT-29 (colonic), Caco-2 
(colonic), HEC-1 (endometrial) and infect mononuclear cells on the basolateral side of 
epithelial barrier (Bomsel, 1997). In 2002, Carreno et al demonstrated with HEC-1 cells 
that R5 (YU2, JRCSF, BaL) HIV-1 transcytosis was enhanced under pro-inflammatory 
conditions (Carreno et al., 2002). Furthermore, it was shown that a genital epithelial cell 
line of ectocervical origin sequestered and transmitted HIV-1 to H9 CD4 positive T cells 
or PBMC (Wu et al., 2003). Finally, the ability of HIV-1 to retain infectivity after 
transcytosis across a tight monolayer of primary genital epithelial cells (PGECs) was 
confirmed by activation of luciferase activity in TZM-bl cells by basally collected medium 
(Bobardt et al., 2007). However, there are also studies that oppose the view of HIV-1 
transmission across the mucosa, since recently HIV-1 was found not to cross the vaginal 
mucosa within 4 h using a model of a reconstituted human epithelium (Bouschbacher et 
al., 2008). 
Since there is a body of evidence that demonstrated that epithelial cells can 
transfer HIV-1 to susceptible cells, we aimed to determine whether oral (TR146), oro-
pharyngeal (FaDu) and vaginal (A431) cell lines possessed the ability to transmit HIV-1 
to susceptible cells. These cell lines were exposed to HIV-1 YU2 (R5) and LAI (X4) and 
transfer events were monitored by staining for β-galactosidase activity in the TZM-bl 
reporter cell line. Qualitatively, transfer was observed at the point of interaction between 
epithelial cells and surrounding TZM-bl reporter cells, and a similar amount of R5 and X4 
viral transfer from all three epithelial cell lines was observed. We conclude that HIV-1 is 
able to be transmitted from oral and vaginal epithelial cells to susceptible TZM-bl reporter 
cells. 
 
6.2  Methods  
The full methods are detailed in Chapter 2.11.1. Briefly, FaDu, TR146, and A431 
cells were plated at low density (50-60% confluence), exposed to 0.2 MOI HIV R5 and 
X4 overnight, and then washed thoroughly and plated in fresh medium. Freshly grown 
TZM-bl cells were then overlaid onto the HIV-1 exposed epithelial cells and incubated for 
a further 48 h. The cells were fixed, stained for β-galactosidase activity with an X-Gal 
stain and the blue colonies photographed at 200x magnification. 
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6.3  Results 
We wished to verify whether HIV-1 remained infectious while bound to the 
surface of epithelial cells. We tested this by assessing the ability of epithelial bound virus 
to trigger β-galactosidase reporter gene expression in engineered reporter cells (TZM-
bl). These HeLa derived cells expresses CXCR4 and were engineered to express CD4, 
CCR5 (Platt et al., 1998). They were further modified to incorporate reporter cassettes 
expressing luciferase and β-galactosidase under the control the HIV-1 LTR where 
expression of the reporter is triggered by the production of HIV-1 tat (Wu X. et al., 
unpublished data and (Derdeyn et al., 2000). 
All three epithelial lines were able to transfer infectious virus to TZM-bl reporter 
cells as demonstrated by the blue cells stained for β-galactosidase in Figure 6.1. TZM-bl 
cells themselves were used as a positive control to show a transmission event from one 
susceptible cell to another by overlaying unexposed TZM-bl cells onto HIV-1 exposed 
TZM-bl cells. As expected, a high number of blue colonies were observed. In stark 
contrast, the negative control comprising virally unexposed epithelial lines overlaid with 
TZM-bl cells show no blue colonies, as expected. All three epithelial cell lines (FaDu, 
TR146 and A431) were clearly able to transfer captured YU2-R5 and LAI-X4 HIV-1 to the 
TZM-bl reporter cell as demonstrated by the blue foci. However, transfer was less 
common (fewer blue foci) than for the positive TZM-bl control. Notably, there is neither 
an obvious difference in the efficiency of transmission of R5 or X4 virus nor a difference 
between the ability of the different cell lines to transmit infectious particles. One striking 
feature was the ability to observe discrete blue foci at the point of interaction between 
epithelial colonies and TZM-bl cells (Figure 6.1, black triangles). Further, the negative 
controls demonstrated that the system is not ‘leaky’ since virally unexposed epithelial 
cells were unable to induce blue foci (and thus TZM-bl β-galactosidase activation). Only 
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Figure 6-1: Transfer of captured HIV-1 from epithelial cells to permissive cells. TR146, 
FaDu, A431 and TZM-bl cells were incubated with HIV-1 R5 (YU2) and LAI (X4) virus for 24 h and 
following extensive washing, TZM-bl indicator cells were added for a further 48 h. Negative 
controls include TR146, FaDu and A431 cells without the addition of virus, plated with TZM-bl 
reporter cells. Exposed TZM-bl cells were used as a positive control to indicate transfer between 
susceptible cells. Black triangles highlight transfer events at the point of contact between 
epithelial cells and TZM-bl cells. Data are representative of three independent experiments. Light 
microscopy at 200X magnification. 
 
6.4  Discussion: 
In this chapter we determined whether HIV-1 captured by oral and vaginal 
epithelial cells was transmissible to susceptible TZM-bl reporter cells using β-
galactosidase activation as a read out mechanism. In a co-culture assay, HIV-1 was 
shown to be transmitted from oro-pharyngeal, oral, and vaginal epithelial lines to TZM-bl 
cells in a manner consistent with previous findings (Giacaman et al., 2008; Liu et al., 
2003; Maher et al., 2005; Vacharaksa et al., 2008; Wu et al., 2003). No difference in the 
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ability of the different lines to transmit virus was observed. Neither did X4 or R5 trophic 
virus appear to be favoured when passed from the epithelial lines to susceptible cells. 
Data obtained in Chapter 4 (section 4.2.1) detecting HIV-1 gp120 on the surface 
of epithelial lines indicated that pharyngeal (FaDu) cells were more efficient at binding 
HIV-1 than oral (TR146) and vaginal (A431) cells (~30% versus ~5% respectively). This 
gave rise to the possibility that more viral transfer might occur from FaDu cells as 
compared with TR146 and A431 cells, which could be crudely quantified with the TZM-bl 
transfer assay. However, there appeared to be no obvious difference between the 
epithelial cell lines in their ability to transfer virus (Figure 6.1), suggesting the efficiency 
of transfer was equal despite the increase in HIV-1 binding to FaDu cells (Chapter 4). 
 The most directly comparable study to our work is a publication by Giacaman et 
al (2008) where TERT-2 oral cells (with or without pre-stimulation with P. gingivalis) were 
exposed to HIV-1, washed, trypsinized and then plated onto a TZM-bl cell monolayer. 
However, unlike our study (Figure 6.1), control wells of TERT-2 without exposure to HIV-
1 was either not shown or not performed. Therefore, it was impossible to determine 
whether β-galactosidase activation (blue colonies) was due to HIV-1 transfer or non-
specific activation of the HIV-LTR as a result of cell-cell contact between TERT-2 and 
TZM-bl reporter cells. In addition, the authors suggested that viral transfer to TZM-bl 
originates from internalized but still infectious HIV-R5 (Giacaman et al., 2008). This 
conclusion was based on their previous work using TERT-2 cells where a short, three 
minute trypsin treatment at room temperature was used to remove virus particles from 
the epithelial surface before incubation with PBMCs (Vacharaksa et al., 2008). p24 
release from the PBMCs was then monitored by ELISA to show the transfer of infectious 
virus from the TERT-2 to the PBMCs. However, neither removal of HIV-1 from the 
epithelial surface nor the presence of internalized virus was determined by either flow 
cytometry or confocal microscopy (e.g. by observing viral p24 colocalization with 
intracellular compartments). Therefore, it is possible that in the Giacaman et al (2008) 
study, surface associated virus was transferred, as opposed to internalized virus. This is 
strongly supported by our data in Chapter 4 (Figure 4.4), which showed that trypsin 
treatment at 37°C for 5 min was insufficient to remove all the bound virus particles from 
surface of epithelial cells (as detected by gp120 flow cytometry). Therefore, perhaps a 
more cautious statement indicating that transfer was due to, as they call it themselves, 
“cell associated trypsin resistant virus” (Giacaman et al., 2008). The aforementioned 
statement from their paper better reflects their findings and is more consistent with our 
data. We stress that we have not fully addressed whether HIV-1 transfer is the result of 
surface bound or internalized virus. However, we strongly suspect, given our data, that 
transfer is via surface bound virus. Irrespective, since the purpose of this Chapter was to 
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determine whether HIV-1 can be transferred from epithelial cells to permissive cells per 
se, there was no need to distinguish between these two possibilities.   
 Other studies have used the p24 accumulation assay (by ELISA) as a measure of 
infectious HIV-1 transfer to permissive cells but have reached the same conclusions as 
our study using TZM-bl reporter cells. For example, HIV-1 exposed normal human oral 
keratinocytes can transfer infectious NL4.3 (X4) and BaL (R5) to PBLs that were lysed 
for p24 ELISA (Liu et al., 2003). Similarly, genital epithelial cell line Ect1 captured and 
transmitted many different HIV-1 strains to H9 T cells and IL-2-stimulated PBMC when 
co-cultured over several days and lysed for p24 ELISA (Wu et al., 2003). The advantage 
of the p24 ELISA assay is that it is highly quantitative; however, counting plaques in 
many replicate wells allows more quantitative use of the TZM-bl assay. Irrespective, our 
data are consistent with these studies and the conclusion is that infectious HIV-1 can be 
transferred from epithelium to permissive cells. 
 If epithelial cells can capture and sequester virus even after extensive PBS 
washing, then in vivo salivary flow and vaginal mucous flow may not be sufficient to flush 
all infectious particles when HIV exposure has occurred. Permissive cells circulating in 
the sub mucosa may then encounter the bound virus either as it transcytoses the 
epithelium or when they are recruited by epithelial cells during an inflammatory 
responses through cytokine and chemokine signals. 
 
6.5  Conclusion 
The aim of the chapter was to establish whether oral and vaginal epithelial cells 
were able to transfer captured infectious HIV-1 to susceptible TZM-bl reporter cells that 
indicate infection with β-galactosidase activity. We conclude that oro-pharyngeal, oral 
and vaginal cells transfer infectious HIV-1 to permissive cells, probably from the surface, 
despite not having an integrated copy of the viral genome (Chapter 5).  Thus, epithelium 
may act as a mediator of systemic infection through transfer of infectious HIV-1 to 
permissive cells.  
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Chapter 7 Oral and vaginal epithelial responses to HIV-1 
7.1  Introduction 
Previously, we found that HIV-1 binds to various oral and vaginal epithelial cell 
lines (Chapter 4) but does not integrate (Chapter 5) and, therefore, it was concluded that 
HIV-1 is unable to productively infect epithelial cells. Nevertheless, in Chapter 6, 
epithelial lines were shown to transfer captured infectious virus to TZM-bl reporter cells. 
As the literature indicates that epithelial cells can respond to HIV-1 (Ferreira et al., 2011; 
Nazli et al., 2010), we wished to further characterise this aspect of viral-epithelial 
interaction. This was achieved by investigating the interactions been HIV-1 envelope 
protein or whole virus with oral and vaginal epithelium using three separate approaches. 
First, cytokine production in response to HIV-1 envelope gp120 and multimeric/trimeric 
gp140 exposure was monitored. Second, activation of intracellular signalling pathways 
after exposure to whole X4 and R5 virus was assessed by Western blotting. Finally, the 
global epithelial response in TR146 and primary oral epithelium was determined after 
exposure to HIV-1 R5 and X4 using Affymetrix human microarrays.  
Many studies have treated various cell types with gp120 and observed mixed 
responses (Del Corno et al., 2005; Kapasi et al., 2002; Martinelli et al., 2007; Shan et al., 
2007; Singhal et al., 1999). Most relevant to the current thesis are two studies using 
kidney epithelium (Kapasi et al., 2002; Singhal et al., 1999).  Firstly, gp120 (HIV-1 451  X4-
trophic (Bandres et al., 1998)) was shown to modulate the proliferation of human 
glomerular epithelial cells by enhancing proliferation at low concentrations (0.1 ng/mL) 
but decreasing growth and promoting apoptosis at higher concentrations (1-100 ng/mL) 
(Singhal et al., 1999). The protein kinase C and tyrosine kinase pathways were 
implicated and expression of c-Jun and c-Fos (members of the AP-1 transcription factor 
complex that can be activated via one of the three MAPK pathways: p38, JNK and 
ERK1/2) was increased with high concentration (100 ng/mL) of gp120. Following up, 
apoptosis caused by gp120 in these cells was shown to be dependent on 
phosphorylation of p38 and CD4 expression (Kapasi et al., 2002). Thus, in kidney 
epithelial cells (which express CD4 unlike oral and vaginal epithelial cells) the MAPK 
pathway has been implicated in responding to HIV-1 gp120. 
There are other studies indicating that HIV-1 affects the mucosal barrier. HIV-1 
infected individuals have barrier dysfunction in intestinal epithelium which allows bacteria 
to traverse the mucosa (Epple et al., 2009a; Epple et al., 2009b). To determine whether 
similar dysfunction can lead to HIV-1 traversing the vaginal epithelium, Nazli et al. (2010) 
monitored the transepithelial resistance (TER), an electrical measurement for the 
strength of the mucosal epithelial monolayer in vitro, and showed a decrease in the 
strength of the tight junctions in epithelial monolayers and a concordant decrease in tight 
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junction, RNA and protein expression. Gp120 treatment was sufficient to reduce tight 
junction protein ZO-1 by fluorescent microscopy and TER measurement in primary 
endometrial epithelium and an intestinal epithelial line (Nazli et al., 2010). Finally, the 
authors showed that the cytokines TNF-α, IL-6, IL-10 and IL-1β were significantly 
increased in apical medium of ADA (R5 virus) exposed primary endometrial epithelium. 
These studies strongly suggest that epithelial cells can sense and respond to HIV-1. 
There have been a number of publications analysing the global gene response of 
immune cells to HIV-1 using microarrays. One publication provided an overview of 34 
published articles in this area between 2001-2006 (Giri et al., 2006), which included data 
validated by qPCR or protein expression. They identified many pathways that had been 
previously reported as being activated or suppressed by HIV-1 or HIV-1 proteins, which 
included p-38, ERK1/2, Smad3 and NF-κB, (Acheampong et al., 2005; Cicala et al., 
2006; Cicala et al., 2002; Coberley et al., 2004; Guadalupe et al., 2003; Janket et al., 
2004; Muthumani et al., 2005; Pulliam et al., 2004; Sankaran et al., 2005; Vazquez et al., 
2005; Wen et al., 2005). By extension, one might hypothesize that similar pathways 
probably play a role in epithelial responses to HIV-1.  However, there is a paucity of 
microarray data for oral and vaginal epithelial cell responses to HIV-1. Only one directly 
relevant study was performed by Acheampong et al. (2005), which used a CLONTECH 
Atlas human apoptosis cDNA expression array to assess the response of primary oral 
keratinocytes treated with HIV-1 gp120, Nef and HIV-1 Tat. HIV gp120, Tat and Nef were 
all found to induce substantial apoptosis at a concentration of 10 ng/ml via the TNF/TNF-
R Fas/Fas ligand pathways. 
HIV can trigger apoptosis in susceptible cells by four main pathways: extrinsic-
induced when a  ligand (FasL, TNF or TRAIL) activates a death receptor (TNF receptors) 
on the cell surface involving caspases, intrinsic mitochondrial induced apoptosis, T-cell 
mediated cytotoxicity and perforin/granzyme dependent killing of cells (caspase-
independent) and autophagy (Février et al, 2011; Cummins et al., 2010). Many 
components of the virus such as env, Tat, Vpr, Nef are toxic to cells and directly play into 
the various death pathways even in uninfected cells (Cummins et al., 2010). Therefore, it 
is possible that HIV could also influence cell death pathways in epithelial lines. 
The aim of this chapter was to characterise how oral and vaginal epithelia 
respond to HIV-1 using TR146 and A431 epithelial cell lines. First, we examined whether 
HIV-1 env gp120 and gp140 multimer proteins were able to induce cytokine production. 
Second, we assessed whether epithelial signalling pathways (MAPK (p38, JNK, 
ERK1/2), NF-κB and IRF3) were activated by X4 and R5 virus, and looked for cytotoxicity 
by measuring the damage response as by monitored by the release of lactate 
dehydrogenase (LDH). Finally, we undertook a preliminary microarray experiment to 
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characterise the global gene expression profile of TR146 and primary oral epithelial cells 
treated with R5 and X4 virus.  The hypotheses were two fold, (i) that since HIV-1 is able 
to bind all three epithelial cell lines (Chapter 3), addition of gp120/gp140 alone may be 
sufficient to elicit cytokine production, and (ii) given that R5 and X4 virus bind 
predominantly protein and non-protein moieties, respectively (Chapter 4), that there 
would be differences in the signalling pathway response of oral and vaginal epithelium as 
well as global gene expression profile of oral epithelium to HIV-1 R5 and X4. 
While we found a lack of cytokine (IL-1α, IL-6, G-CSF, GM-CSF) induction by 
gp120 or multimeric gp140, there appears to be clear recognition of YU2-R5 and LAI-X4 
whole virus by TR146 and A431 cells, since signalling pathways in both epithelial cell 
types were activated. While TR146 cells appeared less responsive than A431 cells, 
differences in signalling pathway activation were observed for X4 and R5 virus in both 
epithelial cell types. This was confirmed in oral epithelial cells at the gene expression 
level by microarray analysis. Notably, epithelial cell damage was induced by both R5 and 
X4 virus. Together, the data indicate that R5 and X4 virus are recognized by oral and 
vaginal epithelial cells but that each virus appears to activate different signalling 
pathways and gene expression profiles, which may have consequences for R5 and X4 
virus infection in vivo. 
7.2 Methods 
7.2.1 Activation of epithelial cytokines by HIV-1 envelope 
TR146 and A431 cells were grown to confluence and then serum starved for 2 h 
prior to stimulation with HIV-1 envelope glycoproteins gp120 BAL-R5 (expression vector 
by Marvin Reitz), CN54-X4 clade C (Morikawa et al.,1990.) and mutlimeric/trimeric 
gp140s UG21-X4 (Jeffs et al., 2004 and 2006) and ZM96-R5 clade C (Rodenburg et al., 
2001) at 1 μg/mL in serum-free medium for 24 h. Supernatants were collected, frozen at 
-80°C and select cytokines quantified by Luminex multiplex bead assay according to the 
manufacturer’s instructions. The multimeric gp140 UG21 and ZM-96 mammalian 
glycosylated proteins were produced by mammalian cell transfection rather than in 
bacteria. UG21 was a kind gift from Dr Simon Jeffs (Imperial College London). Please 
refer to Chapter 2.9 for full method. 
7.2.2  Activation of intracellular signalling pathways in response to HIV-1 in oral 
and vaginal cells 
Epithelial cells were grown to confluence, serum starved overnight, and the next 
day YU2-R5 and LAI-X4 viruses were added at an MOI 5 for 2 h at 37°C. Conditioned 
medium controls (culture medium from uninfected cells but grown identically) were 
added to control wells using the same volume as the medium containing virus particles. 
Cells were incubated for 2 h, washed with cold PBS, and lysed with cold RIPA buffer 
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containing Triton X-100, protease and phosphatase inhibitors. The protein extracts were 
quantified by BCA assay and gels were loaded with equal amounts of protein in each 
well. Please refer to Chapter 2.5.1 for full method. 
7.2.3 Microarray analysis of primary and TR146 epithelial cells treated with HIV-1  
TR146 and primary oral epithelial cells were grown to confluence and exposed to 
HIV-1 LAI-X4 and YU2- R5 virus at an MOI of 100 for 8 h 37°C.  Cells were washed 
thoroughly and RNA isolated for quality control and labelling for microarray analysis by 
Affymetrix chips. The resulting gene lists were compared with each other to find the gene 
intersections using Venny (Oliveros, 2007) , a program that creates Venn diagrams from 
any input lists and the common genes up- or down-regulated in TR146 and primary oral 
epithelium were analysed using the on-line tool Database for Annotation, Visualization 
and Integrated Discovery (DAVID) (Huang da et al., 2009). Please refer to Chapter 2.10 




7.3.1 Activation of epithelial cytokines by HIV-1 envelope 
Since the vagina is a more susceptible milieu for HIV transmission than the oral 
cavity, we hypothesized that oral and vaginal epithelial cells may produce a different 
cytokine profile in response to HIV-1 envelope stimulation, which may potentially account 
for the underlying differences in susceptibility between the two mucosal sites. Therefore, 
oral and vaginal cell lines were treated with recombinant gp120 (BAL, CN54) and 
multimeric glycosylated gp140s (UG21, ZM96) to determine whether the HIV-1 envelope 
protein elicited a cytokine response in epithelial cells after 24 h. However, three 
independent experiments with A431 cells and two with TR146 cells failed to demonstrate 
activation of IL-1α, IL-6, G-CSF or GM-CSF by gp120 or multimeric gp140 at 1 μg/ml (Fig 
7.1 and 7.2). It should be noted that TR146 cells naturally secrete higher amounts of IL-
6, G-CSF and GM-CSF than A431 cells. 
  




Figure 7-1: IL-6, IL-1α, G-CSF, GM-CSF concentration in culture supernatants from gp120 
(BAL, CN54) and gp140 (UG21, ZM96) (1μg) treated epithelial cells as determined by 
Luminex assay. Two or three technical replicates were averaged and standard deviation shown 
by error bars. Data are representative of three (A431 in pink) or two (TR146 in grey) independent 
experiments. 
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7.3.2  Activation of intracellular signalling pathways in response to HIV-1 in oral 
and vaginal cells 
Our group has previously shown that the oral and vaginal epithelium is 
responsive to the human pathogenic fungus Candida albicans (Moyes et al., 2011; 
Moyes et al., 2010). The key signalling pathways activated in epithelial cells were found 
to be MAPK (p38, JNK, ERK1/2) and NF-ΚB from this work and our unpublished work on 
TLR agonists. Activation of epithelial cells by other microbial stimuli, e.g. bacteria and 
viruses, also demonstrate activation of MAPK and NF-ΚB, but also the virally-activated 
toll-like receptor (TLR)-mediated IRF3 pathway (Carty and Bowie, 2010; Gomez and 
Prince, 2008; Handfield et al., 2008; Kinane et al., 2008; Mans et al., 2006).  Therefore, 
we decided to monitor MAPK, NF-ΚB and the TLR/IRF3 pathways after interactions with 
HIV-1 at the level of the molecules represented in various shades of purple (Figure 7.2).  
 
Figure 7-2: Simplified schematic overview of the NF-ΚB, MAPK and TLR signalling 
pathways. Proteins in shades of purple were assessed by Western blotting.  See appendix for full 
pathway diagrams and Literature Review (section 1.8) for more details on the pathways. 
 
TR146 and A431 cells were challenged with R5 (YU2) and X4 (LAI) viruses for 2 
h at 37°C and harvested for Western blot analysis. The total protein was isolated and 
assayed for (i) MAPK pathway activation via phosphorylation of ERK1/2 (p-ERK1/2),  
- 113 - 
JNK (p-JNK), and p-38 (p-p38) (ii) NF-κB activation via phosphorylation of the inhibitor 
IκBα (p-IκBα) and (iii) TLR-mediated IRF3 activation via phosphorylation of IRF3 (p-
IRF3). The 2 h time point was determined to be optimal in our previous studies 
investigating the activation of these pathways by western blot in epithelial lines (Moyes et 
al., 2011 and 2011). The presence or absence of virus in each experimental condition 
was demonstrated by detecting HIV-1 p24 expression. One strength of our approach 
was that we compared data from virus treated cells with data from cells treated with 
conditioned medium from the same source (the virus-producing cell lines without viral 
production). This provides more confidence that activation is not simply due to a property 
of the medium containing the virus stock.  
Exposure of TR146 cells to HIV-1 R5 and X4 demonstrated differential activation 
of MAPK signalling as well as NF-ΚB signalling (Figure 7.3). For the MAPK pathway, p-
ERK1/2 was not activated by X4 virus but was activated by R5 virus, albeit only slightly. 
However, since the control conditioned medium alone (CX: without X4 virus, and CR: 
without R5 virus) and the untreated control (U) also activated p-ERK1/2, especially CX, it 
is difficult to conclude that HIV-1 activates p-ERK1/2.  Indeed, one could interpret that X4 
virus may in fact inhibit ERK1/2 signalling given the significantly reduced signal 
compared with conditioned medium alone (CX) and the untreated control. While neither 
R5, nor X4 virus activated p-JNK, R5 virus did activate p-p38 to a considerable degree 
over conditioned medium alone (CR). Again, X4 virus may specifically inhibit p-p38 
activation as the conditioned medium control (CX) activates p-p38 more strongly than the 
X4 virus. A similar finding was found for X4 virus activation of NF-ΚB in that a fainter 
band was observed for p-IΚB- compared with the conditioned medium control (CX). 
Given the strong signal for p-IΚB- in the untreated cell control it would appear that p-
IΚB- is not activated by R5 virus. Finally, like p-JNK, a lack of p-IRF-3 signal was 
observed for all TR146 samples, indicating no activation of the TLR-mediated IRF-3 
pathway by HIV-1 virus. Together, the data suggests that in TR146 oral epithelial cells, 
R5 virus activates the MAPK-p38 pathway whereas X4 virus may potentially suppress 
p38, ERK1/2 and NF-ΚB signalling.  
Interestingly, there were both similarities and differences in the A431 vaginal cell 
response to R5 and X4 virus as compared with TR146 oral cells. Notably, R5 virus 
activates p-ERK1/2 in comparison with the conditioned medium control (CR) and 
untreated control, whereas X4 virus may inhibit p-ERK1/2 activation given the 
significantly reduced signal compared with the conditioned medium control (CX). Also, 
R5 virus but not X4 virus specifically activates p-JNK and p-IRF3 compared with their 
conditioned medium controls. Treatment with both R5 and X4 lead to activation of p-p38, 
but the untreated control signal was relatively high so the data should be interpreted with 
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caution. As for NF-κB signalling, there was little observable difference in p-IkB- 
between X4 and R5 virus compared with conditioned medium and untreated controls. 
Thus, it is difficult to conclude that either X4 or R5 virus activates NF-κB signalling. 
 
Figure 7-3: Activation of MAPK (ERK1/2, JNK, p38), NF-ΚB and IRF3 signalling pathways in 
TR146 oral and A431 vaginal epithelial cell lines in response to whole virus challenge (MOI 
of 5). X4: LAI-X4, R5: YU2-R5, CX: control conditioned medium for X4, CR: control conditioned 
medium for R5, U: untreated cell control. Data are representative of 2-3 independent experiments. 
 
In summary, vaginal and oral epithelial cells respond differently to X4 and R5 
whole virus stimulation. Overall, the signalling pathways investigated were activated to a 
lesser degree in TR146 oral cells than A431 vaginal cells. Notably, R5 virus activates 
p38 pathway in TR146 cells, whereas X4 virus may inhibit p38 and NF-ΚB signalling. 
Likewise, R5 virus activates ERK1/2, JNK, p38 and IRF3 in A431 vaginal cells, whereas 
X4 virus appears to only activate p38. Clearly, X4 and R5 viruses activate different 
signalling pathways in epithelial cells, even when applied at the same MOI.  
7.3.2.1  Cell damage 
In order to assess cell damage induced by R5 and X4 virus treatment, 
supernatants were collected and assayed for lactase dehydrogenase (LDH). This 
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cytoplasmic enzyme is released from cells when the cellular membrane is damaged. We 
found that both R5 and X4 virus induced LDH release but more release was induced by 
R5 virus (Figure 7.4), indicating greater damage. Notably, like the untreated cell control, 
the conditioned medium controls for both virus stocks did not induce LDH release, 
demonstrating no damage. Since the control conditioned medium was obtained from the 
same cells used to grow virus stocks, but just without the presence of virus, and are as 
acidic (by visual inspection of yellow colour), this suggests that damage was induced by 
the presence of virus. 
 
Figure 7-4: Epithelial cell damage induced by R5 and X4 virus as measured by LDH assay 
in culture supernatants after 24 h. LAI: X4 virus. YU2: R5 virus. LAI C: LAI control conditioned 
medium. YU2 C: YU2 control conditioned medium. Data are representative of two independent 
experiments.   
7.3.3  Global gene expression responses in oral epithelial cells in response to 
HIV-1  
Given that HIV-1 R5 and X4 bind to oral and vaginal epithelial cells (Chapter 4) 
and activate signalling pathways (above) we decided to perform a preliminary microarray 
experiment in primary oral epithelial and TR146 cells to discover how oral epithelium 
responds on a global scale to challenge with R5 and X4 virus. Although we would also 
liked to have assessed vaginal epithelial cell responses, especially since A431 cells were 
more responsive than TR146 cells and provided differences in R5 and X4 virus signalling 
responses (above), we are unable to obtain primary vaginal epithelial cells as we did not 
have ethical approval for such studies. Therefore, we proceeded with comparing the 
gene responses of primary epithelial cells (gingival origin) with TR146 buccal cells, as 
this would provide valuable information with regard to potential differences in HIV-1 
responses between normal and carcinoma epithelial cells. Given the expense of 
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preliminary nature of this aspect of the work, only a singleton array was performed per 
condition. However, given their singleton nature, caution is advised with regard to 
intrepretation of the data and in drawing specific conclusions. Ideally, for future work 
multiple samples per condition (3 or more) would need to be assayed. We chose a time 
point, 8 h, that would allow for intracellular signalling pathways (2-4 h) to have had an 
effect on gene expression in the epithelial lines as determined by our own unpublished 
studies (David Moyes, personal communication). Because the effect of a low MOI could 
be subtle, we chose to use a high MOI in this preliminary, proof of principle study. 
In primary oral cells treated with YU2-R5 virus, 1959 genes were up-regulated 
three-fold or greater versus the untreated cell control, while 1455 genes were down-
regulated at least three-fold (Figure 7-5). In the same cells treated with LAI-X4 virus, 936 
genes were up-regulated three-fold or greater while 680 were down-regulated at least 
three-fold. Thus, in primary cells, a greater number of genes changed expression levels 
in response to R5 versus X4 virus. 
In TR146 oral cells treated with YU2-R5, 37 genes are up-regulated three-fold or 
greater, while 74 genes are down-regulated at least three-fold (Figure 7-5). In the same 
cells treated with LAI-X4, 20 genes were up-regulated and 15 genes down-regulated at 
least three-fold. Thus, just like in primary cells, in TR146 cells a greater number of genes 
changed expression levels in response to R5 versus X4 virus. Notably, the TR146 cell 
line was less responsive to HIV-1 compared with primary oral epithelial cells. Since only 
a singleton array was performed for each cell type (HIV-1 R5, X4 or untreated), statistical 
analysis could not be undertaken; however, the common genes either up- or down-
regulated in both TR146 and primary cells are represented in Figure 7-5. Intersecting 
gene lists were then analysed for gene ontology (biological process, cellular 
compartment, molecular function and pathway) using DAVID. 




Figure 7-5: Representation of microarray experimental design for microarray experiment. 
Genes up regulated denoted with +, down regulated with - (3-fold for primary cells and 3-fold for 
TR146). The number of genes up- and down-regulated in both primary and TR146 cells are 
shown in the intersection. A) Shows the numbers of genes changed for each cell type and the 
commonality between treatment with R5 and X4 HIV-1. B) Shows the comparison of the R5 
treatment in both cell types versus the X4 treatment in both cell types. 
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7.3.3.1 Genes up-regulated in primary and TR146 epithelial cells in response to R5 
virus 
 
A comparison of the gene lists up and down regulated in TR146 cells and primary 
oral cells by treatment with HIV YU2-R5 was undertaken. Of the 37 genes increased 
over three-fold in TR146, all were increased over three-fold in primary oral cells exposed 
YU2-R5 virus at an MOI of 100. Analysis of this gene list with the DAVID program 
revealed several pathways appeared activated as compared to a random list of genes in 
the human genome. The most significant hits (p<0.05) were response to protein stimulus, 
wound response and positive regulation of apoptosis/programmed cell death. Although 
no particular cellular compartment was identified, the molecular function with p<0.05 is 
enzyme binding and the pathway identified is TGF-β signalling. 
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Table 7-1: Common genes up-regulated in both TR146 and primary oral epithelial cells in 
response to YU2-R5 after 8h. Entries with most highly significant p-values are displayed. 




protein stimulus 4 0.001672 
heat shock 70kDa protein 8; inhibitor of DNA binding 3, 
dominant negative helix-loop-helix protein; cysteine-rich, 
angiogenic inducer 61; inhibitor of DNA binding 1, dominant 




wounding 5 0.028476 
inhibitor of DNA binding 3, dominant negative helix-loop-helix 
protein; vanin 1; plasminogen activator, urokinase receptor; 
serpin peptidase inhibitor, clade E (nexin, plasminogen 





apoptosis 6 0.030273 
inhibitor of DNA binding 3, dominant negative helix-loop-helix 
protein; aryl-hydrocarbon receptor repressor; programmed cell 
death 6; vanin 1; RAS p21 protein activator (GTPase activating 
protein) 1; eukaryotic translation initiation factor 5A- 





death 6 0.03142 List same as above 
GO:0010941 
regulation of cell 








junction plakoglobin; Rho-related BTB domain containing 3; 
plasminogen activator, urokinase receptor; RAS p21 protein 
activator (GTPase activating protein) 1; serpin peptidase 
inhibitor, clade E (nexin, plasminogen activator inhibitor type 








inhibitor of DNA binding 3, dominant negative helix-loop-helix 
protein; inhibitor of DNA binding 1, dominant negative helix-
loop-helix protein; inhibin, beta A 
 
#: number of genes implicated in list for association with particular function or pathway.  
p-value: (or EASE score) is a modified Fisher Exact Probability P-value. The smaller it is the more 
significant it is. 
H0  = the gene list is not enriched for  given pathways versus a random list from the genome. 
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7.3.3.2  Genes down-regulated in primary and TR146 epithelial cells in response to 
R5 virus  
When genes down-regulated at 3 fold level by R5 treatment are considered in 
both the primary oral and TR146 cells, a list of 68 common genes are identified. 
Negative regulation of apoptosis and programmed cell death emerge in the “top ten” 
biological processes (Table 7.2). Also significant (p<0.05) but not included in the “top 
ten” are phosphorylation, positive regulation of notch signalling, regulation of cell 
adhesion/migration, integrin mediated signalling, intracellular signalling cascade  (Table 
7.2). Cellular compartments that are implicated are the cytosol, endosome, transcription 
factor complex and the microtubule cytoskeleton. Finally, molecular functions identified 
include integrin binding, microtube binding, serine threonine kinases and the Wnt 
signalling pathway (Table 7.2). 
 
7.3.3.3  Genes up-regulated in primary and TR146 epithelial cells in response to X4 
virus 
Only twenty common genes were up-regulated in TR146 and primary oral 
epithelial cells when incubated with X4-LAI virus. Given such a few number of genes 
were identified, it was difficult to establish gene network relationships with certainty. 
However, the top significance biological processes were distinct from those elicited by 
R5 virus and included: response to bacteria, negative regulation of MAPK, regulation of 
phosphorylation, and transcription (Table 7.3). However, similarities were also observed 
between R5 and X4 virus, including cell cycle regulation. Interestingly, just above the 
level for significance were: cytokine mediated signalling pathway (p=0.0505) and 
response to cytokine stimulus (p=0.056). Although no genes were significant for 
molecular function, the MAPK pathway was implicated (Table 7.3). 
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Table 7-2: Common genes down-regulated in both TR146 and primary oral epithelial cells 
in response to YU2-R5 after 8 h. “Top ten entries” with most highly significant p-values are 
displayed. 





apoptosis 9 1.4E-04 
superoxide dismutase 2, mitochondrial; mitogen-activated 
protein kinase kinase kinase 7; protein kinase C, iota; 
similar to Rho-associated, coiled-coil containing protein 
kinase 1; Rho-associated, coiled-coil containing protein 
kinase 1; tumor protein p63; prion protein; interleukin 1, 
alpha; superoxide dismutase 2, mitochondrial; transcription 
factor 7-like 2 (T-cell specific, HMG-box); S-phase kinase-





death 9 1.55E-04 




regulation of cell 
death 9 1.58E-04 
List identical to above 
 
GO:0006916 
anti-apoptosis 7 2.67E-04 
superoxide dismutase 2, mitochondrial; protein kinase C, 
iota; tumor protein p63; prion protein; interleukin 1, alpha; 
superoxide dismutase 2, mitochondrial; transcription factor 
7-like 2 (T-cell specific, HMG-box); S-phase kinase-
associated protein 2 (p45) 
GO:0048598 
embryonic 
morphogenesis 7 0.002134 
protein kinase, cAMP-dependent, regulatory, type I, alpha 
(tissue specific extinguisher 1); matrix metallopeptidase 13 
(collagenase 3); mitogen-activated protein kinase kinase 
kinase 7; tumor protein p63; transcription factor 7-like 2 (T-
cell specific, HMG-box); neurofibromin 2 (merlin); pre-B-cell 
leukemia homeobox 2. 
GO:0042981 
regulation of 
apoptosis 11 0.002297 
mitogen-activated protein kinase kinase kinase 7; 
superoxide dismutase 2, mitochondrial; similar to Rho-
associated, coiled-coil containing protein kinase 1; Rho-
associated, coiled-coil containing protein kinase 1; tumor 
protein p63, jun oncogene; interleukin 1, alpha; prion 
protein; transcription factor 7-like 2 (T-cell specific, HMG-
box); protein kinase C, iota; mitogen-activated protein 
kinase 9; superoxide dismutase 2, mitochondrial; S-phase 




death 11 0.00247 List identical to above list 
GO:0010941 
regulation of cell 




organization 6 0.002994 
Dystonin; protein kinase C, iota; similar to Rho-associated, 
coiled-coil containing protein kinase 1; Rho-associated, 
coiled-coil containing protein kinase 1; PDZ and LIM domain 
7 (enigma); v-crk sarcoma virus CT10 oncogene homolog 
(avian); neurofibromin 2 (merlin) 
GO:0051726 
regulation of cell 
cycle 7 0.003105 
hect domain and RLD 5; jun oncogene; interleukin 1, alpha; 
cyclin E2; transformation/transcription domain-associated 
protein; G-2 and S-phase expressed 1; S-phase kinase-
associated protein 2 (p45) 
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GO TERM % PValue Genes 
Cellular  compartment 
 
GO:0005829 
cytosol 13 0.00839 
mitogen-activated protein kinase kinase kinase 7; coiled-coil 
containing protein kinase 1, jun oncogene, cyclin E2; 
transcription factor 7-like 2 (T-cell specific, HMG-box); 
ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A; 
ribosomal protein S11 pseudogene 5; ribosomal protein 
S11; protein kinase, cAMP-dependent, regulatory, type I, 
alpha (tissue specific extinguisher 1); C-terminal binding 
protein 1; protein kinase C, iota; 3-hydroxy-3-
methylglutaryl-Coenzyme A synthase 1 (soluble); 5-
methyltetrahydrofolate-homocysteine methyltransferase 
reductase; v-crk sarcoma virus CT10 oncogene homolog 
(avian) 
GO:0005768 
endosome 6 0.01038 
low density lipoprotein receptor; protein kinase C, iota; 
CAP-GLY domain containing linker protein 1; 
phosphatidylinositol 4-kinase, catalytic, beta; v-crk sarcoma 




factor complex 5 0.0118 
C-terminal binding protein 1; jun oncogene; 
transformation/transcription domain-associated protein; 
transcription factor 7-like 2 (T-cell specific, HMG-box); pre-
B-cell leukemia homeobox 2 
GO:0015630 
microtubule 
cytoskeleton 7 0.02754 
Dystonin; similar to Rho-associated, coiled-coil containing 
protein kinase 1; Rho-associated, coiled-coil containing 
protein kinase 1; CAP-GLY domain containing linker protein 
1; tubulin, delta 1; myristoylated alanine-rich protein kinase 
C substrate; G-2 and S-phase expressed 1; transducin 
(beta)-like 1 X-linked receptor 1 
Molecular function 
GO:0005178 
integrin binding 3 0.03036 
Dystonin, intercellular adhesion molecule 1, ADAM 
metallopeptidase domain 10 
GO:0019992 
diacylglycerol 
binding 3 0.03938 
protein kinase C, iota; similar to Rho-associated, coiled-coil 
containing protein kinase 1; Rho-associated, coiled-coil 
containing protein kinase; protein kinase C, eta 
GO:0008017 
microtubule 
binding 3 0.04367 





kinase activity 6 0.04808 
mitogen-activated protein kinase kinase kinase 7; protein 
kinase C, iota; similar to Rho-associated, coiled-coil 
containing protein kinase 1; Rho-associated, coiled-coil 
containing protein kinase 1; serine/threonine-protein kinase 




pathway 7 4.19E-04 
C-terminal binding protein 1; mitogen-activated protein 
kinase kinase kinase 7; similar to Rho-associated, coiled-coil 
containing protein kinase 1: Rho-associated, coiled-coil 
containing protein kinase 1; jun oncogene; mitogen-
activated protein kinase 9; transcription factor 7-like 2 (T-




cancer 8 0.00515 
C-terminal binding protein 1; jun oncogene; mitogen-
activated protein kinase 9; cyclin E2; transcription factor 7-
like 2 (T-cell specific, HMG-box); v-crk sarcoma virus CT10 
oncogene homolog (avian); S-phase kinase-associated 





pylori infection 4 0.01018 
jun oncogene; mitogen-activated protein kinase 9; ATPase, 
H+ transporting, lysosomal 70kDa, V1 subunit A; ADAM 
metallopeptidase domain 10 
hsa04510: Focal 5 0.04350 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 
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adhesion receptor); similar to Rho-associated, coiled-coil containing 
protein kinase 1; Rho-associated, coiled-coil containing 
protein kinase 1, jun oncogene; mitogen-activated protein 
kinase 9; v-crk sarcoma virus CT10 oncogene homolog 
(avian) 
#: number of genes implicated in list for association with particular function or pathway.  
p-value: (EASE score) if H0 is that the gene list is not enriched for a given pathways versus a 
random list from the genome. 
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Table 7-3: Common genes up-regulated in both TR146 and primary oral epithelial cells in 
response to LAI-X4 after 8 h. Entries with most highly significant p-values are displayed. 
GO TERM # P-Value Genes 
Biological process 
GO:0009617 
Response to bacterium 3 0.0085 
interleukin-1 receptor-associated kinase 3; jun oncogene; 
chemokine (C-C motif) ligand 20 
GO:0010605 
negative regulation of 
macromolecule metabolic 
process 4 0.0143 
NACC family member 2, BEN and BTB (POZ) domain 
containing; interleukin-1 receptor-associated kinase 3; 
jun oncogene; hypermethylated in cancer 2 
GO:0051726 
regulation of cell cycle 3 0.0236 jun oncogene; interleukin 1, alpha; cyclin G2 
GO:0043407 
negative regulation of 
MAP kinase activity 2 0.0263 
dual specificity phosphatase 6; interleukin-1 receptor-
associated kinase 3; dual specificity phosphatase 6 
GO:0045449 
regulation of transcription 6 0.0279 
NACC family member 2, BEN and BTB (POZ) domain 
containing; interleukin-1 receptor-associated kinase 3; 
jun oncogene; zinc finger and BTB domain containing 6; 
hypermethylated in cancer 2; zinc finger protein 14 
GO:0042325 
regulation of 
phosphorylation 3 0.0444 
dual specificity phosphatase 6; interleukin-1 receptor-
associated kinase 3; jun oncogene 
GO:0019220 
regulation of phosphate 
metabolic process 3 0.0477 List identical to above list 
Cellular Compartment    
GO:0005654 
nucleoplasm 3 0.0413 
NACC family member 2, BEN and BTB (POZ) domain 
containing; dual specificity phosphatase 6; jun oncogene 
Pathways    
hsa04010:MAPK 
signaling pathway 
3 0.0247 dual specificity phosphatase 6; jun oncogene; interleukin 
1, alpha 
#: number of genes implicated in list for association with particular function or pathway.  
p-value: (EASE score) if H0 is that the gene list is not enriched for a given pathways versus a 
random list from the genome. 
 
7.3.3.4 Genes down-regulated in primary and TR146 epithelial cells in response to 
X4 virus 
Only 16 common genes were down-regulated in TR146 and primary oral 
epithelial cells when incubated with LAI-X4 virus. Given so few genes were identified,  it 
was difficult to establish the network relationships with certainty. Only data for the cellular 
compartment involved are listed in Table 7.4. 
Table 7-4: Common genes down-regulated in both TR146 and primary oral epithelial cells 
in response to LAI-x4 after 8 h. “Top ten entries” with most highly significant p-values are 
displayed. 
GO TERM # P-Value Genes 
GO:0043232 
intracellular non- 9 0.001377 
ribosomal protein L17 pseudogene 22; ribosomal protein 
L17 pseudogene 36; ribosomal protein L17 pseudogene 
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membrane-
bounded organelle 
20; similar to ribosomal protein L17; ribosomal protein 
L17 pseudogene 33; ribosomal protein L17 pseudogene 
34; ribosomal protein L17 pseudogene 9; ribosomal 
protein L17; ribosomal protein L17 pseudogene 18; 
ribosomal protein L17 pseudogene 7; ribosomal protein 
L17 pseudogene 39; 
junction plakoglobin; heterogeneous nuclear 
ribonucleoprotein A1-like 3; similar to heterogeneous 
nuclear ribonucleoprotein A1; heterogeneous nuclear 
ribonucleoprotein A1 pseudogene 2; heterogeneous 
nuclear ribonucleoprotein A1; heterogeneous nuclear 
ribonucleoprotein A1 pseudogene; small proline-rich 
protein 2B; keratin 23 (histone deacetylase inducible); 
histone cluster 2, H2aa3; histone cluster 2, H2aa4; cyclin 
A1; inhibitor of DNA binding 2, dominant negative helix-
loop-helix protein; activating transcription factor 3 
GO:0043228 
non-membrane-
bounded organelle 9 0.001377 As above 
GO:0005829 
cytosol 5 0.038752 
ribosomal protein L17 pseudogene 22; ribosomal protein 
L17 pseudogene 36; ribosomal protein L17 pseudogene 
20; similar to ribosomal protein L17; ribosomal protein 
L17 pseudogene 33; ribosomal protein L17 pseudogene 
34; ribosomal protein L17 pseudogene 9; ribosomal 
protein L17; ribosomal protein L17 pseudogene 18; 
ribosomal protein L17 pseudogene 7; ribosomal protein 
L17 pseudogene 39; 
junction plakoglobin; heterogeneous nuclear 
ribonucleoprotein A1-like 3; similar to heterogeneous 
nuclear ribonucleoprotein A1; inhibitor of DNA binding 2, 
dominant negative helix-loop-helix protein; aspartyl-tRNA 
synthetase 
#: number of genes implicated in list for association with particular function or pathway.  
p-value: (EASE score) if H0 is that the gene list is not enriched for a given pathways versus a 
random list from the genome. 
 
7.4  Discussion:  
The aim of this Chapter was to characterise how oral and vaginal epithelia 
respond to R5 and X4 virus, which may help us understand the underlying difference in 
susceptibility of these respective mucosal sites to HIV-1 infection. We hypothesised that 
differences may exist in the epithelial responses to R5 and X4 virus, since R5 and X4 
virus may to bind different surface moieties as suggested by varying degrees of trypsin 
sensitivity of HIV binding epithelium (Chapter  4.3.2).  
First, we determined whether HIV-1 envelope proteins gp120 (BAL, CN54) and 
gp140 (Ug21, ZM96) were able to induce cytokines in TR146 oral or A431 vaginal 
epithelial cells but found that none of the proteins tested were able to induce IL-6, IL-1α, 
G-CSF or GM-CSF in these cell lines. This was, in part, unexpected since Nazli et al. 
(2010) showed cytokine induction (TNF-α, IL-6, IL-10, IL-1β) for HIV-1 ADA (R5) treated 
primary endometrial cells and determined that transepithelial resistance and ZO-1 tight 
junction protein expression was gp120-dependant. We expected that IL-6 would be 
produced and act as our positive control. We did not test for TNF-α or IL-10 since neither 
TR146 or A431 cells secreted these cytokines when exposed to multiple stimulators, 
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including TLR1-9 agonists (unpublished) and the fungal pathogen C. albicans (Moyes et 
al., 2010). However, we do show that HIV-1 gp120 as well as (mammalian produced) 
glycosylated gp140s do not induce four key cytokines known to be secreted by these 
oral and vaginal cell lines (Moyes et al., 2010) and which are involved in initiating 
immune responses (Weindl et al., 2007). The differences in cytokine induction between 
our work and that of Nazli et al. (2010) most likely stem from the different origin of the 
epithelium used (endometrial versus oral/vaginal), the primary (Nazli) versus carcinoma 
(our work) status of the cells, and the fact we utilized purified envelope protein as 
opposed to whole virus. It would have been ideal to test whole virus exposed 
supernatants for cytokine induction but this was not possible for technical reasons, as 
the Luminex machine was located outside of the Category 3 facility. To remove HIV-1 
exposed samples from the Category 3 facility requires either heat inactivation (60°C for 
10 min - 1 h) or fixation (1% gluteraldehyde or 1-2% formaldehyde) of the virus. 
However, pilot studies showed that these treatment regimes denatured the cytokines in 
the culture supernatants thereby diminishing our ability to detect them by luminex with 
any accuracy (data not shown). Alternative approaches including inactivation of HIV-1 by 
UV treatment were also unsuccessful (data not shown). 
Second, we investigated the ability of R5 and X4 virus to activate signalling 
pathways in TR146 and A431 epithelial cells. The reasoning behind this stemmed from 
our findings in Chapter 4, where we found that R5 and X4 virus appear to bind different 
surface moieties on epithelial cells. Thus, we hypothesised that R5 and X4 virus may 
activate different signalling pathways in oral and vaginal epithelial cells. Also, since 
primary endometrial cells produce cytokines in response to ADA (R5) virus (Nazli et al., 
2010), then intracellular signalling cascades are clearly activated in epithelial cells in 
response to HIV-1.  An assortment of signalling pathways were targeted based on 
unpublished results from our group where agonists of TLR3 and TLR7/8 activated 
MAPK, NF-κB, IRF3 (David Moyes, personal communication). These pathways were 
also known to be implicated in HIV-1 responses in immune cells and therefore were 
targeted in these preliminary studies. Western blotting was used to visualize their active 
phosphorylated forms.  We found that (i) In TR146 cells, R5 virus activates the p38 
pathway whereas X4 virus may inhibit p38, ERK1/2 and NF-κB signalling, (ii) In A431 
cells, R5 virus activates ERK1/2, JNK, p38 and IRF3 whereas X4 virus appears to only 
activate p-38, and (iii) that A431 vaginal cells were more responsive to HIV-1 than 
TR146 oral cells. Although the implication of NF-κB and MAPK pathways in HIV-1 
responses is consistent with previous microarray studies (Acheampong et al., 2005; 
Cicala et al., 2006; Cicala et al., 2002; Coberley et al., 2004; Guadalupe et al., 2003; 
Janket et al., 2004; Muthumani et al., 2005; Pulliam et al., 2004; Sankaran et al., 2005; 
Vazquez et al., 2005; Wen et al., 2005), there is a lack of data regarding epithelial 
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signalling responses to HIV-1. Since epithelial cell recognition of microbial pathogens are 
known to differ from that of immune cells (i.e. dendritic cells, T-cells, macrophages), it is 
difficult to interpret our findings in the context of the current literature. Only two studies 
were found in relation to our work, both using kidney epithelium. The first study 
demonstrated that gp120 was able to activate the protein kinase C and tyrosine kinase 
pathways and implicated the transcription factors c-Jun and c-Fos (via the MAPK 
pathway) in their activation (Singhal et al., 1999). Our data using whole virus 
demonstrated activation of all three MAPK pathways (ERK1/2, JNK, p38), predominantly 
by R5 virus in A431 vaginal cells. However, whether MAPK activation resulted in c-Jun 
and c-Fos activation is unknown, although both these transcription factors are known to 
be activated in TR146 and A431 cells in response to fungal pathogens (Moyes et al., 
2011; Moyes et al., 2010).  The second study showed that apoptosis caused by gp120 in 
kidney epithelium was dependent on p38 activation (Kapasi et al., 2002). Although we 
did not investigate apoptosis, interestingly we did find that in A431 cells both R5 and X4 
virus activated p38, whereas in TR146 cells only R5 virus activated p38 with X4 virus 
potentially inhibiting p38 signalling. Thus, the data may suggest that R5 potentially 
promotes apoptosis in both oral and vaginal epithelial cells, whereas X4 promotes 
apoptosis only in oral epithelial cells and may inhibit apoptosis in vaginal epithelial cells. 
However, significant additional work would be required to determine if this hypothesis 
has merit. It would have been worthwhile considering apoptosis assays such as 
Invitrogen ApoDETECT AnnexinV-FITC flow alongside detection of membrane integrity 
or ApoTarget™ Caspase Colorimetric Protease Assay Sampler Kit (caspase-2,  
caspase-3,  caspase-6, caspase-8, caspase-9).  Alternatively, R&D systems offer a 
TUNEL assay to detect fragmented DNA, the hallmark of apoptosis, with incorporation of 
labelled TdT. Future work  should also address the outcome of these signalling pathways 
looking at TNF, interferon, interferon stimulated genes and other relevant cytokines. 
We also assessed for the ability of R5 and X4 virus to induce epithelial damage 
by monitoring LDH release into the culture medium and found that both R5 and X4 virus 
supernatant induced LDH release from TR146 and A431 cells, suggestive of cell 
damage. This data is, in part, consistent with cell death/apoptosis induction as a result of 
gp120 treatment of kidney epithelium and oral epithelium (Acheampong et al., 2005; 
Kapasi et al., 2002; Singhal et al., 1999). However, it should be stressed that since the 
viral stocks used in this study remained in the medium when these supernatants were 
analysed, it is possible that some/all of the LDH detected originated from the virus-
producing cells and not epithelial lines. In addition, we found that R5 induces more 
damage than X4 virus in both TR146 and A431 cells. This was very intriguing and may 
be potentially explained by the fact that R5 virus activated more signalling pathways in 
A431 cells than X4 virus and in the case of TR146 cells was less inhibitory than X4 virus.  
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Finally, we performed a preliminary exploratory microarray experiment in order to 
explore the global changes in gene expression that occurred in oral epithelial cells by 
assessing the transcriptional profile of TR146 and primary oral epithelial cells in 
response to R5 and X4 virus.  Since only singleton arrays were used, this analysis can 
only give an indication of the oral epithelial response to HIV-1 rather than a complete 
analysis, which would require triplicates for each experimental condition followed by 
ANOVA analysis with multi-test correction statistical methods . However, although the 
data do not comply with MIAME guidelines for publication (Brazma et al., 2001), they do 
provide some interesting preliminary findings. Notably, that in both TR146 and primary 
oral cells, the number of genes altered by YU2-R5 virus was greater than that of LAI-X4 
virus. This is consistent with a microarray study in PBMCs showing distinct differences in 
responses to X4 and R5 gp120 (Cicala et al., 2006). Our findings may be explained by 
the fact that R5 virus predominantly binds protein moieties on the surface of the tested 
epithelial cell lines whilst X4 virus predominantly binds non-protein moieties (Chapter 
4.3.2). It also potentially fits with the idea that R5-trophic viruses might be more 
inflammatory since they are generally responsible for founding initial HIV-1 infections in 
vivo (Xiao et al., 2000).  
We also found that more genes are altered in expression in primary gingival cells 
as compared with TR146, which may seem surprising since TR146 cells are considered 
to be in a less regulated state, being a carcinoma cell line. However, TR146 cells have 
become lab-adapted and therefore may be less responsive than primary cells in this 
context. This highlights the fact that carcinoma cell lines are not a perfect substitute for 
primary oral cells in infection research (Moharamzadeh et al., 2012; Yadev et al., 2011). 
However, due to availability and ease of manipulation, carcinoma cell lines can provide 
information that can then be verified in primary cells that are more scarce and 
challenging to culture. It would be ideal to repeat western and microarray experiments 
with primary cells from relevant sites originating from several donors with several virus 
isolates. 
Finally, we found that while R5 and X4 virus activate different functional gene 
groups in TR146 cells, the majority of genes activated by both virus trophisms in primary 
oral epithelium are common (although there are twice as many genes activated by R5). 
This finding may be explained by the different origins of the cells (TR146 buccal versus 
primary gingival) as well as the carcinoma status of TR146 cells (above). Irrespective, it 
would appear that distinct signalling pathways may be activated in TR146 cells in 
response to R5 and X4 viruses, whereas common pathways are activated in primary oral 
epithelium. This is supported by the western blot signalling data showing that, unlike R5 
virus, X4 virus may specifically inhibit p38 and NF-κB signalling, which may also 
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contribute to the decreased number of genes found altered by X4 virus as compared with 
R5 virus. Furthermore, there is consistency between the array and signalling data sets. 
For example, inhibition of p38 signalling by X4 virus in TR146 cells by Western 
correlated well with “negative regulation of MAPK” in the arrays with X4. We are further 
comforted by the fact that the pathways identified (MAPK, NF-κB) are similar to those 
found to be regulated in other HIV related microarray studies in different cell types 
(Acheampong et al., 2005; Cicala et al., 2006; Cicala et al., 2002; Coberley et al., 2004; 
Giri et al., 2006; Guadalupe et al., 2003; Janket et al., 2004; Muthumani et al., 2005; 
Pulliam et al., 2004; Sankaran et al., 2005; Vazquez et al., 2005; Wen et al., 2005). In 
addition, a validation of the finding that apoptosis pathways may be affected by YU2-R5 
could be achieved by using the R&D systems human apoptosis antibody array that 
would allow the quantification of 35 apoptosis genes in one sample. This would allow  
the identification of the type of apoptosis involved in HIV exposure of the epithelium. 
Recombinant envelope proteins did not elicit cytokines, while whole virus did, as 
shown by the microarray data. This can be explained by the fact that a great excess of 
whole virus was used in the microarray study. Also, whole virus contains many more 
protein components toxic to cells (Tat, Nef, Env) as compared to recombinant envelope 
which is purified.  
In summary, our data suggests that oral and vaginal epithelium act as immune 
sensors as well as a barriers to infection, since the signalling and gene pathways 
activated are similar to those implicated in the response of immune cells to HIV-1 
infection. However, with regard to the array work, a fully controlled study with both oral 
and vaginal epithelial cells and different R5 and X4 viruses is required to fully ascertain 
the global gene expression profile of mucosal epithelium in response to HIV-1. 
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Chapter 8 Interactions between HIV-1 and Candida 
8.1 Introduction 
In the previous chapters the interaction between oral and vaginal epithelial cells 
and HIV-1 has been explored. However, aside from (host) epithelial cells, the other main 
cellular constituents of mucosal surfaces are resident microbiota. The epithelium is 
populated by diverse commensal microbiota that can turn pathogenic and cause 
inflammation under suitably predisposing conditions or when homoeostasis is disturbed. 
The last few years has seen an increase in research attention given to co-pathogens and 
their effect on HIV-1 infection. The presence of co-pathogens can lead to changes in 
gene expression that appears to promote HIV-1 infection by attracting immune cells and 
increasing inflammatory cytokines. For example, Neisseria gonorrhoeae was shown to 
induce the expression of human β-defensin-5 and 6, leading to an increase in HIV-1 
infectivity since defensins attract dendritic cells that can subsequently be exposed to 
HIV-1 present in the vaginal epithelium (Klotman et al., 2008). In other work, 
supernatants collected from endometrial epithelial cells infected with HSV-1/2, N. 
gonorrhoeae, and TLR ligands FimH (TLR4), flagellin (TLR5), and Poly (I:C) (TLR3) 
induced HIV-LTR reporter gene expression (Ferreira et al., 2011). Thus, inflammation 
induced by co-pathogens in the vaginal milieu may have an effect on HIV-1 infection by 
altering host gene expression and inflammatory mediators of epithelial cells. 
The idea that oral microbiota can promote HIV-1 disease has also gained 
popularity. Infection with the periodontal pathogen Porphyromonas gingivalis correlates 
with increased CCR5 expression on oral and tonsil epithelial cells, promoting receptor-
mediated recognition and binding of HIV-1 and transfer to susceptible immune cells 
(Giacaman et al., 2008). Also, bacterial extracts from oral pathogens Fusobacterium 
nucleatum and P. gingivalis were shown to induce the release of inflammatory signals 
that could lead to HIV-1 reactivation (Gonzalez et al., 2010). In addition, F. nucleatum 
and P. gingivalis were shown to activate NF-κB and increase cytokine expression 
(Milward et al., 2007), therefore potentially having an additive effect in promoting HIV-1 
infection in the oral cavity (Chapter 7.3.2). Thus, the human microbiota may stimulate 
inflammation that, in turn, may promote activation of HIV-1 gene expression and the 
exposure of susceptible immune cells to the virus in the mucosa. 
Oral microbiota may also bind to HIV-1 directly (Gruber et al., 2003) and protect 
the virus from being cleared by the flow of saliva and mucosal secretions, potentially 
facilitating transfer. One such microbe is Candida albicans, an opportunistic fungus that 
causes oral candidiasis in ~50% of untreated HIV-infected subjects and ~90% of AIDS 
patients (Phelan et al., 1987). In two studies, the HIV-1 gp41/gp160 envelope protein 
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was shown to directly bind C. albicans, increase C. albicans adhesion to HIV-1 infected 
cells, decrease phagocytosis of the yeast form, and increase secreted aspartyl protease 
release (a fungal virulence factor) (Wurzner et al., 1997) (Gruber et al., 1998). The same 
authors also claimed that HIV-1 Tat alone induced hyphal growth in C. albicans and 
increased phagocytosis (Gruber et al., 2001). However, another group showed that a 
small peptide portion of Tat entered and accumulated in C. albicans yeast cells and 
inhibits hyphal formation by inhibiting the cell cycle in G1 phase (Jung et al., 2006). In 
addition, apart from C. albicans, HIV-1 gp41 has been shown to bind other Candida 
species including C. dubliniensis and C. tropicalis. gp41 is able to modulate C. albicans 
adhesion to HIV-1 infected T cells as well as uninfected epithelial and endothelial cells 
(Gruber et al., 2003). Most recently, a complement receptor 3 (CR3) analogue in C. 
albicans (Hgt1) was identified that interacts with HIV-1 (Lesiak-Markowicz et al., 2011), 
although the evidence provided for a direct interaction is tenuous. Thus, our current 
understanding of Candida-HIV-1 interactions is elementary and somewhat confusing. 
 Work with HTLV and biofilm formation indicates that HTLV forms a carbohydrate 
(glycosylated) “cocoon” around itself in order to bind host cells and evade the immune 
system, thereby enhancing infectious capacity and improving transmission within the 
host (Pais-Correia et al., 2010; Thoulouze and Alcover, 2011). Like HTLV, HIV-1 is a 
simian derived retrovirus with two single stranded RNAs as its genome. Although work 
with HIV-1 in this area has not been undertaken, it is possible that given the highly 
glycosylated nature of gp120, HIV-1 may bind to biofilms laid down by the host 
microbiota including the carbohydrate/polysaccharide moieties of Candida species. In 
nature, the majority of the molecular mass of HIV-1 gp120 is made up of N-linked 
glycans (Allan et al., 1985; Checkley et al., 2011). Candida also has abundant 
glycosylation sites for attachment of N-linked and O-linked glycans, and many mutants 
defective in N- and O- glycosylation have been developed to assess cell-cell interactions 
(Bates et al., 2006; Bates et al., 2005; Munro et al., 2005). Thus, glycosylation moieties 
may be involved in HIV-1 and C. albicans interactions. 
The aims of this chapter were to determine (i) whether exposure of oral and 
vaginal epithelial cells to C. albicans alters the gene expression of HIV-1 associated 
receptors, thereby potentially promoting viral binding to epithelial cells, (ii) whether HIV-1 
directly binds Candida species and can be transferred to susceptible reporter cells, and 
(iii) whether the fungal moieties that bind HIV-1 and potentially mediate viral transfer. We 
investigated these by real-time PCR, p24 Western blotting, transfer of infectious virus to 
TZM-bl cells, and the utilisation of C. albicans glycosylation mutants and purified cell wall 
polysaccharide moieties. We determined that (a) there were minimal alterations in HIV-1 
receptor gene expression when epithelial cells were exposed to C. albicans, (b) HIV-1 
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directly binds Candida species and can be transferred to susceptible cells, and (c) fungal 
chitin and -glucan may be responsible for HIV-1 binding but only chitin appears to 
permit viral transfer to susceptible cells. 
8.2 Methods 
8.2.1 HIV related gene expression in epithelial lines following yeast stimulation 
For HIV related gene expression in epithelial lines following stimulation with 
SC5314 C. albicans (see section 2.4.2.1), A431 and TR146 cell monolayer were 
stimulated for 24h with 2x104 SC5314 yeast cells (2 yeast per 100 cells or MOI 0.02) and 
then RNA harvested and qRT-PCR performed as detailed in Chapter 2.4.2 (also in Table 
2.1 and 2.2).  
8.2.2 Yeast binding to HIV-1 and transfer of infectious HIV-1 
For yeast binding p24 western and yeast transfer to TZMbl cells, refer to 2.1.8.2 
and 2.1.15, respectively. Briefly, C. albicans and other Candida and yeast species cells 
were grown overnight at 30°C in YPD with shaking and 1 x 105 cells were exposed to 
approximately one infectious viral particle per cell (MOI confirmed as indicated) and 
incubated with shaking at 30°C for the indicated amount of time. Cells were centrifuged 
and washed thoroughly, and then either diluted with Laemelli’s buffer for boiling and 
Western blot analysis or incubated in DMEM 10 with amphotericin B (a fungicide) and 
plated onto TZM-bl cells in 96 well plates. Cells were fed with additional medium 
containing amphotericin B before being fixed and stained for β-galactosidase (blue foci). 
8.3 Results 
8.3.1 HIV-1 receptor gene expression in oral and vaginal epithelial cells in 
response to C. albicans. 
The resting expression levels of the HIV-1 receptor-associated genes are shown in 
Figure 8.1 and closely mirror those found in Chapter 3 (Fig. 3.1). Briefly, TR146 cells 
only express high levels of SDC-1, whereas A431 cells express moderate levels of SDC-
1 and ICAM-1. The HIV-1 canonical receptors CD4, CCR5, CXCR4 (and DC-SIGN) were 
very lowly expressed or undetectable. SDC-4 was also lowly expressed in both epithelial 
cell types. After exposure to C. albicans SC5314 for 24 h, the expression of all genes did 
not alter dramatically. Although some genes appear to demonstrate a decrease in 
expression in one or both cell types, the data is skewed since it derives from expression 
levels that are already very low and thus cannot be deemed relevant.  In conclusion, no 
major changes in HIV-1 gene receptor levels occur in response to C. albicans SC5314 at 
0.02 MOI 




Figure 8-1: Gene expression of HIV-1 associated receptors in oral TR146 and vaginal A431 








































































































- 134 - 
albicans SC5314 24 h incubation (yeast MOI of 0.02) (B), and fold change after 24 h treatment 
incubation with C. albicans (C). Graphs are representative of three independent experiments, 
each performed in duplicate and quantified using three technical replicates. 
8.3.2 Binding of HIV-1 to C. albicans 
 Although binding of HIV-1 gp41 by different species of Candida has been 
previously reported (Gruber et al., 2003), the binding of whole R5 and X4 virus to 
Candida has not previously been investigated to our knowledge. Thus, we incubated 
different Candida species (two strains of C. albicans and C. dubliniensis, C.tropicalis, C. 
krusei, C. glabrata, C. guilliermondii and Saccharomyces cerevisiae, see Methods 2.11) 
for 24 h with YU2-R5 and NL4.3-X4 virus and assessed for the presence of HIV-1 p24 by 
Western blot (Figure 8.2). It should be noted that for this experiment the MOIs of the two 
viruses were not the same (MOI of 8 for X4 and MOI of 0.5 for R5 or 8 x 105 X4 virus 
added versus 5 x 104 R5 virus added). Irrespective, when the viruses are considered 
individually, X4 virus appears to bind the two C. albicans strains most strongly, followed 
by C.tropicalis, then C. glabrata and S. cerevisiae equally well, and finally the remaining 
Candida species less strongly. Therefore, X4 virus binds to all the fungal species tested. 
Although the MOI of the R5 virus was lower, HIV-1 p24 could still be detected for all 
fungal species with strongest binding to C. albicans SC5314. Interestingly, binding to 
another C. albicans strain (529L) was as weak as with the other fungal species. 
Furthermore, although C. dubliniensis has been exposed to higher titre of X4 virus, the 
p24 band for R5 appears to be stronger, although this may be an anomaly.  
 
Figure 8-2: Detection of HIV-1 p24 on different fungal species.  Different fungal species were 
incubated with R5 and X4 virus for 24 h at 30°C and p24 detected by Western blot. Data are 
representative of 2 independent experiments.  
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Given that R5 is the trophism that normally initiates primary systemic HIV-1 
infections, all future work was performed using R5 virus. However, for the repeat binding 
experiment we used a different R5 virus (JRCSF-R5) and decreased the length of 
incubation to 2 h. We did this for two reasons; first, to determine whether viral binding 
would occur in a shorter time frame than 24 h and, second, that the poor detection of 
YU2-R5 may be due to removal of this virus after 24 h by unknown fungal mechanisms. 
We found that JRCSF-R5 virus bound strongly to all fungal species by 2 h, with C. 
guilliermondii having the poorest signal for p24 by Western blot (Figure 8.3).  
 
Figure 8-3 Detection of HIV-1 p24 on different fungal species.  Different fungal species were 
incubated with JRCSF-R5 virus for 2 h at 37°C and p24 detected by Western blot. Data 
representative of 2 experiments. 
 
Given that we showed HIV-1 can be transferred from epithelial cells to permissive 
cells (Chapter 6), we hypothesized that HIV-1 may also be transferred from Candida 
(e.g. from resident microbiota in vivo) to permissive cells. To test this, an assay was 
developed with C. albicans to determine whether this fungus could bind HIV-1 R5 and X4 
virus and then release infectious virus to permissive TZM-bl reporter cells. For this assay 
to be successful, either Fungizone or Amphotericin B (antifungal agents), was required to 
be added to the culture medium in order to prevent C. albicans from over-growing and 
killing the TZM-bl cells before blue foci (representing infection) could be evaluated. 
Figure 8.4 shows the presence of blue colonies 48 h after C. albicans (SC5314) with 
bound HIV-1 was placed onto the TZM-bl cells, indicating that the HIV-LTR driven 
reporter was activated, resulting in gene β-galactosidase expression. Therefore, C. 
albicans can bind and transfer HIV-1 R5 and X4 virus to permissive host cells. 
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Figure 8-4: Transfer of HIV-1 from C. albicans to permissive TZM-bl cells. C. albicans was 
incubated with HIV-1 YU2-R5 and NL4.3-X4 overnight, washed thoroughly, and plated onto TZM-
bl cells in the presence of Fungizone. Blue colonies are shown by arrows and represent activation 
of TZM-bl cells by visualising for β-galactosidase activity. Data are representative of 5 
independent experiments. 
 
Next, we wished to determine whether HIV-1 could bind to both yeast and hyphal 
forms of C. albicans and whether the virus could be transferred from both morphologies 
to susceptible cells. To test this, we incubated C. albicans mutants locked in the yeast 
(eed1) (Zakikhany et al., 2007), pseudohyphal (tup1) (Braun and Johnson, 1997)and 
hyphal (nrg1) (Murad et al., 2001)  (see 2.11) growth phases with YU2-R5 virus for 24 
h, followed by incubation with TZM-bl cells for 48 h. Figure 8.5 shows that all C. albicans 
mutants as well as the wild type SC5314 were able to bind R5 virus (p24 detection) and 
transfer virus to TZM-bl reporter cells. Therefore, viral transfer was independent of C. 
albicans morphology. However, it was noted that the two hyphal producing strains (wild 
type SC5314 and nrg1) transferred fewer viral particles than the non-hyphal forming 
strains (eed1 and tup1). 
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Figure 8-5:  C. albicans yeast and hyphae bind and transmit R5 virus to TZM-bl reporter 
cells. Yeast locked Δeed1, pseudohyphal locked Δtup1 and hyphal locked Δnrg1. MOI =1. Top 
panel shows p24 western: R5 shows YU2-R5 exposed yeast and – represents untreated yeast 
control. Bottom panel shows yeast transfer of infectious HIV-1 to TZM-bl reporter cells. Data are 
representative of two experiments. 
 
Since all the Candida strains and yeast/hyphal locked mutants were able to bind 
HIV-1, this indicated that the virus probably binds cell surface structures common to all 
fungi. The cell wall of fungi including C. albicans (yeast and hyphae) is composed of 
three main components: chitin, -glucan and proteins that are highly N- and O-
glycosylated (Chaffin, 2008). Since the outer most layer is formed of highly glycosylated 
proteins, we first tested whether C. albicans mutants defective in N- and O- protein 
glycosylation lost their ability to bind HIV-1 and transfer virus. We utilised three key C. 
albicans mutants known to be defective in either N- glycosylation (Δoch1) (Bates et al., 
2006), O- glycosylation (Δmnt1/2) (Munro et al., 2005), or both N- and O-glycosylation 
(Δpmr1) (Bates et al., 2005) (see section 2.11) . Figure 8.6 shows a schematic 
representation of the sugars/glycans affected in these genetic mutants (Murciano et al., 
2011). However, we found that all the glycosylation mutants were able to bind (Figure 
8.7) and transfer (Figure 8.8) YU2-R5 virus as well as the parent C. albicans strain 



































- 138 - 
 
Figure 8-6: Schematic representation of N- and O- glycosylation gene activity in C. 
albicans. Gene activity shown for Pmr1, Och1 and Mnt1/2. Adapted from (Murciano et al., 2011). 
 
 
Figure 8-7: Detection of HIV-1 p24 on different C. albicans glycosylation mutants.  C. 
albicans glycosylation mutants were incubated with YU2-R5 virus for 24 h at 30°C and p24 
detected by Western blot. Data are representative of 2 independent experiments. 
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Figure 8-8: C. albicans glycosylation mutants can transfer YU2-R5 virus to TZM-bl reporter 
cells. HIV-YU2 MOI 1.29. Data are representative of 3 independent experiments. 
 
Our data indicated that HIV-1 is unlikely to be binding to the glycosylation 
residues of surface proteins in C. albicans. Thus, we next investigated whether HIV-1 
was able to bind to the other two main constituents of the C. albicans cell wall: chitin and 
-glucan. Another reason for testing this was because of our data demonstrating that the 
two hyphal producing strains (wild type and nrg1) appeared to transfer fewer viral 
particles than the non-hyphal forming strains (tup1 and eed1)  (Fig 8.5). Although C. 
albicans hyphae possess more chitin than yeast cells the chitin is not as exposed as in 
yeast cells (in yeast cells chitin is exposed in bud scars during separation of the mother 
and daughter cell) (Munro et al., 1998). Thus, we hypothesised that if chitin was involved 
in HIV-1 binding and transfer, then the lack of exposed chitin on the surface of hyphal 
cells may explain why the two hyphal producing strains transferred fewer viral particles 
than the non-hyphal forming strains (Fig 8.5). 
Thus, we obtained purified chitin (crab) and -glucan (David Williams, University 
of Tennessee) and investigated their ability to bind and transfer YU2-R5 virus. This was 
undertaken together with the N- and O-glysosylation mutants for comparison. We also 
wanted to include purified N- and O-mannan in these studies rather than the 
glycosylation mutants; however, the purified mannan was soluble, unlike the chitin and -
glucan which were provided as insoluble particulate material. Establishing an assay to 
test HIV-1 binding to soluble mannan was not possible within the time frame of this 
thesis. However, performing these experiments with chitin and -glucan was rapid since 
the insoluble particulates could easily be centrifuged and washed after exposure to HIV-
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Figure 8.9 shows that YU2-R5 virus binds strongly to both chitin and -glucan, at 
levels similar to C. albicans wild type (SC5314) and parent (CAI4) strains. Since HIV-1 
binding was approximately equivalent to that of three glycosylation mutants (which do 
not possess N- or O-mannan), we tentatively concluded that HIV-1 probably binds to the 
chitin and -glucan components of the C. albicans cell wall and is unlikely to bind the 
glycosylation moieties of surface proteins. However, confirmation of this using purified 
mannan is required. 
 
Figure 8-9: Detection of HIV-1 p24 to C. albicans chitin, -glucan and different 
glycosylation mutants.  YU2-R5 virus was incubated with C. albicans chitin, -glucan and 
different glycosylation mutants for 24 h at 30°C and p24 detected by Western blot. Data are 
representative of 2-4 independent experiments.  
 
We then investigated whether both chitin and -glucan could transfer infectious 
R5 virus to TZM-bl reporter cells. Very interestingly, Figure 8.10 shows the number of 
blue colonies per well (MOI=145) and that HIV-1 can be efficiently transferred from chitin 
but not from -glucan when compared with the wild type C. albicans SC5314. Therefore, 
-glucan transfers HIV-1 significantly less effectively compared with chitin or wild type 
cells whilst binding HIV-1 with the same intensity. 
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Figure 8-10: C. albicans and insoluble glucose moieties mutants transfer of YU2-R5 virus 
to TZM-bl reporter cells. SC5314 MOI=145. The same number of virus particles were incubated 
with similar volume insoluble moieties. Error bars represent standard deviation between wells 
(12). * and **p<0.001 by Student T-test. Data representative of 2 independent experiments. 
 
8.4 Discussion  
The presence of co-pathogens at mucosal surfaces may promote HIV-1 infection 
either through facilitating the exposure of HIV-1 to permissive immune cells in the 
epithelium (Klotman et al., 2008) or by inducing inflammation leading to activation of the 
HIV-LTR (Ferreira et al., 2011). Although epithelial cells are known to bind HIV-1 and 
transfer virus to permissive immune cells (Asin et al., 2004; Asin et al., 2003; 
Vacharaksa et al., 2008; Wu et al., 2003), as also demonstrated in Chapter 6, whether 
co-pathogens can also bind HIV-1 and transfer virus is largely unknown. C. albicans 
infections are common oral manifestations of HIV-1 infection, and as such there appears 
to be a link between HIV-1 and C. albicans infection (Flint and American Society for 
Microbiology., 2009). Some studies have shown that C. albicans can bind to certain HIV-
1 components (Gruber et al., 2001; Gruber et al., 2003; Gruber et al., 1998; Wurzner et 
al., 1997) but the data are scarce. In this chapter we investigated this interaction further 
and find that while C. albicans does not alter HIV-1 receptor gene expression in oral and 
vaginal epithelial cells at the tested MOI, C. albicans does bind HIV-1 and is able to 
transfer infectious virus to permissive cells. Furthermore, we provide evidence that chitin 
and -glucan (but probably not mannoproteins) are the fungal cell wall components 
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 All the Candida and S. cerevisiae species tested were able to bind HIV-1 X4 and 
R5 virus as determined by p24 detection using Western blotting. These data are partially 
consistent with the HIV-1 gp41 peptide binding ELISA data previously determined, which 
showed that while 2 types of C. albicans and other species (C. dubliniensis and 2 types 
C. tropicalis) were able to bind gp41, but that C. krusei, C. glabrata and S. cerevisiae 
were unable to bind gp41 (Gruber et al., 2003). We additionally showed that C. 
guilliermondii can also bind HIV-1. This fungal-viral interaction is notable and is likely to 
occur at mucosal surfaces when these fungal species are exposed to HIV-1. 
Our data indicated that binding of HIV-1 to Candida would be independent of 
hypha formation, given that of the fungal species tested, only C. albicans and C. 
dubliniensis form true hyphae. This was confirmed using C. albicans mutants locked in 
the yeast (eed1), pseudohyphal (tup1) and hyphal (nrg1) forms, all of which were 
able to bind to HIV-1 R5 virus as determined by the p24 Western analysis. This is in 
contrast to previous findings that suggested the yeast form of C. albicans binds more 
poorly to HIV-1 gp41 than hyphae using the ELISA assay (Gruber et al., 2003). The 
differences between our data and that of Gruber et al (2003) most likely lie in the 
different assay used to investigate Candida-HIV-1 interactions (p24 Western versus 
gp41 peptide ELISA). 
Given that all the fungal species tested were able to bind HIV-1 and that this was 
independent of morphology, we hypothesised that common cell wall structures (chitin, -
glucan and mannoproteins) shared by all fungal species are the likely components 
mediating viral binding. Using a series of glycosylation mutants defective in N- and O-
glycosylation and purified insoluble chitin and -glucan particles, we found that chitin and 
-glucan appear to be the main fungal binding factors for HIV-1. Notably, we found no 
role for N- and O-glycosylation of proteins, which is in line with the supposition of 
Wurzner et al. (Wurzner et al., 1997), even though they did not directly test their 
supposition experimentally. However, chitin and -glucan are present in all fungal 
species, and since HIV-1 appears to bind C. albicans more strongly than other Candida 
species, this either indicates that more chitin and -glucan is exposed in C. albicans than 
in other Candida species or that other fungal factors also contribute to HIV-1 binding. 
Of major interest was that C. albicans was able to transfer HIV-1 to permissive 
TZM-bl cells and that this might be mediated by chitin. Although the ability of other 
Candida species and S. cerevisiae to transfer HIV-1 to permissive cells was not 
investigated, we assume they would be able to transfer HIV-1 as chitin is present in the 
cell walls of all these fungal species. Of even greater interest was that HIV-1 was not 
transferred (or transfer greatly reduced) to TZM-bl cells from -glucan These intriguing 
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data may suggest that -glucan binds to HIV-1 in a specific manner that may alter the 
HIV-1 envelope (gp41/120) structure so that it becomes inaccessible to canonical 
receptors (e.g. CD4, CCR5, CXCR4) on susceptible cells. It appears that glucan in 
complex with melanin (Seniuk et al., 2011) or as glucan sulphate (Tao et al., 2011a; Tao 
et al., 2011b), has potential as an anti-infective against HIV and bacteria (Mantovani et 
al., 2008). Thus, this highly interesting property indicates that -glucan could act 
potentially as a HIV-1 microbicide by preventing transfer of immobilized HIV-1 on 
mucosal surfaces to immune cells in the sub-mucosa. However, further characterization 
of these findings is clearly required. 
It should also be noted that -glucans are polysaccharides of D-glucose 
monomers. Thus, interactions between HIV-1 gp41/gp120 and glucose residues present 
in the C. albicans cell wall may also explain the resistance of immobilized HIV-1 to 
removal from epithelial cells by trypsin digestion (which targets protein-protein 
interactions) as determined in Chapter 4, especially by X4 virus. Although speculative, 
this provides an additional potential mechanism for why R5 rather than X4 virus is 
preferentially transmitted across mucosal tissues, in that specific retention of X4 virus by 
-glucan/glucose moieties in resident microbiota and mucosal secretions would prevent 
HIV-1 transfer to permissive cells in the sub-mucosa. Unfortunately, due to time 
constraints, we did not test whether X4 virus was retained more avidly or efficiently than 
R5 virus. 
Very recently, a study identified a C. albicans gene, HGT1, which encodes the 
high-affinity glucose transporter 1 (Hgt1p) that may mediate binding to HIV-gp160 
(Lesiak-Markowicz et al., 2011). However, the study was unconvincing and based only 
on the binding of the hgt1 mutant to a HIV-1 gp160 peptide as determined by ELISA. 
Also, gp160 binding was not eliminated in the hgt1 mutant and in fact was only reduced 
by less than 30%. Purified Hgt1 protein was not investigated and would have provided 
more definitive data regarding HIV-1 binding. Given that we found strong HIV-1 binding 
to all the fungal species tested as well as chitin and -glucan (common to all fungi), it is 
unlikely that HIV-1 would target a single, specific protein for binding to C. albicans. 
Although this study was published after the experimental work of this thesis was 
completed, it would have been very interesting to test the hgt1 strain, together with the 
parent and revertant strains, in our assay systems to determine their HIV-1 binding 
capacity and ability to transfer infectious virus to permissive cells. 
In order to take this work forward, -glucan and chitin could be masked by 
blocking antibodies in order to determine if this would affect p24 binding to these 
moieties and transfer to susceptible cells. Also -glucan linkages can be 1-3 or 1-6, 
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therefore these moieties could be inhibited separately to determine which is required for 
HIV-1 binding and the inhibition of transfer. In addition, the TZM-bl cells could be 
substituted for primary myeloid cells to verify the -glucan data.  
An experimental analysis of how HIV could “piggyback” on C. albicans hyphae 
that are invading mucosal tissues to infect susceptible cells was not considered. One 
could perhaps attempt this in primary explants or multilayered reconstituted epithelial 
models that would then be infected with fluorescently-labelled HIV and Candida and 
analysed using immunohistochemistry, FISH and/or primer-probe PCR for HIV 
integration in the epithelium. 
 
8.5 Conclusion 
HIV-1 interactions with Candida were characterised in this chapter. All fungal 
species tested (C. albicans, C. dubliniensis, C. tropicalis, C. krusei, C. glabrata, C. 
guilliermondii and S. cerevisiae) were shown to bind HIV-1 R5 and X4 after  24 h and R5 
after 2h exposure as determined by p24 Western analysis. HIV-1 binding was 
independent of (yeast or hyphal) morphology and appeared to be mediated by chitin and 
-glucan in the cell wall, but not by N- and O-glycosylation structures of surface proteins. 
Notably, C. albicans was able to transfer infectious HIV-1 to susceptible reporter TZM-bl 
cells and this might be mediated by chitin. Of specific interest was that binding of HIV-1 
by -glucan may prevent transfer of HIV-1 to permissive cells, which identifies -glucan 
as a potential microbicide to prevent mucosal HIV-1 transmission.  
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Chapter 9 Conclusion 
 
The HIV pandemic has affected well over 40 million people worldwide since it 
was first identified thirty years ago. Like all viruses, HIV depends heavily on host-cell 
factors that enable the virus to enter cells, manifest the infection and produce progeny 
virions. Information regarding the interactions of HIV-1 with epithelial surfaces of the 
human oral and vaginal mucosa is limited in comparison with immune cells, and the 
exact cellular and molecular events involved in initial HIV-1 entry and mucosal infection 
are poorly understood. HIV-1 may use various strategies to infect the human host via 
mucosal surfaces and its transmission probably involves common steps, including 
survival of HIV-1 in mucosal secretions, interaction of HIV-1 with epithelial cells, 
transport/transmigration of the virus across the epithelium, and infection of 
CD4+/chemokine receptor+ target cells in the sub mucosa. In addition to these HIV-1-
epithelial based events, disease progression in HIV-1 positive individuals is thought to be 
more rapid in the presence of co-pathogens, reducing survival and increasing the risk of 
HIV-1 transmission. These co-pathogens may include C. albicans, which is the most 
common fungal pathogen of humans and accounts for more than 50% of all fungal 
infections. Therefore, this project set out to investigate several aspects of HIV-1-mucosal 
interactions. The three main aspects of the work were: 
1. To determine whether HIV-1 binding, integration and productive infection occurs in 
oral and vaginal epithelial cells. 
2. To assess epithelial responses to HIV-1. 
3. To characterise HIV-1 and C. albicans interactions. 
 
9.1 HIV-1 binding, integration and productive infection in oral and 
vaginal epithelial cells 
Using flow cytometry and Western blotting to detect gp120 and p24, we 
demonstrated that oral (TR146, FaDu) and vaginal (A431) epithelial cell models do not 
express discernable levels of CD4, CCR5 or CXCR4, but they do bind both X4 and R5 
virus probably via non-canonical receptors. Once captured, HIV-1 remains infectious and 
can be transferred to permissive TZM-bl reporter cells. However, HIV-1 integration as 
measured by a primer-probe PCR was not detected. We conclude that while productive 
HIV-1 infection is unlikely to occur in epithelial cells under normal conditions (e.g. in 
health), epithelial cells may provide a potential route to establish systemic infection 
through sequestration and transfer of HIV-1. 
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One must consider the alternate view that healthy epithelia are quite effective 
barriers to HIV transmission (Greenhead  et al., 2000). In many places they are 
multilayered, and the mucosae where they reside are hostile places for viruses to exist 
and remain infectious, let alone be transmitted. Since epithelial cells do not normally 
appear to get HIV-infected, they may play a passive role in retaining virus but the primary 
routes of transfer through them may only be by abrasion, or in the context of a co-
infection causing inflammatory damage, or loosening of tight junctions that allow the 
virus to reach scavenging susceptible cells such as macrophages and dendritic cells in 
the mucosa (Greenhead et al., 2000; Shattock et al., 2003). 
One of the key findings was that X4 virus binding to both oral and vaginal 
epithelial cells was more resistant to trypsin than R5 virus binding. This indicates that X4 
viruses may predominantly utilise non-protein moieties (such as GalCer or 
carbohydrate/lectin-based molecules) to bind epithelial cells and R5 viruses may 
predominantly utilise protein moieties (such as HSPG’s or ICAM-1). However, during the 
course of this write-up, a study also implicated mannose receptor in HIV-1 binding to 
vaginal epithelial cells (Fanibunda et al., 2011). It would, therefore, be interesting to 
determine a role for mannose receptor in mediating HIV-1 binding to and transfer from 
epithelial cells, perhaps using blocking antibodies or mannose to inhibit viral binding to 
the mannose receptor. Given that HIV-1 capture by epithelial cells may be a key first 
step in viral transfer to permissive immune cells, identification and manipulation of the 
non-canonical viral-specific receptors that mediate HIV-1 binding may have the potential 
to prevent primary systemic infections. As such, this should be a focus of future work. 
Furthermore, since oral, oro-pharyngeal and vaginal epithelial lines are able to transfer 
infectious virus to permissive cells, the next logical step would be to quantify the amount 
of transfer that occurs from these different epithelial cell lines. This would provide an 
indication of the efficiency of transfer and the subsequent relevance of this for infection in 
vivo. Also, blocking of receptors with small molecule inhibitors or antibodies should be 
prioritised in order to identify which impair transfer of HIV from epithelium to permissive 
cells. 
An additional issue which is rarely discussed is that, currently, the consensus is 
that HIV-1 binding to epithelium is only mediated by HIV-1 gp120 interactions with 
receptors on the epithelial surface (Yahi et al., 1992; Yahi et al., 1995). However, when 
new viral progeny are produced they incorporate the host membrane during budding 
(Cantin et al., 2005; Paquette et al., 1998) as well as only approximately 14 virus spikes 
per particle (Zhu et al., 2006). Thus, the majority of the proteins on the viral outer surface 
(membrane) are host derived. As such, it is possible that these host proteins also play a 
role in the attachment of HIV-1 to epithelial cells rather than, or in concert with, HIV-1 
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gp120. To verify whether gp120 alone is required for viral-epithelial interactions, future 
experiments should expose epithelium to envelope (gp120)-deficient clones of HIV-1. 
This would allow us to determine whether HIV-1 binding of epithelium can be gp120 
independent.  
It is currently unknown how HIV-1 remains infectious on the epithelium (Dezzutti 
et al., 2001; Wu et al., 2003). One possibility is that HIV-1 gets taken into the epithelial 
cell by endocytosis and is retained in vesicles inside the cell prior to transfer of virus 
during interactions with permissive cells. Alternatively, HIV-1 may get enwrapped in 
microvillus structures on the surface of the epithelium protecting the virus from the harsh 
external environment. Data from our group (but not part of this thesis) demonstrates that 
when HIV-1 is pseudotyped with VSV-G envelope and therefore enters epithelial cells via 
the endocytic pathway, a productive HIV-1 infection ensues (Kohli et al., 2012 
submitted). This demonstrates two key points. First, that epithelial cells possess the 
cellular machinery to assemble and secrete infectious viral progeny if receptor-mediated 
entry is by-passed. Second, that HIV-1 does not normally enter epithelial cells via the 
endocytic pathway, otherwise a productive infection would ensue with live virus. These 
data would suggest that, post-capture, HIV-1 remains on the epithelial surface (possibly 
enwrapped in microvillus structures) and that viral transfer occurs from the surface. 
However, these possibilities would require further detailed investigations. 
 
9.2 Epithelial responses to HIV-1 
Since HIV-1 was able to bind to epithelial cells, albeit not resulting in a productive 
infection, we next attempted to unravel the responses of oral (TR146) and vaginal (A431) 
epithelial cell lines to HIV-1 exposure and determine the underlying signalling events. 
Although, HIV-1 gp120s and trimeric gp140s did not induce the tested cytokines in oral 
or vaginal epithelial lines, epithelium does appear to recognise whole virus particles. In 
TR146 cells, YU2-R5 virus activates the p38 pathway whereas LAI-X4 virus may inhibit 
p38, ERK1/2 and NF-kB signalling. In A431, however, YU2-R5 virus activates the three 
main branches of the MAPK pathway (p38, JNK and ERK1/2) as well as IRF3, whereas 
LAI-X4 virus only activates p-38. Therefore, oral and vaginal cells appear to respond 
differently to HIV-1 R5 and X4 virus. A greater exploration or signalling pathways is 
warranted looking at TNF, IRF7 and IFN-induced genes as well as other intracellular 
signalling pathways. Notably, exposure of epithelial cells to HIV-1 R5 and X4 virus also 
induces cellular damage. Exploring the activation of various apoptotic pathways would 
be desirable in order to determine the origin of cellular damage.  The role of these 
individual signalling pathways in mediating HIV-1 responses and damage is currently 
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unknown, but future experiments using either small chemical inhibitors or siRNA’s would 
be informative in identifying the essential processes involved in the epithelial response to 
HIV-1. Furthermore, it would be valuable to confirm these findings in primary oral and 
vaginal epithelium. 
The differences in signalling response to HIV-1 were confirmed in oral epithelial 
cells (primary and carcinoma) at the gene expression level by preliminary singleton 
microarray analysis. YU2-R5 increased apoptosis and cell death pathways and regulated 
the cell cycle while promoting transcriptional repression and cytokine activity. YU2-R5 
also decreased negative regulation of apoptosis, regulation of cell adhesion and integrin 
mediated signalling. Conversely, LAI-X4 increased negative regulation of MAPK 
signalling, transcription and cell cycle regulation. Along with the previous data, this 
implies that oral epithelium is not an inert barrier to HIV-1 infection but instead responds 
to virus challenge, with similar pathways activated as those previously reported in 
immune cells. Given that these data were based on singleton arrays with oral epithelial 
cells, additional microarray investigation of both oral and vaginal epithelium with triplicate 
and properly controlled biological repeats would be highly informative in determining how 
epithelium responds to HIV-1 on a global scale. This would also possibly provide insights 
into host mediated events that may promote R5 over X4 virus selectivity during initial 
infection. 
The potential importance of immune-regulation in HIV-1 transmission was 
recently indicated in study of HIV-exposed seronegative sex workers, which correlated 
high levels of anti-proteases in the vaginal mucosa with lower levels IL-1α, monokine 
induced by interferon-γ (MIG) and interferon-γ-induced protein 10 (IP-10) in vaginal 
cercovaginal lavages (Lajoie et al., 2012). These women also had limited T-cell 
inflammation in the mucosa as compared with other commercial sex workers and HIV-
positive commercial sex workers. Overall the data lend support to the idea that immune 
quiescence may protect against systemic HIV-1 infection, which could be explored in 
future investigations. 
 
9.3 Characterisation of HIV-1 and C. albicans interactions 
Finally, we investigated the interaction of HIV-1 with human opportunistic 
pathogens in the genus Candida, predominantly C. albicans. All Candida species and C. 
albicans yeast and hypahe were able to bind and transfer HIV-1 to permissive cells. 
Notably, we identified two C. albicans cell wall molecules, chitin and -glucan, that were 
capable of binding HIV-1. Neither has previously been implicated in interactions with 
HIV-1. Perhaps more importantly we found that HIV-1 could only be transferred to 
- 149 - 
permissive cells from chitin but not -glucan, indicating that -glucan may be able to 
sequester HIV-1 and thereby prevent primary infections. As -glucan does not induce 
cytokine secretion or inflammation in epithelial cells (Moyes et al., 2010), -glucan has 
considerable potential in prophylactic treatment and therapeutics to prevent HIV-1 
infection. Thus, further investigations in this area are highly warranted. 
Very recently, a study identified a C. albicans gene, HGT1, which encodes the 
high-affinity glucose transporter 1 (Hgt1p) that may mediate binding to HIV-gp160 
(Lesiak-Markowicz et al., 2011). Given that we found strong HIV-1 binding to all the 
fungal species as well as chitin and -glucan (common to all fungi), it is unlikely that HIV-
1 would target a single, specific protein for binding to C. albicans. However, since HIV-1 
binding to epithelial cells is trypsin sensitive (and thus, in part, protein mediated), 
especially R5 virus, it might also be useful to determine what proportion of HIV-1 binding 
to Candida is protein dependent and independent in future experiments. 
As mentioned above, our group has discovered that HIV-1 is able to integrate into 
the epithelial genome when it enters via endocytic mechanisms (Kohli et al 2012 
submitted). Although viral entry via endocytosis does not appear to occur under normal 
conditions (e.g. in health), it would be very interesting to test whether under inflammatory 
conditions, such as those caused by co-infections with secondary pathogens, HIV-1 
could integrate into the epithelial genome. Since HIV-1 can directly bind C. albicans 
hyphae and the hyphal form is essential for epithelial invasion and inflammation, future 
studies investigating whether HIV-1 can ‘piggy-back’ on C. albicans hyphae to gain entry 
into epithelial cells would be of considerable interest. This would enable HIV-1 to by-pass 
conventional receptor-mediated mechanisms to gain entry into epithelial cells and 
integrate into the genome, thereby establishing a productive infection in mucosal tissues. 
A similar process of HIV-1 transmission may also occur with other oral and vaginal 
microbiota such as Lactobacillus species (vaginal) and Streptococcus species (oral). 
However, no data on this currently exists and such a hypothesis would need thorough 
investigation. 
Lastly, recent studies using murine models suggest that viruses may take 
advantage of immune tolerance to local microbiota in order to evade the immune 
response and to promote infection (David, 2011; Kane et al., 2011; Kuss et al., 2011). 
One group used the mouse mammary tumour virus (MMTV), which is passed from 
mother to offspring, to show that when the mice were treated with antibiotics to eliminate 
gut bacteria, the pups could mount an effective immune response and clear the virus 
(Kane et al., 2011). Using knockout mice the authors implicated TLR4, its co-receptor 
CD14, IL-6 and IL-10 in mediating MMTV transmission and suggest the following 
sequence of events: TLR4/CD14 binds bacterial LPS and activates signal pathways that 
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results in IL-6 production which in turn induces IL-10 secretion. IL-10 dampens the 
immune response, thereby allowing MMTV to establish a chronic infection. Another 
group investigated the transmission of poliovirus and also found that gut microbiota had 
a role to play in viral transmission, as antibiotic treated mice demonstrated better survival 
rates than control animals following oral polio infection (Kuss et al., 2011). Polio also 
replicated less efficiently in the intestines of antibiotic treated mice versus mice that had 
not received antibiotics. The authors found that interaction of poliovirus with LPS 
increased viral infectivity. Thus, a picture appears to be emerging in the literature 
whereby mucosal viruses may potentially hijack the immune system by utilizing the 
tolerance mechanism developed to resident microbiota. This mechanism could also 
apply to other mucosally transmitted viruses such as HIV-1 and should be investigated in 
future experiments. For example, using the humanized mouse models for HIV-1 
infection, RAG-hu (Berges et al., 2008), or the humanized bone marrow/liver/thymus 
mice (Melkus et al., 2006) one could pre-treat mice with antibiotics and identify whether 
the mice can clear HIV-1 upon vaginal and rectal challenge with X4 and R5 virus. The 
latter mouse model, where human fetal liver and human fetal thymus are implanted into 
irradiated NOD-scid IL2rγnull , develop systemic human immune cell types monocytes, 
macrophages and dendritic cells as well as T and B cell responses to HIV (Brainard et 
al., 2009). Although many virologists are not convinced by small animal models of 
human immunity, others are hopeful that they will help further our understanding of HIV 
transmission and biology (Singh et al., 2012; Nischang et al., 2012; Chang et al., 2012). 
If successful, undertaking similar experiments in new world monkey's challenged with 
SIV would be of interest. 
In summary, microbes clearly interact with one another at mucosal surfaces in 
health and disease to generate different responses from the host. These interactions can 
improve an individual microbe’s ability to colonise, invade or induce pathology. The 
breadth of these interactions can lead to difficulties in elucidating the microbial 
mechanisms used in the pathology of a disease, especially when these microbes are 
investigated in isolation from the wider microbiota or their potential partners. We must, 
therefore, continue to unravel this ever more complicated, intricate puzzle to gain a fuller 
understanding of events at mucosal surfaces and thus identify more effective therapies 
for the treatment and prevention of these infections. 
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Appendix C: Gp120 antibodies tried in flow cytometry 
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Please consider the enclosed manuscript entitled “Oral epithelial cells bind and transfer infectious 
HIV-1 to permissive cells but are not productively infected” for publication in PLoS ONE. 
The majority of HIV-1 infections worldwide are acquired via mucosal surfaces, predominantly across 
the female or male genital tracts. Currently, the oral epithelium is generally recognized as a barrier to 
HIV-1 transmission. However, given the ambiguous literature on this fundamentally important topic, 
we aimed to determine whether HIV-1 binds, enters and integrates into oral epithelial cells, whether 
productive infection ensues, and whether sequestered infectious virus can be transferred to 
permissive cells. We utilized epithelial cell lines representative of two oral sites that are rarely 
investigated with regard to oral transmission but are one of the first cell types that are likely to come 
into contact with HIV-1 in the oral cavity. Buccal (TR146) and pharyngeal (FaDu) epithelial cells, both 
of stratified squamous cell origin, were utilized to permit convenient and direct comparisons to be 
made with regard to HIV-1 life cycle events. 
Our extensive data demonstrate that HIV-1 X4 and R5 virus can readily bind oral epithelial cells (via 
non-canonical viral-specific receptors) but integration of the viral genome into epithelial cell DNA and 
de novo virus production were not detected. Thus, productive infection does not occur in oral 
epithelial cells. However, oral epithelial cells possess the cellular machinery to support productive 
HIV-1 infection if the virus enters via the endocytic pathway or if conventional entry mechanisms are 
by-passed. Once captured, HIV-1 also remains infectious on the surface of oral epithelial cells, which 
has important implications in vivo given the occurrence of viral transmission in nursing infants and 
during oro-genital contact in adults. The oral route may thus facilitate direct viral transfer to 
permissive cells in the sub-mucosa, thereby establishing acute infection by disseminating HIV-1 in 
the body. Therefore, although often considered a rare site of HIV-1 infection, the oral mucosa may 
have been overlooked as a potential route of viral transmission and mediator of systemic infection.  
We would like to stress the novelty aspects of our work to PLoS ONE. First, TR146 and FaDu 
epithelial cell lines have not previously been used to investigate HIV-1 binding or infection. Thus, the 
entire data set is novel. Second, to our knowledge gp120 detection on the surface of epithelial cells 
and trypsin resistance to gp120 detection as measured by flow cytometry is also novel. Finally, the 
viral integration experiments using the qPCR based primer-probe method has not previously been 
used in oral epithelial studies. Finally, we stress that the research group that provided us with primary 
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Whether the oral mucosa can act as a portal of entry for HIV-1 infection remains a controversial 
issue. Given the fundamental importance such entry may have in the spread of HIV, there are 
relatively few publications in this area. To address this issue we utilized two epithelial cell lines 
representative of buccal (TR146) and pharyngeal (FaDu) sites of the oral cavity to determine (i) 
HIV-1 receptor gene and protein expression, (ii) whether HIV-1 integration into oral epithelial cells 
occurs, (iii) whether productive viral infection ensues, and (iv) whether infectious virus can be 
transferred to permissive cells. Using flow cytometry to measure captured virus by HIV-1 gp120 
protein detection and western blot to detect HIV-1 p24 gag protein, we demonstrate that both buccal 
and pharyngeal epithelial cells capture X4 and R5 virus, probably via non-canonical receptors and 
are able to transfer infectious virus to permissive cells. However, HIV-1 integration, as measured by 
real-time PCR and presence of early gene mRNA transcripts and de novo protein production were 
not detected in either epithelial cell type. Our data demonstrate that although productive HIV-1 
infection of oral epithelial cells leading to progeny virion production and viral dissemination is 
unlikely, it may provide a potential route as a mediator of systemic infection through attachment 
and transfer of HIV-1 to permissive cells. 
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The majority of HIV-1 infections worldwide are acquired via mucosal surfaces, predominantly 
across the female or male genital tracts [1]. In contrast, HIV-1 transmission through the oral mucosa 
is thought to be uncommon [2-7]. We and others have shown that several mechanisms may account 
for this, including neutralizing antibodies in seropositive individuals and innate anti-HIV inhibitory 
factors in saliva and/or epithelium [8-12]. However, studies in primates indicate that oral 
transmission is a possible occurrence since non-traumatic oral exposure to SIV results in regional 
dissemination followed by systemic infection [13-16]. Therefore, although oral epithelium may 
present a barrier to HIV-1 transmission, it may also be a conduit for viral entry. This is particularly 
important given the occurrence of viral transmission in nursing infants and during oro-genital 
contact in adults. 
Entry of HIV-1 into permissive host cells requires expression of the receptor CD4 and a 
fusion co-receptor (chemokine receptors CCR5 (R5-tropic) or CXCR4 (X4-tropic)) [17]. However, 
the vast majority of reports indicate that oral epithelial cells do not express CD4 [18-22] and 
express CCR5 and CXCR4 at either undetectable or very low levels [11,18,21,23,24]. Despite these 
receptor dependencies, HIV-1 may also infect CD4
-
 cells such as spermatozoa [25], fibroblasts [26] 
and oligodendrocytes [27], as well as epithelial cells from other mucosal sites including the thymus 
[28], cervix [29] and the gastrointestinal tract [30]. Hence, HIV-1 may utilize several alternative 
receptor mechanisms for binding and entry into cells. Besides binding to canonical entry receptors, 
the viral envelope protein gp120 also binds to several other cell-surface molecules including DC-
SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) [31,32], 
GalCer (glycosphingolipid galactosylceramide) [27,33,34], and heparan sulphate proteoglycans 
(HSPGs) such as syndecan-1 [35,36]. GalCer and HSPGs are commonly expressed on epithelial 
cells and may promote HIV-1 binding [11,36,37]. Importantly, there is a preference for R5-tropic 
viral transmission across mucosal surfaces [38], but a full and satisfactory explanation for this has 




































































The fundamental issue of whether oral epithelial cells can be productively infected with HIV-
1 remains controversial. Although the recovery rate of infectious HIV-1 from saliva is low, proviral 
DNA has been detected in oral epithelial cells [39]. Likewise, the presence of HIV-1 gag RNA has 
been demonstrated in both buccal cells [40,41] and oral biopsies [41,42]. These findings suggest 
that HIV-1 proviral DNA may integrate into the epithelial cell genome, but the literature remains 
ambiguous as to whether a productive infection ensues. For example, using primary gingival 
epithelial cells, one study showed susceptibility to R5 but not X4 tropic viral strains in a CD4-
independent manner [43], whilst another study showed X4 rather than R5 susceptibility [18], with 
epithelial cells being able to secrete infectious virus. Primary epithelial cells isolated from adenoids, 
palatine tonsils and salivary glands may also be productively infected with HIV-1 [43-48]. 
However, others have found no evidence of productive HIV-1 infection in oral epithelial cells 
[20,21]. Rather, HIV-1 is preferentially sequestered and transferred to permissive cells to establish a 
primary infection [21,36,49-52]. 
Given the ambiguous literature on this fundamentally important topic, we aimed to determine 
whether HIV-1 binds, enters and integrates into oral epithelial cells, whether productive infection 
ensues, and whether sequestered infectious virus can be transferred to permissive cells. We utilized 
epithelial cell lines representative of two oral sites that are rarely investigated with regard to oral 
transmission but are one of the first cell types that are likely to come into contact with HIV-1 in the 
oral cavity. Buccal (TR146) and pharyngeal (FaDu) epithelial cells, both of stratified squamous cell 
origin, were utilized to permit convenient and direct comparisons to be made with regard to HIV-1 
life cycle events. We demonstrate that both epithelial cell types were able to capture X4 and R5 
virus but integration of the viral genome into epithelial cell DNA and de novo virus production were 
not detected. Notably, VSV-G-packaged HIV-1 was replication competent in both epithelial cell 
lines. Finally, both epithelial cell types were able to transfer infectious virus to permissive cells, 
which in vivo would permit infection of immune cells in the sub-mucosa and dissemination of HIV-







































































Primary epithelial cells (gingival) were obtained from wisdom tooth extractions and were kindly 
provided by Maxine Partridge and collection approved by the Guy’s Ethics Research Committee. 
 
Cell lines, primary cells, viruses and virus-like particles 
Human oral buccal (TR146) and pharyngeal (FaDu) carcinoma cell lines and 293T (renal epithelial) 
cells were obtained from the American Type Culture Collection. Human glioma cells (NP2) 
expressing human CD4 and CXCR4 or CCR5 have been previously described [53]. The following 
reagents were obtained through the AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH: TZM-bl cells (catalogue no. 8129), PM1 cells (catalogue no. 3038), 8E5/LAV 
cells (catalogue no. 95), C8166 T cells (catalogue no. 404 donated by Robert Gallo), JTLRG-R5 
(catalogue no. 11586) and HIV-1 molecular clones pYU2 (R5-utilizing, catalogue no.1350) and 
pLAI.2 (X4-utilizing, catalogue no. 2532). The HIV-1 gag-pol expression vector p8.91 and the 
vesicular stomatitis virus envelope protein (VSV-G) expression vector pMDG were kindly provided 
by Didier Trono (University of Geneva, Switzerland). The HIV gp160 envelope vectors (pHXB2 
(X4), pYU2 (R5) and pSVIII 89.6 (dual tropic)) were a gift from Professor Greg Towers, University 
College London. The retroviral packaging vector pCSGW encoding GFP was a kind gift from 
Adrian Thrasher, Institute of Child Health, University College London, UK. All cell lines were 
maintained in Dulbecco's Modified Eagle's Medium (DMEM, PAA) supplemented with 10% fetal 
bovine serum (FBS) (PAA), 100 U of penicillin per mL, and 100 µg of streptomycin per mL (PAA) 
at 37C and 5% CO2. NP2 cells were additionally supplemented with 1 mg/mL of G418 
(Invitrogen) and 1µg/mL
 







































































Viral vectors used for production of VSV-G and HIV gp160 pseudotyped HIV were prepared by 
transient transfection of 293T cells using a protocol adapted from Besnier et al. [54]. Briefly, 293T 
cells were seeded at 95% confluency
 
in a 10 cm
3
 dish and the following day cells were transfected 
with 3 g each of pMDG and p8.91 and 4.5 g of pCSGW using the polyanionic transfection 
reagent Jet PEI (Polyplus Transfection) according to the manufacturer’s instructions. After 24 h the 
media was replaced and 48, 72 and 96 h post-transfection virion-containing culture supernatants 
were harvested and filtrated through a 0.45µm pore size membrane and stored in aliquots at -80C 
until required. Production of infectious stocks of live virus was performed by transient transfection 
of 293T cells as described above, with 5 µg of the infectious molecular clone pLAI.2 (X4) and or 
pYU2 (R5) used per transfection. For trypsin sensitivity experiments and detection of integration 
into epithelium, YU2 virus was grown in NP2-R5 and JLTRG-R5 cells while LAI virus was grown 
in C8166 cells for 1- 2 weeks with addition of fresh medium until cells showed cytopathic effects 
and were then harvested and frozen in aliquots. 
 
Virus titration 
Infectious virus stock (LAI and YU2) titers were determined by plaque assay. Briefly, TZM-bl cells 
(1 × 10
4
 cells/well) were cultured overnight (96-well plates) and incubated with eight replicates of 
ten serial dilutions (0.5 log) of virus stock in a total of 100 μL growth media per well. After 48 h, 
virus supernatant was removed and the cells were fixed with 0.05% glutaraldehyde for 5 min at 
room temperature and washed twice with phosphate-buffered saline (PBS). Expression of β-
galactosidase was determined by staining cells with X-Gal stain [1mg/mL X-Gal in 5 mM 
KFe4(CN6) 3H2O, 5 mM KFe3(CN6) 3H2O, and 1 mM MgCl2] and incubating culture plates at 37°C 
for 2 h. Virus infectivity was
 
estimated as plaque forming units (PFU) per mL. Titration of VSV-G 
pseudotyped HIV-1 and HIV gp160 pseudotyped HIV-1 was carried out using 293T cells or NP2 
cells, respectively. Cells were seeded at 1 x 10
5




































































37°C. Serial dilutions (1:2) of virus supernatant were applied to the cells (500 L) and incubated 
overnight. The following day the media was exchanged and 48 h after transduction with virion-
containing culture supernatants the percentage of GFP-expressing cells was determined by flow 
cytometry using the FACSCanto machine (BD Biosciences). Data was analyzed with FACSDiva 
software and WinMDI (copyright 1993-2000 Joseph Trotter http://facs.scripps.edu) to calculate the 
infectious units per mL. 
 
HIV-1 receptor expression by quantitative reverse transcription-PCR 
RNA was isolated from resting TZM-bl, TR146 and FaDu cells using GenElute Mammalian Total 
RNA Miniprep Kit (Sigma), followed by treatment with Turbo DNA free DNAse (Ambion) 
according to the manufacturer’s instructions. All samples were confirmed DNA free prior to 
analysis. cDNA was synthesized from 1 g of RNA using HIV reverse transcriptase (Ambion) 
according to the manufacturer’s instructions. Primers were obtained from RTPrimerDB 
(http://medgen.ugent.be/rtprimerdb/) and PrimerBank (http://pga.mgh.harvard.edu/primerbank) 
[55,56]. Gene expression of CD4, CCR5, CXCR4, DC-SIGN, SDC-1 (syndecan-1) and SDC-4 
(syndecan-4) was quantified by real-time PCR using SYBR Green JumpStart Taq Ready Mix 
(Sigma) with 4 pmol primers and 1 μL cDNA in 10 μL reactions on the Corbett Research Rotor-
Gene 6000 (Qiagen) using the following cycling parameters: 95°C for 3 min; followed by 95°C for 
3 s, annealing for 10 s and extension for 20-30 s for 40 cycles. Data was analyzed with Corbett 
Research Rotor-Gene 6000 Series Software 1.7 using the two standard curve method with β-actin 
used as the normalizer gene. Primer sequences, annealing and extension temperatures are listed in 
Table 1. 
 
HIV-1 receptor expression by flow cytometry 
TZM-bl, NP2-X4, NP2-R5, TR146 and FaDu resting cells were washed with PBS and incubated 




































































supplemented with 1% BSA and 0.01% azide (wash buffer), and resuspended at 1 × 10
6
 cells in 1 
mL wash buffer. To identify surface expressed HIV-1 receptors and co-receptors, 100 L of cells 
were incubated at room temperature for 1 h with mouse anti-human CD4 (1:4 catalogue no.724), 
CCR5 (1:20, catalogue no. 4090), CXCR4 (1:80, catalogue no. 4083), DC-SIGN (1:100 catalogue 
no. 6884) monoclonal antibodies (all obtained from the AIDS Research and Reference Reagent 
Program), GalCer (1:200, anti-galactocerebroside, Millipore) or heparan sulfate proteoglycan 
(1:200, Millipore) monoclonal antibodies. Primary antibodies were detected with goat anti-mouse 
IgG conjugated with fluorescein isothiocyanate (FITC) (Jackson ImmunoResearch). After thorough 
washing, cells were fixed in 200 L 4% formaldehyde and the percentage of FITC-expressing cells 
was determined by flow cytometry. 
 
Detection of HIV-1 binding and replication by Western Blot 
TR146, FaDu and TZM-bl cells were seeded at 5 x 10
5
 cells per well and the following day infected 
with YU2 (R5) or LAI (X4) virus at a multiplicity of infection (MOI) of 0.2. After overnight 
incubation at 37
o
C the cells were washed to remove unbound virus. Cells were harvested in 250 L 
1 x RIPA buffer [50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium 
deoxycholate and 0.1% SDS, supplemented with Halt complete protease inhibitor cocktail (Perbio 
Science)], placed on ice for 30 min, and stored at -80C until required. Total protein lysates 
(mammalian and viral) were normalized for protein content using the bicinchoninic acid (BCA) 
assay (Pierce) and separated using 12% SDS-PAGE gels. Proteins were transferred to PVDF 
membranes, probed with anti-HIV-1 gag monoclonal antibody recognizing p24 and p55 isoforms 
(catalogue no.6457)) and secondary goat anti-mouse IgG horseradish peroxidase (HRP)-conjugated 
antibody (Jackson ImmunoResearch), before developing using Immobilon-ECL (Millipore). -actin 






































































Detection of HIV-1 binding and packaged viral RNA by PCR 
TR146, FaDu and TZM-bl cells were seeded at 5 x 10
5
 cells per well and the following day infected 
with YU2 (R5) or LAI (X4) virus at an MOI of 0.2. After overnight incubation at 37
o
C the cells 
were washed to remove unbound virus. Total RNA was isolated as above and confirmed DNA free 
prior to analysis. Equal amounts of total RNA was used to detect packaged viral RNA by first 
synthesizing cDNA using Superscript cDNA Synthesis Kit (Invitrogen) and an HIV-1 
specific primer (5'-GTC ATG AAA CAA ACT TGG C-3'). A 2 L aliquot of cDNA was then 
subjected to nested PCR using primers to amplify a 2 kb fragment of the HIV pol gene. First round 
PCR was performed in a 20 µL reaction containing
 1 x PCR buffer, 100 µM dNTP’s, 1.5 mM 
MgSO4, 2.5 U Taq polymerase (New England Biolabs) and 10 pmol
 
 of each primer (Forward: 5'-
AAT GAT GAC AGC ATG TCA GGG AGT-3'; Reverse: 5'-AGT CTT TCC CCA TAT TAC TAT 
GCT TTC-3'). Cycle
 
parameters were as follows: 95°C for 5 min; 94°C for 10 s, 55°C for 30 s, and 
72°C for 1 min for 30 cycles; and an extension of 72°C for 10 min. For subsequent nested PCR, 1 
L of the first round PCR reaction was used as a template to amplify an internal region of the pol 
gene and was performed in a 10 µL reaction containing 1 x SYBR Green JumpStart Taq Ready Mix 
(Sigma), and 3 pmol
 
of each primer (Forward: 5'-TTC TTC AGA GCA GAC CAG-3'; Reverse: 5'-
ACT TTT GGG CCA TCC ATT-3'). Cycle parameters
 
were 95°C for 3 min; followed by 95°C for 
1 min, 55°C for 30
 
s, and 72°C for 1 min for 35 cycles; and an extension of 72°C for 10 min. PCR 
products were resolved on a 2% agarose
 
gel and visualized by ethidium bromide staining. 
 
Whole virus binding and trypsin sensitivity 
TZM-bl, TR146 and FaDu cells (5 x 10
4
) were infected with either YU2 (R5) or LAI (X4) virus at 
an MOI of 5 overnight at 4C. Cells were washed three times with PBS and blocked in PBS/10% 
BSA for 10 min at room temperature. To determine whether HIV-1 binding was trypsin sensitive, 
prior to blocking, cells were treated with trypsin (0.05%)-EDTA (0.02%) (PAA, UK) for 5 min at 




































































F425 B4e8 (1:200) (AIDS Research and Reference Reagent Program) followed by Cy5-conjugated 
AffinityPure goat anti-human IgG secondary (1:400) (Jackson ImmunoResearch), each for 30 min 
at 4C. Cells were washed three times with PBS, resuspended in 4% formaldehyde and subjected to 
flow cytometry. Binding percentages for whole virus were calculated as increased Cy5 shift of 
HIV-1 infected labelled cells from uninfected labelled cells. Given the higher background with a 
new batch of antibody, binding percentages for the trypsin sensitivity data were calculated as 
increased Cy5 shift relative to HIV-1 infected secondary alone labelled cells.  
 
Detection of HIV-1 integration by primer-probe Alu-LTR PCR assay 
To determine whether HIV DNA was able to integrate into epithelial cells a real-time PCR assay 
was performed with HIV-1 LTR and human Alu-specific primers with a U5 specific probe as 
previously described [57]. TR146, FaDu and PM-1 (control) cells were seeded at 5 x 10
5
 cells per 
well and the following day infected with YU2 (R5) or LAI (X4) virus, pre-treated with RNAse-free 
DNAse (Roche, UK) at 37C for 1 h with 4mM MgCl2. MOI’s ranged from 1 to 140. Heat-
inactivated virus (60C for 1 h) without DNAse treatment was used as a DNA contamination 
control. Cells and virus were incubated for 48 h at 37
o
C, after which cells were washed three times 
with PBS before DNA was extracted using the GenElute™ Mammalian Genomic DNA Miniprep 
Kit (Sigma, Poole, UK) according to the manufacturer’s instructions with Proteinase K digestion for 
20 min. Isolated DNA samples were digested with DpnI (New England Bioloabs, UK) to degrade 
any plasmid DNA contaminant. DNA was then quantified by Nanodrop and either 50 ng or 100 ng 
DNA was analysed by real-time PCR on a Rotorgene 6000 (Qiagen, UK) using primers 0.2 M 
MH535 forward (5’-AACTAGGGAACCCACTGCTTAAG-3’) and 0.8 M reverse SB704 (5’-
TGCTGGGATTACAGGCGTGAG-3’) with 0.2 M probe P-HUS-SS1 (5’FAM-
TAGTGTGTGCCCGTCTGTTGTGTGAC-TAMRA-3’) using Jumpstart Ready Mix (Sigma, 
Poole, UK) in 10 μL reactions. For each PCR reaction the same concentration of DNA was used for 




































































cycles of 94C for 15 s, 60C for 30 s and 72C for 60 s. DNAse-treated virus exposed samples 
were compared with heat-inactivated virus exposed samples. Positive integration events were taken 
as a lower Ct in the DNAse treated virus exposed sample than the heat-inactivated virus control.  
 
Productive viral infection by detection of spliced HIV-1 tat by PCR 
TR146, FaDu and TZM-bl cells were seeded at 5 x 10
5
 cells per well and the following day infected 
with YU2 (R5) or LAI (X4) virus at an MOI of 0.2. After overnight incubation at 37
o
C unbound 
virus was removed by washing and total RNA isolated (GenElute Mammalian Total RNA Miniprep 
Kit; Sigma). Genomic DNA was removed with Turbo DNAse free (Ambion) according to the 
manufacturer’s instructions and samples were confirmed DNA free prior to analysis. Equal amounts 
of total RNA was used to synthesize viral cDNA transcripts using the HIV-specific oligo ART-7 5’- 
TTC TAT TCC TTC GGG CCT GTC G -3’. A 1 L aliquot of cDNA was then subjected to PCR 
using primers spanning the tat1 and 2 exon junctions (tat-junction forward: 5’- TAG ATC CTA 
GAC TAG AGC CC-3’ and tat-junction reverse 5’- TTG GGA GGT GGG TCT GAA ACG-3’) in a 
20 µL reaction containing
 
1 x PCR buffer, 100 µM dNTP’s, 1.5 mM MgSO4, 2.5 U Taq polymerase 
(New England Biolabs) and 10 pmol
 
of each primer. Cycle
 
parameters were as follows: 95°C for 5 
min; followed by 94°C for 10 s, 55°C for 30 s, and 72°C for 1 min for 35 cycles; with a final 
extension of 72°C for 10 min. PCR products were resolved on a 2% agarose
 
gel and visualized by 
ethidium bromide staining. 
 
HIV-1 integration and productive infection using pseudotyped virus-like particles 
TR146, FaDu, NP2-R5 and NP2-X4 cells were seeded at 1 x 10
5
 cells per well and cultured 
overnight at 37°C. Serial dilutions (1:2) of HIV-1 gp160 pseudotyped (X4, R5 and dual tropic) and 
VSV-G pseudotyped HIV-1 were applied and incubated overnight at 37°C. HIV-1 integration and 
de novo virus protein production were determined by the presence of GFP-expressing cells by flow 




































































presence of 500 μM of the HIV-1 reverse transcriptase inhibitor AZT (NIH AIDS Reagent Program 
Cat no.3485). 
 
Detection of de novo HIV-1 production by indicator cell infection 
TR146, FaDu, and TZM-bl cells were seeded at 5 x 10
5
 cells per well and the following day 
infected with YU2 (R5) or LAI (X4) virus at an MOI of 0.2. After overnight incubation at 37
o
C the 
cells were extensively washed with HBSS (Invitrogen) to remove unbound virus. Fresh media was 
applied to the cells and the plates were incubated at 37
o
C for up to 7 days to allow any de novo-
produced infectious virus to be released into the medium. Culture medium (potentially containing 
infectious virus) was then applied to 3 x 10
5
 TZM-bl indicator cells and incubated for a further 24 h 
at 37
o
C. Cells were fixed, washed twice with PBS and stained for β-galactosidase expression with 
X-Gal stain. Individual wells were visualized by light microscopy at 100 X magnification. 
 
HIV-1 transfer assay 
FaDu, TR146 and TZM-bl cells were seeded at 1 x 10
5
 cells and the following day infected with 
YU2 (R5) or LAI (X4) virus at an MOI of 0.2. After overnight incubation at 37
o
C the cells were 
thoroughly washed in HBSS to remove any unbound virus. Controls included FaDu and TR146 
cells without the addition of virus. TZM-bl cells (3 x 10
5
) were then overlaid onto the epithelial 
cells and the plates incubated for a further 48 h at 37
o
C. Cells were fixed and stained for β-
galactosidase expression with X-Gal stain. Individual wells were photographed by light microscopy 
at 100 X magnification. 
 
Results 
Expression of HIV-1 receptors in oral epithelial cells 
The initial step of HIV-1 infection of any cell type is surface receptor binding. Therefore, we first 




































































SIGN and HSPG’s, excluding GalCer as this non-protein moiety can not be investigated by gene 
expression) HIV-1 receptors in oral epithelial cells by quantitative PCR (Fig. 1). This demonstrated 
the absence or minimal expression of CD4, CCR5 and CXCR4 in both TR146 and FaDu cells 
compared with control TZM-bl cells. In addition, in all three cell types DC-SIGN was minimally 
expressed and the HSPG syndecan-1 was highly expressed. The only major difference observed 
between the two oral epithelial cell types was the high expression of the HSPG syndecan-4 in FaDu 
cells (at levels greater than TZM-bl cells), which was undetectable in TR146 cells. 
We next determined the surface expression of CD4, CCR5, CXCR4, DC-SIGN, GalCer, and 
HSPG’s on oral epithelial cells by flow cytometry (Fig. 2). Both TR146 (buccal) and FaDu 
(pharyngeal) cell lines expressed undetectable levels of CD4 and low levels of CCR5 and CXCR4 
(~6-8%) compared with control TZM-bl cells, which are HeLa cell derivatives engineered to 
express higher levels of CD4 (32%), CCR5 (17%) and CXCR4 (85%), supporting the gene 
expression data. NP2 cells expressing either CCR5 (85%) or CXCR4 (88%) were also used as 
positive controls and expressed high levels of CD4 (50-60%). With regard to non-canonical 
receptors, both TR146 and FaDu cells expressed similar amounts of DC-SIGN (6-8%) and HSPG’s 
(6-10%) but FaDu cells expressed greater amounts of GalCer than TR146 cells (25% and 15%, 
respectively). Of note, the similar amounts of surface HSPG’s expressed on TR146 and FaDu cells 
appears to be in contrast to the differences in gene expression data for syndecan-4 (Fig. 1); 
however, this was expected since the detecting antibody recognizes other HSPG’s including 
syndecan-1, which is highly expressed in both TR146 and FaDu cells (Fig. 1). TZM-bl cells also 
expressed low levels of DC-SIGN (14%), GalCer (14%) and HSPG’s (7%). Likewise NP2-X4 and 
–R5 cells expressed low levels of DC-SIGN (5-20%), but higher levels of GalCer (25-50%). 
 
HIV-1 binding to oral epithelial cells 
We next determined whether HIV-1 can be captured by both oral epithelial cell types. TR146, FaDu 




































































After extensive washing the presence of attached virus was determined using three separate 
approaches. 
First, total protein was isolated using RIPA buffer and the detection of HIV-1 p24 gag protein 
determined by immunoblot analysis. p24 was present in both TR146 and FaDu protein lysates at 
levels similar to that found with TZM-bl cells, indicating that both R5 and X4 virus are captured by 
both buccal and pharyngeal epithelial cells (Fig. 3A). We confirmed that R5 and X4 virus are also 
captured by primary oral epithelial cells (gingival) (Fig. 3A). Given that primary epithelial cells 
demonstrated identical HIV-1 binding data to TR146 and FaDu cells, all other experiments were 
performed with TR146 and FaDu cells only. 
Second, using a more quantitative approach, the presence of immobilized virus on the surface 
of TR146 and FaDu cells was determined by flow cytometry using a using a Cy5-labeled anti-
human secondary antibody to detect a monoclonal primary that detected HIV-1 gp120 F425 B4e8. 
Both R5 and X4 virus was detected on TR146 and FaDu cells demonstrating direct binding of 
infectious virus to both epithelial cell types (Fig. 3B). However, FaDu cells appeared to capture 
both R5 and X4 virus more efficiently than TR146 cells (27-32% versus 4-7%, respectively) and to 
a similar degree as control TZM-bl cells (21-59%). A second monoclonal primary F425 A1g8 
antibody showed similar binding to the epithelial lines as F425 B4e8 (data not shown). 
Third, we also determined the presence of captured virus through the detection of packaged 
HIV RNA by amplification of the HIV-1 pol gene using nested PCR. Given that this approach was 
used to confirm the p24 protein and whole virus binding data, we performed this experiment using 
R5 virus only. Successful amplification of the HIV-1 pol gene indicated the presence of R5 virus on 
both TR146 and FaDu cells in addition to TZM-bl cells (Fig. 3C). It should be noted that the 
Western blot (Fig. 3A) and PCR (Fig. 3C) data are qualitative and may not reflect differences in the 
efficiency of R5 and X4 HIV-1 binding to TR146 and FaDu cells, which was more apparent when 




































































Finally, we determined that binding of both R5 and X4 virus to TR146, FaDu and TZM-bl 
cells was trypsin sensitive, with between 73-97% of R5 and 33-78% of X4 virus being removed 
upon 5 min incubation with trypsin at 37
o
C (Fig. 3D). This suggests that R5 and X4 virus interact 
predominantly with protein moieties on epithelial cells to mediate binding but that X4 virus may 
also utilize additional non-protein moieties, as X4 binding was less sensitive than R5 binding to 
trypsin digestion to both TR146 and FaDu cells. Taken together, the data demonstrate that both R5 
and X4 virus directly bind buccal and pharyngeal epithelial cells, with possible preferential binding 
to pharyngeal cells. 
 
HIV-1 mRNA transcription and de novo viral protein production 
Given that HIV-1 was able to bind both TR146 and FaDu cells, we hypothesized that epithelial cells 
may support productive infection resulting in HIV-1 mRNA transcription and de novo viral protein 
production. This would ultimately result in the assembly of new viral progeny, demonstrating that a 
productive infection has been established. To investigate this we utilized four different approaches. 
First, we used a PCR-based system to detect spliced HIV-1 tat mRNA in the target epithelial 
cells 24 h post-infection with infectious R5 and X4 virus.  The presence of high levels of spliced tat 
mRNA indicates HIV-1 integration and de novo production of viral mRNA transcripts, which in 
permissive cells is representative of a productive HIV-1 infection that results in new viral progeny 
being produced. We found that spliced tat mRNA was only detected in control TZM-bl cells but not 
in TR146 or FaDu cells (Fig. 4A). 
Second, to determine if de novo virus production could be detected we probed protein lysates 
of TR146, FaDu and TZM-bl cells for p55 gag protein by Western blot 24 h post-infection with 
YU2 (R5) or LAI (X4) virus. Detection of p55 gag protein is only observed if de novo viral protein 
production has occurred. Fig. 4B shows p55 gag protein expression only in the control TZM-bl cells 




































































Third, given that most analyses were undertaken 24 – 48 h post-infection with HIV-1, we 
hypothesized that epithelial cells may require a longer time period for viral progeny to be produced. 
Therefore, after addition of infectious R5 and X4 virus to TR146 and FaDu cells for 24 h, the cells 
were thoroughly washed and the medium replenished for up to 7 days. Culture supernatants taken at 
day 4 and 7 (potentially containing new viral progeny) were then transferred onto TZM-bl indicator 
cells for 48 h. Any de novo virus production and subsequent infection of TZM-bl cells would cause 
HIV-LTR driven -galactosidase production, which would be visible as blue foci in the assay. 
However, no blue foci were observed indicating that no new virions were produced after prolonged 
virus incubation in either epithelial cell type (data not shown). 
Fourth, we utilized the three-plasmid expression system developed by Naldini et al [58] to 
generate HIV-based vectors pseudotyped with HIV-1 envelopes, HXB (X4), YU2 (R5) or 89.6 
(dual tropic). Supernatants containing replication defective retroviral particles were used to 
transduce TR146, FaDu and NP2-R5/X4 cells. NP2 cells were used because the receptor expression 
is maintained using selective media and thus efficiency of viral infection was greater than with 
TZM-bl cells, so these cells were used as the positive control. Unlike the HIV canonical receptor 
expressing NP2 cells, TR146 and FaDu cells failed to drive expression of the GFP reporter gene 
resulting in undetectable GFP fluorescence up to 48 h post-infection (Fig. 4C). Taken together, our 
extensive data sets indicate that productive HIV-1 infection does not occur in TR146 and FaDu 
epithelial cells. 
 
HIV-1 integration into epithelial cells 
Although both R5 and X4 virus was unable to productively infect TR146 and FaDu cells, it was 
possible that, post-capture, HIV-1 was able to gain entry and integrated into the epithelial cell DNA 
to establish a latent infection. To test for this possibility we performed a real-time PCR assay to 
detect integrated viral DNA using primer sets specific for HIV-1 LTR and human Alu sequences 




































































performed at an MOI of 1; however, after incubation of epithelial cells with R5 or X4 virus for 48 
h, no integration was detected in either cell line (data not shown). Therefore, further experiments 
were carried out at increased MOI’s, which also showed that both R5 (MOI of 7.5) and X4 (MOI of 
10) virus failed to integrate into either TR146 or FaDu cells, whereas in the control cell lines (NP2-
R5 and C8166) amplification of the integration product was detected after 28 and 32 cycles, 
respectively (Table 2). To confirm that lack of viral integration into the epithelial cell genome was 
not due to the presence of insufficient amounts of HIV-1, a final experiment using X4 virus at an 
MOI of 140 was performed, which also failed to produce detectable levels of HIV-1 integration 
(Table 2). 
 
Productive HIV-1 infection is not restricted when HIV-1 enters via the endocytic pathway 
Although we had convincing data that HIV-1 does not integrate and establish a productive infection 
in TR146 and FaDu cells, we sought to determine whether epithelial cells possessed the cellular 
machinery to support productive infection if conventional receptor-mediated entry mechanisms 
were by-passed. To test this, we utilized the three-plasmid expression system as described above 
[58] to generate VSV-G protein-pseudotyped HIV-1 vectors encoding GFP. By utilizing the 
endocytic entry of VSV-G, we found strong GFP fluorescence by flow cytometry in both TR146 
(22%) and FaDu (38%) epithelial cells, at levels moderately lower than TZM-bl cells (50%) (Fig. 
5). The difference in TR146 and FaDu infection efficiency may be due to the faster growth rate of 
FaDu cells over TR146 cells. Irrespective, the data indicate that epithelial cells are able to support 
productive HIV-1 infection if HIV-1 enters via the endocytic pathway. Addition of the HIV-1 
reverse transcriptase inhibitor AZT abolished GFP fluorescence with the VSV-G pseudotyped virus, 
indicating the specificity of HIV-1 production in both epithelial cell types. 
 




































































One proposed mechanism of HIV-1 transmission across mucosal surfaces is via transfer of 
infections virus to underlying permissive cells post-capture by epithelial cells. Given that both R5 
and X4 virus can be captured by oral epithelial cells (Fig. 3) but does not result in integration (Table 
2) or productive viral infection (Fig. 4), we determined whether immobilized HIV-1 remained 
infectious post-capture. TR146 and FaDu cells were incubated with R5 and X4 virus for 24 h to 
allow for viral binding and following extensive washing, TZM-bl indicator cells were added for up 
to a further 48 h. Transfer of virus from TR146 and FaDu cells to TZM-bl cells would result in -
galactosidase activation and the appearance of blue foci. Fig. 6 indicates the presence of blue foci, 
most clearly at the border between epithelium and overlaid TZM-bl cells, which demonstrates that 
R5 and X4 virus can be transferred from the surface of both buccal and pharyngeal cells to 
permissive cells. These experiments were performed with multiple controls including absence of 
HIV-1 and incubation of TZM-bl cells with unconditioned and conditioned medium, but none of 




Although most HIV infections worldwide are transmitted through
 
mucosal surfaces, their 
transmission through the oral mucosa and
 
its secretions is thought to be uncommon [6]. Given that 
the oral cavity is a prime site for HIV-1 transmission in nursing infants and during oral-genital 
contact, it is profoundly important to understand the fate of HIV-1 after exposure to oral tissues. 
One view is that HIV-1 can directly infect epithelial cells with low efficiency, thereby establishing a 
primary infection. Another view is that HIV-1 is captured by epithelial cells and subsequently 
transcytosed or transferred to permissive cells in the sub-mucosa, thereby disseminating the virus in 
the body. Using buccal (TR146) and pharyngeal (FaDu) epithelial cells, our study supports the 
second view, as both cell types were able to capture and transfer infectious virus to permissive cells, 




































































1 in the body. We also demonstrate that following HIV-1 binding, viral genome integration and 
other markers for potential de novo virus production, such as mRNA transcription and viral protein 
production do not occur in oral epithelial cells. However, epithelial cells possess the cellular 
machinery to support HIV-1 replication since the above-mentioned post-entry processes are not 
restricted if conventional HIV-1 entry is circumvented through endocyctic pathways. Therefore, we 
propose that oral epithelial cells may play an important function in HIV-1 dissemination through 
their ability to bind HIV-1 and transfer viable virus to permissive cells and may support productive 
infection if receptor-mediated HIV-1entry is circumvented. 
 HIV-1 binding requires expression of canonical (CD4, CCR5, CXCR4) or non-canonical 
(e.g. DC-SIGN, GalCer and HSPG’s) receptors on the host cell surface. Using qualitative and 
quantitative analyses we demonstrate that both R5 and X4 virus are able to bind directly to TR146 
and FaDu epithelial cells. However, binding appears to be independent of canonical HIV-1 receptor 
expression, since extremely low or undetectable levels of CD4, CCR5 and CXCR4 expression were 
found in both cell types, which is in concordance with most studies investigating expression of 
these receptors in epithelial cells [7,19,20,22,43,48]. Rather, viral binding is probably mediated via 
non-canonical receptors such as GalCer and HSPG’s, given their greater expression levels in both 
buccal and pharyngeal epithelial cells, but unlikely to be via DC-SIGN which was expressed at low 
levels. Interestingly, FaDu cells expressed high levels of the HSPG syndecan-4, which was 
undetectable in TR146 cells. Given that X4 and R5 virus appear to bind FaDu cells more efficiently 
than TR146 cells, HIV-1 may preferentially or more efficiently bind the pharyngeal site of the oral 
cavity via syndecan-4. The utilization of both protein (e.g. HSPG) and non-protein (e.g. GalCer) 
moieties by HIV-1 to bind oral epithelial cells is supported by the fact that R5 and X4 binding was 
reduced but not abolished after trypsin digestion. Notably, X4 virus may preferentially utilize non-
protein moieties since a greater number of X4 virus remained attached after trypsin digestion as 
compared with R5 virus. Also, while most primary HIV-1 infections occur with R5 virus [59] and 




































































and cell-free systems [43], our extensive binding data indicate no such preference in buccal and 
pharyngeal epithelial cells as both R5 and X4 virus appear to bind equally well to either cell type. 
This study did not determine the efficiency of HIV-1 retention in comparison with other immune 
cells such as dendritic cells, since the purpose of these experiments was solely to determine whether 
HIV-1 binds epithelial cells. 
Whether viral entry and genome integration occurs in oral epithelial cells is currently unclear, 
but this may be reflective of the experimental procedures used in different studies. One study using 
immortalized OKF6/TERT-2 cells (floor of mouth) showed that HIV-1 may directly integrate into 
oral epithelial cells without establishing a productive infection [21]. However, the lack of DNAse 
treatment of virus stocks prior to infection or DpnI treatment of DNA samples after infection may 
not have been sufficient to remove potential plasmid contamination. Although nuclear extracts were 
used and heat-inactivated controls included, this may not have been sufficient to prevent false 
positives for viral integration. HIV-1 integration may also occur through utilization of the host cell 
recombination machinery, since mutations in HIV-1 integrase resulting in a defective enzyme do 
not necessarily eliminate provirus formation [60]. Other studies have demonstrated that integration 
and productive infection by X4 virus but not R5 virus occurs in primary gingival cells [18]. 
However, these cells were shown to express significant levels of CXCR4 and GalCer, which 
together can be used as alternative receptors to CD4. Using a sensitive real-time PCR assay we 
provide strong evidence that both R5 and X4 virus are unable to integrate their genomes into the 
DNA of both TR146 and FaDu epithelial cells. The samples were rigorously treated with DNAse 
and DpnI digestion to prevent contaminating HIV-1 DNA; the method also measures the amount of 
carry-over DNA, as all samples are quantified relative to a matched heat-inactivated control. 
To further study the fate of the virus after binding to oral epithelial cells we employed three 
different approaches: HIV-1 gp160 pseudotyped virus, detection of spliced HIV-1 tat mRNA, and 
de novo production of p55 gag protein. All three suggested that HIV-1 infection, de novo HIV-1 




































































these assays do not ascertain if entry or internalization of the virus occurred since the tat mRNA 
PCR was not sensitive enough to detect the presence of low levels of spliced tat mRNA, which can 
be expressed from non-integrative viral DNA [61,62]. These observations, together with the general 
absence of CD4/CXCR4/CCR5 expression in both cell types, support the view that productive HIV-
1 infection requires canonical receptor expression on the host cell. Despite this, our findings are in 
contrast with some studies demonstrating productive viral infection in epithelial cell lineages 
isolated from tonsilar tissue [44-46], adenoids [43], salivary glands [47,48] and primary gingival 
keratonicytes [18,43]. However, the findings of these studies appear to correlate with greater 
expression of CXCR4 and/or GalCer in epithelial cells from these oral sites. Furthermore, the in 
vivo relevance of one study demonstrating productive infection of X4 virus but not R5 virus in 
primary gingival cells [18] was questioned by Quinones-Mateu [20], as it used the artificial 
compound polybrene to promote HIV-1 viral entry into the epithelial cell [18] (see below). 
Several studies have reported that HIV-1 is endocytosed by epithelial cells [63], which can 
then lead to productive infection. To address this we utilized a GFP-encoding VSV-G pseudotyped 
HIV-1 virus, which utilizes the endocytic pathway for cell entry and by-passes conventional CD4 
receptor-mediated entry mechanisms. This virus was able to establish a productive infection in both 
TR146 and FaDu cells that could be inhibited with AZT, demonstrating two key points. First, HIV-
1 does not enter epithelial cells via the endocytic pathway (otherwise a productive infection would 
ensue with live virus) and that HIV-1 binding is probably mediated through non-canonical viral-
specific receptors. Second, epithelial cells possess the cellular machinery to assemble and secrete 
infectious viral progeny if receptor-mediated entry is by-passed (as VSV-G pseudotyped HIV-1 
virus establishes productive infection). Together with the fact that HIV-1 infection of TZM-bl cells 
(epithelial-like cells expressing CD4, CXCR4 and CCR5) also results in the assembly and secretion 
of infectious viral progeny, our data suggests that oral epithelial cells are able to support productive 
viral infection if HIV-1 is able to gain entry into the cell. This may explain why the use of 




































































Our findings raise the intriguing possibility that if conditions arise in vivo that enable receptor-
mediated entry to be by-passed, for example during inflammatory responses, productive HIV-1 
infection may be supported in oral epithelial cells. 
Although under normal conditions productive HIV-1 infection does not appear to occur in 
epithelial cells, the virus remains attached to epithelial cells giving rise to the possibility that 
captured virus may be transmitted to permissive cells in the underlying mucosa. Utilizing a cell 
overlay experiment we show that HIV-1 retains infectivity on the epithelial cell surface and can be 
readily transferred to TZM-bl cells to establish a productive infection. Transfer of virus to 
permissive cells has also been observed for other oral epithelial cell lineages [18,21,36,52] and 
appears to occur in a CD4/CCR5/CXCR4 and GalCer independent manner. These findings have 
major implications for HIV-1 infection in vivo as this may provide a window of opportunity for the 
virus to be transferred to intraepithelial T lymphocytes, dendritic cells and tissue macrophages in 
the sub-mucosa, thereby establishing an acute infection and disseminating the virus in the body. 
Indeed, evidence that trans infection might occur in vivo has been provided in simian experiments, 
which demonstrated systemic viral dissemination 24 h after atraumatic exposure of the oral mucosa 
to SIV-1 [16]. Furthermore, using ex vivo tissue explants Tugizov et al. [64] recently demonstrated 
that HIV-1 is efficiently transcytosed through adult and fetal polarized oral epithelial cells, although 
only virions emerging after transcytosis from fetal epithelial cells appeared to be infectious. 
In summary, we demonstrate that HIV-1 is able to bind to oral epithelial cells via non-
canonical viral-specific receptors but that genome integration and productive viral infection does 
not occur. However, oral epithelial cells possess the cellular machinery to support productive HIV-1 
infection if the virus enters via the endocytic pathway or if conventional entry mechanisms are by-
passed. Once captured, HIV-1 also remains infectious on the surface of epithelial cells, which may 
facilitate direct viral transfer to permissive cells in the sub-mucosa thereby establishing acute 
infection. Therefore, although often considered a rare site of HIV-1 infection, the oral mucosa may 




































































Of vital importance for future work is the identification of the non-canonical viral-specific receptors 
that allow HIV-1 binding. Manipulation of these receptors may have the potential to prevent 
epithelial transfer of HIV-1 and prevent productive infection in permissive cells. 
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Figure Legends 
Figure 1. Basal HIV-1 receptor mRNA expression in resting oral epithelial cells. TR146, FaDu and 
TZM-bl cells were examined for mRNA expression of CD4, CCR5, CXCR4, DC-SIGN and the 
HSPG’s syndecan-1 and -4 by quantitative RT-PCR. Data are presented as mRNA transcripts 
(arbitrary units) normalized to -actin in a minimum of three independent experiments. Bars 
indicate ± standard deviation from the mean. 
 
Figure 2. Basal HIV-1 receptor surface expression in resting oral epithelial cells. TR146, FaDu, 
TZM-bl and NP2-R5 and –X4 expressing cells were examined for surface expression of CD4, 
CCR5, CXCR4, DC-SIGN, GalCer and HSPG’s by flow cytometry using monoclonal primary 
antibodies specific to each receptor with a FITC-labeled secondary antibody. HSPG’s were not 
analyzed in NP2-R5 or -X4 expressing cells. Data are presented as percentage of cells expressing 
each receptor in a minimum of three independent experiments. Bars indicate ± standard error of the 
mean. 
 
Figure 3. HIV-1 R5 and X4 binding to oral epithelial cells. Primary epithelial cells, TR146, FaDu 
and TZM-bl cells were incubated with cell free YU2 (R5) or LAI (X4) infectious virus overnight 
under identical conditions and extensively washed. (A) Detection of p24 gag protein by Western 
blotting using -actin as a loading control; (B) Detection of immobilized virus on the cell surface 
by flow cytometry using a Cy5-labeled anti-human secondary antibody to detect  HIV-1 gp120 
monoclonal primary detected on APC channel. Gates set around unlabelled cell control, this number 
is then set to 0 and the percent cells shifted to the right of the gate are deemed positive. Then, 




































































cell percentages to obtain the % fluorescence values shown. Data are representative of four 
independent experiments and bars indicate ± standard deviation from the mean (C) Detection of 
packaged HIV R5 RNA by amplification of the HIV-1 pol gene using nested PCR. (D) % reduction 
in detection of immobilized virus on the cell surface by flow cytometry after trypsin treatment. 
Virally exposed cells are compared with cells labelled with secondary alone. Data sets are 
representative of three independent experiments.  
 
Figure 4. Post-integration HIV-1 mRNA transcription and de novo viral protein production in oral 
epithelial cells. (A) Detection of spliced HIV-1 tat mRNA in TR146, FaDu and TZM-bl control 
cells by PCR 24 h post-infection with YU2 (R5) or LAI (X4) infectious virus. (B) p55 gag protein 
detection in TR146, FaDu and TZM-bl control cells by Western blot after 24 h infection with R5 
(YU2) and LAI (X4) virus. (C) Infection of TR146, FaDu and NP2-R5/X4 control cells with GFP-
linked single-cycle X4, R5 and dual tropic HIV-1 gp160 pseudotyped virus and detection of GFP 
incorporation into epithelial cell DNA by flow cytometry. Data are representative of three 
independent experiments. 
 
Figure 5. HIV-1 entry via the endocytic pathway results in productive viral infection in oral 
epithelial cells. Two fold serial dilutions of VSV-G pseudotyped HIV-1 (MOI 1 – 0.125) were 
added to TR146, FaDu and TZM-bl control cells. Infection is measured by flow cytometry as % 
GFP expression (black bars). The effect of AZT (500mM) on GFP expression was also measured at 
the highest virus inoculum (white bar). Data are representative of three independent experiments 
 
Figure 6. Transfer of captured HIV-1 from epithelial cells to permissive cells. TR146 and FaDu 
and TZM-bl cells were incubated with R5 (YU2) and LAI (X4) virus for 24 h and following 









































































































































Table 1.  Primer sets detecting gene expression of HIV-1 associated receptors 
 














5’- ACTAAAGGTCCATCCAAGCTGA —3’ 
5’- GCAGTCAATCCGAACACTAGCA —3’ 





5’- TGGACCAAGCTATGCAGGTG —3’ 
5’- CGTGTCACAAGCCCACAGAT —3’ 




5’- CCTCATCCTGGCTTTCTTCG  —3’ 
5’- GAATGTCCACCTCGCTTTCC —3’ 





5’- TCAAGCAGTATTGGAACAGAGGA —3’ 








5’- TGAAACCTCGGGGGAGAATAC —3’ 
5’- GGTACAGCATGAAACCCACC —3’ 





5’- CAGGGTCTGGGAGCCAAGT —3’ 
5’- GCACAGTGCTGGACATTGACA —3’ 




5’- CATGTACGTTGCTATCCAGGC —3’ 
5’- CTCCTTAATGTCACGCACGAT —3’ 






































































Table 2.  Detection of integrated HIV-1 genome in oral epithelial cells 
 
Cell line R5-YU2 (MOI = 7.5) X4-LAI (MOI = 10) X4-LAI (MOI = 140) 
FaDu ND Not included ND 
TR146 ND ND ND 
C8166a n/a + (Ct = 32.7) + (Ct = 33.5) 
NP2-R5b + (Ct = 28.8) n/a n/a 
 
a  C8166 cells express CXCR4 and were used for X4 viral infections only. 
b  NP2-R5 cells express CCR5 and were used for R5 viral infections only. 
+,  Integrated HIV-1 product detected (cycle threshold detection in brackets). 
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Please consider the enclosed manuscript entitled “Capture and transfer of infectious HIV-1 by vaginal 
epithelial cells” for publication in Virology. 
The majority of HIV-1 infections worldwide are acquired via mucosal surfaces, predominantly across 
the female genital tract. However, there is ambiguous literature on whether HIV-1 binds, enters and 
integrates into vaginal epithelial cells, whether productive infection ensues, and whether sequestered 
infectious virus can be transferred to permissive immune cells. We utilized an epithelial cell line of 
stratified squamous cell origin (A431), which is representative of a site (vulvovaginal) that is rarely 
investigated with regard to vaginal transmission but is one of the first cell types that is likely to come 
into contact with HIV-1. 
Our extensive data demonstrate that HIV-1 X4 and R5 virus can readily bind vaginal epithelial cells 
(probably via non-canonical viral-specific receptors) but that integration of the viral genome into 
epithelial cell DNA and de novo virus production does not ensue. Thus, productive infection does not 
occur in vaginal epithelial cells. However, notably, vaginal epithelial cells possess the cellular 
machinery to support productive HIV-1 infection if the virus enters via the endocytic pathway or if 
conventional entry mechanisms are by-passed. Also, once captured, HIV-1 remains infectious on the 
surface of vaginal epithelial cells and can be transferred to permissive cells, which has important 
implications in vivo. Thus, the vaginal route may thus facilitate direct HIV-1 transfer to permissive 
cells in the sub-mucosa, thereby establishing acute infection by disseminating HIV-1 in the body. 
We would like to stress the novelty aspects of our work. First, the A431 epithelial cell line has not 
previously been used to investigate HIV-1 binding or productive infection; thus, the entire data set is 
novel. Second, to our knowledge gp120 detection on the surface of epithelial cells and trypsin 
resistance to gp120 detection as measured by flow cytometry is also novel. Third, the viral integration 
experiments using the qPCR based primer-probe method has not previously been used in vaginal 
epithelial studies. Finally, we are unaware of any study using the VSV-G system to demonstrate that 
vaginal epithelial cells possess the cellular machinery to support productive HIV-1 infection if the virus 
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The vast majority of HIV-1 transmission occurs across the vaginal mucosa. In this study we utilized 2 
a vaginal epithelial cell line (A431) to determine HIV-1 receptor expression, HIV-1 capture and 3 
transfer to permissive cells, and viral integration and productive infection. Using flow cytometry 4 
and Western blotting to detect gp120 and p24, we demonstrate that whilst A431 cells do not express 5 
discernable levels of CD4, CCR5 or CXCR4, they do capture both X4 and R5 virus probably via 6 
non-canonical receptors. Once captured, HIV-1 remains infectious and can be transferred to 7 
permissive TZM-bl reporter cells. However, HIV-1 integration and productive infection, as 8 
measured by real-time PCR, presence of early gene mRNA transcripts, and de novo protein 9 
production was not detected. Notably, VSV-G-packaged HIV-1 was replication competent in A431 10 
cells. Thus, while productive HIV-1 infection is unlikely to occur in vaginal cells, they may provide 11 
a potential route to establish systemic infection. 12 
 13 
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Heterosexual transmission accounts for the majority of new HIV-1 infections (Hladik & McElrath, 2 
2008). Both men and women have been shown to have detectable HIV-1 in seminal fluid and 3 
cervicovaginal secretions (Dulioust et al., 1998; Coombs et al., 1998; Goulston et al., 1998; 4 
Goulston et al., 1996). Studies have shown that cell-free and cell-associated HIV-1 can establish 5 
mucosal infection (Phillips et al., 1998; van Herrewege Y et al., 2007), and macaque and human 6 
studies indicate that transmission is facilitated by the presence of HIV-1 target cells (dendritic cells, 7 
Langerhans cells, CD4
+
 T cells and macrophages) in the ectocervix and vagina as well as in the 8 
endocervix and uterus (Yeaman et al., 1998; Shen et al., 2011; Ballweber et al., 2011; Kaldensjo et 9 
al., 2011; Shen et al., 2009; Miller & Shattock, 2003; Khanna et al., 2002; Bhoopat et al., 2001; Hu 10 
et al., 2000; Hu et al., 1998; Spira et al., 1996; Maher et al., 2005; Hu et al., 2004; Greenhead et al., 11 
2000; Hladik et al., 2007; Zhang et al., 1999). HIV-1 entry into permissive cells requires the 12 
expression of the CD4 receptor and a chemokine fusion co-receptor (CCR5 for R5-tropic or 13 
CXCR4 for X4-tropic) (Pierson & Doms, 2003). However, most studies indicate that there is a 14 
general absence or low level surface expression of CD4, CCR5 and CXCR4 in vaginal epithelial 15 
cells (Berlier et al., 2005; Bobardt et al., 2007; Dezzutti et al., 2001), although data for CXCR4 16 
surface expression is somewhat varied (Berlier et al., 2005; Yeaman et al., 2004). 17 
Despite these receptor dependencies, HIV-1 may also infect CD4
-
 cells such as 18 
oligodendrocytes (Harouse et al., 1991), fibroblasts (Tateno et al., 1989) and spermatozoa (Baccetti 19 
et al., 1994), as well as epithelial cells from the gastrointestinal tract (Asmuth et al., 1994) and 20 
thymus (Braun et al., 1996). Thus, HIV-1 may utilize several non-canonical receptor mechanisms 21 
for binding and entry into host cells. The viral envelope protein gp120 has been shown to bind 22 
several cell-surface molecules including DC-SIGN (dendritic cell-specific intercellular adhesion 23 
molecule-3-grabbing non-integrin) (Geijtenbeek et al., 2000; van Kooyk & Geijtenbeek, 2003), 24 
heparan sulphate proteoglycans (HSPGs) such as syndecan-1 (Bobardt et al., 2003; Wu et al., 2003; 25 
Mondor et al., 1998) and GalCer (glycosphingolipid galactosylceramide) (Alfsen & Bomsel, 2002; 26 
  
 4 
Delezay et al., 1997; Harouse et al., 1991). HSPGs and GalCer are commonly expressed on 1 
epithelial cells and may promote HIV-1 binding and transport across the vaginal epithelium 2 
(Bobardt et al., 2007; Wu et al., 2003; Weinberg et al., 2011; Dezzutti et al., 2001; Yeaman et al., 3 
2004). Notably, mucosal transmission of HIV-1 most frequently occurs with R5-utilizing viruses 4 
(Margolis & Shattock, 2006; Zhu et al., 1993); however, a full and satisfactory explanation for R5 5 
selectivity has not yet been provided. 6 
One mechanism of HIV-1 transmission across the vaginal mucosa is thought to occur through 7 
sequestration of the virus by epithelial cells, followed by transfer to permissive cells to establish a 8 
primary infection (Yeaman et al., 1998; Shen et al., 2011; Ballweber et al., 2011; Kaldensjo et al., 9 
2011; Shen et al., 2009; Miller & Shattock, 2003; Khanna et al., 2002; Bhoopat et al., 2001; Hu et 10 
al., 2000; Hu et al., 1998; Spira et al., 1996; Dezzutti et al., 2001). Similarly, HIV-1 binding to 11 
epithelial cells may directly impair barrier integrity facilitating entry (Fanibunda et al., 2011; Nazli 12 
et al., 2010). However, the fundamental issue of whether vaginal epithelial cells can be productively 13 
infected with HIV-1 remains controversial. Whilst some studies support the view that HIV-1 can 14 
integrate into the vaginal epithelial genome and produce progeny virus (Phillips et al., 1998; Furuta 15 
et al., 1994; Phillips et al., 1994; Tan et al., 1993), others discount this view (Dezzutti et al., 2001; 16 
Greenhead et al., 2000; Wu et al., 2003; Spira et al., 1996).  It has been proposed that HIV-1 may 17 
also be sequestered in cytosolic endocytic compartments or transmitted by transcytosis (Hladik & 18 
McElrath, 2008; Hocini & Bomsel, 1999; Hocini et al., 2001; Bobardt et al., 2007; Bomsel, 1997) 19 
without establishing productive infection within epithelial cells. In addition, proviral DNA from X4 20 
tropic viruses has been detected in vaginal epithelial cells (Berlier et al., 2005; Iversen et al., 1998), 21 
suggesting that HIV-1 may potentially integrate into the epithelial genome even if this does not give 22 
rise to productive infection. 23 
Given the current ambiguous literature on this fundamentally important topic, we aimed to 24 
determine whether HIV-1 binds, enters and integrates into vaginal epithelial cells, whether 25 
productive infection ensues, and whether sequestered infectious virus can be transferred to 26 
  
 5 
permissive cells. We utilized the A431 epidermoid carcinoma epithelial cell line of vulval 1 
(squamous) origin, which represents a site commonly exposed to HIV-1 during heterosexual 2 
intercourse but is rarely used to study HIV-1 life cycle events. We demonstrate that A431 cells were 3 
able to capture X4 and R5 virus but that integration of the viral genome into epithelial cell DNA 4 
and de novo virus production does not occur. Notably, VSV-G-packaged HIV-1 was replication 5 
competent in A431 cells. Finally, A431 cells were able to transfer infectious X4 and R5 virus to 6 
permissive TZM-bl reporter cells, which in vivo would represent transfer of virus to immune cells in 7 
the sub-mucosa and dissemination of HIV-1 in the body. 8 
 9 
Results 10 
HIV-1 receptor expression in vaginal epithelial cells 11 
Surface receptor binding is the initial step of HIV-1 infection. Therefore, we first analyzed the gene 12 
expression levels of CD4, CCR5, CXCR4, DC-SIGN and the HSPG’s syndecan-1 and syndecan-4 13 
in A431 cells by quantitative PCR (Fig. 1). GalCer was excluded as this non-protein moiety can not 14 
be investigated by gene expression. This demonstrated the absence of CCR5 and CXCR4 15 
expression in A431 cells but high expression in the control TZM-bl cells. Notably CD4 mRNA was 16 
detected, albeit approximately 12-fold lower than TZM-bl cells. In both cell types, DC-SIGN was 17 
minimally expressed but HSPG syndecan-1 was highly expressed. Syndecan-4 was expressed at 18 
intermediate levels, with approximately 5-fold greater expression in A431 cells as compared with 19 
TZM-bl cells. 20 
Given that mRNA expression often does not correlate with protein expression, we next 21 
determined the surface expression of CD4, CCR5, CXCR4, DC-SIGN, GalCer, and HSPG’s on oral 22 
epithelial cells by flow cytometry (Fig. 2). A431 cells expressed undetectable levels of CD4 and 23 
very low levels of CCR5 and CXCR4 (~6-8%), unlike the control TZM-bl cells which are HeLa 24 
cell derivatives engineered to express high levels of CD4 (40%), CCR5 (85%) and CXCR4 (85%). 25 
The A431 data suggests that the CD4 mRNA detected by gene expression (Fig. 1) did not translate 26 
  
 6 
into surface CD4 protein expression. With regard to non-canonical receptors, both A431 and TZM-1 
bl cells expressed low amounts of DC-SIGN (~5% and 16%, respectively). However, unlike TZM-2 
bl cells, A431 cells expressed greater surface levels of GalCer (~75%) and HSPG’s (35%).  3 
 4 
Binding of HIV-1 to vaginal epithelial cells 5 
Next, HIV-1 binding to vaginal epithelial cells was assessed. A431 and TZM-bl cells were 6 
incubated overnight with cell free YU2 (R5) or LAI (X4) infectious virus. After extensive washing 7 
the presence of captured virus was determined using three approaches. First, total protein was 8 
isolated and the presence of HIV-1 p24 gag protein determined by immunoblot analysis. p24 was 9 
present in A431 protein lysates at levels similar to that found with TZM-bl cells, indicating that 10 
both R5 and X4 virus are captured by vaginal epithelial cells (Fig. 3A). Second, we used a more 11 
quantitative approach by detecting attached virus by flow cytometry using a Cy5-labeled secondary 12 
antibody to detect a human monoclonal primary (F425 B4e8) that bound to HIV-1 gp120. Both R5 13 
and X4 virus was detected on A431 cells (~10%), albeit at lower levels than TZM-bl cells (60-14 
70%), demonstrating direct binding of infectious virus to vaginal epithelial cells (Fig. 3B). A 15 
second monoclonal primary F425 A1g8 antibody showed similar binding to the epithelial lines as 16 
F425 B4e8 (data not shown). Third, we assessed for the presence of packaged HIV RNA by 17 
amplification of the HIV-1 pol gene using nested PCR. This approach was used to confirm the p24 18 
protein and whole virus binding data; therefore, we performed this experiment using only the R5 19 
virus. Amplification of the HIV-1 pol gene indicated the presence of R5 virus on A431 cells in 20 
addition to TZM-bl cells (Fig. 3C). The Western blot (Fig. 3A) and PCR (Fig. 3C) data are 21 
qualitative and may not reflect differences in the efficiency of R5 and X4 HIV-1 binding to A431 22 
cells, which was more apparent using the quantitative flow cytometry approach (Fig. 3B). 23 
Finally, we determined whether binding of R5 and X4 virus to A431 and TZM-bl cells was 24 
trypsin sensitive after 5 min incubation with trypsin at 37
o
C by detecting gp120 using flow 25 
cytometry. Interestingly, while binding of both R5 and X4 virus to TZM-bl cells and R5 virus to 26 
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A431 was trypsin sensitive (~70-80% reduction in binding), X4 binding was more resistant, as 1 
binding was reduced by only ~15 % (Fig. 3D). This suggests that R5 virus interacts predominantly 2 
with trypsin-sensitive protein moieties on vaginal epithelial cells to mediate binding, whilst X4 3 
virus predominantly utilizes non-protein moieties or trypsin-insensitive protein moieties. Taken 4 
together, the data demonstrate that both R5 and X4 virus directly bind vaginal epithelial cells, 5 
although differences may exist in the surface moieties used for attachment. 6 
 7 
HIV-1 mRNA transcription and de novo viral protein production 8 
Since HIV-1 was captured by A431 cells, we hypothesized that vaginal epithelial cells may support 9 
productive infection. This would constitute initiation of HIV-1 mRNA transcription, de novo viral 10 
protein production and, ultimately, assembly of new viral progeny. To investigate this we utilized 11 
four different approaches. First, we used a PCR-based system to detect spliced HIV-1 tat mRNA in 12 
A431 cells 24 h post-infection with R5 and X4 virus. The presence of high levels of spliced tat 13 
mRNA would indicate HIV-1 integration and de novo production of viral mRNA transcripts, which 14 
in permissive cells is representative of a productive HIV-1 infection resulting in production of new 15 
viral progeny. However, we found that spliced tat mRNA was only detected in control TZM-bl cells 16 
and not in A431 cells (Fig. 4A). Second, we assessed protein lysates of A431 and TZM-bl cells for 17 
p55 gag protein by Western blot 24 h post-infection with YU2 (R5) or LAI (X4) virus. Detection of 18 
p55 gag protein would only be observed if de novo viral protein production had occurred. Fig. 4B 19 
shows p55 gag protein expression only in TZM-bl cells but not A431 vaginal epithelial cells. Third, 20 
since most assays were undertaken 24 – 48 h post-infection with HIV-1, we also assessed for HIV-1 21 
progeny after day 4 and 7 in case a longer time period was required to establish a productive 22 
infection in vaginal epithelial cells. However, neither R5 nor X4 culture supernatants at either time 23 
point induced blue foci formation (demonstrating HIV-LTR driven -galactosidase production), 24 
indicating that no new infectious virions were produced (data not shown). Fourth, we utilized a 25 
three-plasmid expression system (Naldini et al., 1996) to generate HIV-based vectors pseudotyped 26 
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with HIV-1 envelopes, YU2 (R5), HXB (X4) or 89.6 (dual tropic). Supernatants containing these 1 
replication defective retroviral particles were used to transduce A431 and NP2-R5/X4 cells. NP2 2 
cells were used as the positive control because receptor expression is maintained using selective 3 
media and thus efficiency of viral infection was greater than with TZM-bl cells. Unlike the NP2-4 
X4/R5 cells, A431 cells failed to drive expression of the GFP reporter gene, resulting in 5 
undetectable GFP fluorescence up to 48 h post-infection (Fig. 4C). Taken together, these extensive 6 
data sets indicate that productive HIV-1 infection does not occur in A431 vaginal epithelial cells. 7 
 8 
Integration of HIV-1 into the vaginal epithelial genome 9 
Although R5 and X4 virus was unable to productively infect A431 cells (Fig. 4), it was possible 10 
that, post-capture (Fig. 3), HIV-1 was able to gain entry and integrate into the epithelial genome to 11 
establish a latent infection. To test this we performed a real-time PCR assay to detect integrated 12 
viral DNA using primer sets specific for HIV-1 LTR and human Alu sequences with a FAM-13 
TAMRA probe specific for the U5 region of the LTR (Mbisa et al., 2009). Initial experiments 14 
performed at an MOI of 1 indicated no integration by either R5 or X4 virus after 48 h (data not 15 
shown). Further experiments demonstrated that increasing the MOI to 7.5 (X4) and 10 (R5) also 16 
failed to permit viral integration into A431 cells, whereas in the control cell lines (NP2-R5 and 17 
C8166) amplification of the integration product was detected after 29 and 33 cycles, respectively 18 
(Table 2). To confirm that lack of viral integration into A431 cells was not due to the presence of 19 
insufficient amounts of HIV-1, a final experiment using X4 virus at an MOI of 140 was performed, 20 
which also failed to produce any detectable levels of HIV-1 integration (Table 2). These data 21 
demonstrate that HIV-1 X4 and R5 do not integrate into the vaginal epithelial genome. 22 
 23 
Productive infection occurs in A431 cells when HIV-1 enters via the endocytic pathway 24 
Although R5 and X4 virus does not integrate and establish a productive infection in A431 cells, we 25 
sought to determine whether vaginal epithelial cells possessed the cellular machinery to support 26 
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productive HIV-1 infection if receptor-mediated entry mechanisms were by-passed. Therefore, we 1 
utilized the same three-plasmid expression system as described above (Naldini et al., 1996) to 2 
generate VSV-G protein-pseudotyped HIV-1 vectors encoding GFP. By utilizing the endocytic 3 
entry of VSV-G, strong GFP fluorescence was observed by flow cytometry in A431 cells (32%) at 4 
levels only slightly lower than TZM-bl cells (50%) (Fig. 5). These data indicate that vaginal 5 
epithelial cells are able to support productive HIV-1 infection if the virus enters via the endocytic 6 
pathway. Addition of the HIV-1 reverse transcriptase inhibitor AZT abolished GFP fluorescence 7 
with the VSV-G pseudotyped virus in both A431 and TZM-bl cells, indicating the specificity of de 8 
novo HIV-1 production. 9 
 10 
HIV-1 transfer from vaginal epithelial cells to permissive TZM-bl cells 11 
A common route of HIV-1 transmission across the vaginal mucosa is thought to be via transfer of 12 
infections virus to underlying permissive cells post-capture by epithelial cells. As R5 and X4 virus 13 
are captured by vaginal epithelial cells (Fig. 3) but do not integrate (Table 2) or establish productive 14 
viral infection (Fig. 4), we next determined whether immobilized HIV-1 remained infectious post-15 
capture. A431 cells were incubated with R5 and X4 virus for 24 h to allow for viral binding and 16 
following extensive washing, TZM-bl indicator cells were added for up to a further 48 h. Transfer 17 
of virus from A431 cells to TZM-bl cells and their subsequent infection would result in -18 
galactosidase activation and the appearance of blue foci. Fig. 6 indicates the presence of blue foci 19 
(arrows shown for A431/R5), which demonstrates that R5 and X4 virus can be transferred from the 20 
surface of vaginal cells to permissive cells. Experiments were performed with additional controls 21 
including absence of HIV-1 and incubation of TZM-bl cells with conditioned medium, none of 22 





The majority of HIV-1 infections worldwide are acquired via mucosal surfaces, predominantly 1 
across the female genital tract (Hladik & McElrath, 2008). As such, it is profoundly important to 2 
understand the fate of HIV-1 after exposure to vaginal mucosa. One view is that vaginal HIV-1 3 
transmission occurs either by direct infection of permissive cells within the vaginal mucosa or 4 
sequestration of the virus by epithelial cells followed by transfer to permissive cells (Yeaman et al., 5 
1998; Shen et al., 2011; Ballweber et al., 2011; Kaldensjo et al., 2011; Shen et al., 2009; Miller & 6 
Shattock, 2003; Khanna et al., 2002; Bhoopat et al., 2001; Hu et al., 2000; Hu  et al., 1998; Spira et 7 
al., 1996; Dezzutti et al., 2001; Hladik & McElrath, 2008; Bobardt et al., 2007; Hocini & Bomsel, 8 
1999; Hocini et al., 2001; Bomsel, 1997). However, another view is that vaginal epithelial cells may 9 
be productively infected with HIV-1 or that the virus establishes a latent (non-productive) infection 10 
by integrating into epithelial genome (Phillips et al., 1998; Furuta et al., 1994;Phillips et al., 1994; 11 
Tan et al., 1993; Iversen et al., 1998; Berlier et al., 2005). Using vulvovaginal (A431) epithelial 12 
cells, our study supports the first view, as epithelial cells were able to capture and transfer infectious 13 
virus to permissive TZM-bl cells but are not productively infected, with no evidence of viral 14 
genome integration. However, our data would also suggest that vaginal epithelial would be 15 
productively infected by HIV-1 if conventional entry is circumvented, such as through endocyctic 16 
pathways. Therefore, we propose that vaginal epithelial cells role in HIV-1 dissemination is through 17 
their ability to bind HIV-1 and transfer viable virus to permissive cells, which in vivo would permit 18 
infection of immune cells in the sub-mucosa and establishment of a primary HIV-1 infection. 19 
Using both qualitative and quantitative analyses we demonstrate that R5 and X4 virus is able 20 
to bind directly to A431 vaginal epithelial cells. Binding appears to be independent of canonical 21 
HIV-1 receptor expression, since extremely low or undetectable levels of CD4, CCR5 and CXCR4 22 
expression were found in A431 cells, which is in concordance with other human studies (Berlier et 23 
al., 2005; Dezzutti et al., 2001; Bobardt et al., 2007). This supports studies with primary vaginal 24 
epithelial cells using inhibitors and neutralising antibodies, which indicate that HIV-1 binding is 25 
independent of CD4, CXCR4 and CCR5 (Bobardt et al., 2007). Rather, given their high surface 26 
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expression, HIV-1 binding is probably mediated via non-canonical receptors such as GalCer and 1 
HSPG’s (e.g. syndecans) but unlikely to be via DC-SIGN, which was expressed at very low levels. 2 
Indeed, one study indicated that HSPGs but not GalCer were the key moieties involved in HIV-1 3 
binding to vaginal epithelial cells (Bobardt et al., 2007). 4 
Our extensive binding data did not indicate an R5 or X4 preference in binding to A431 cells 5 
with both viruses apparently binding equally well. However, trypsin digestion experiments 6 
indicated that R5 virus predominantly utilized protein (e.g. HSPG) moieties to bind vaginal 7 
epithelial cells whereas X4 virus predominantly utilized non-protein (e.g. GalCer) moieties. Apart 8 
from binding GalCer, another potential reason for why X4 virus is more resistant to trypsin 9 
digestion is that X4 virus may somehow be protected by epithelial structures on the surface. 10 
Whether viral genome integration occurs in vaginal epithelial cells is currently unclear, but 11 
this may be reflective of the different experimental procedures and cell types used in different 12 
studies. One study detected proviral HIV-1 DNA in between 29-68% vaginal and cervical clinical 13 
samples, indicating viral integration (Iversen et al., 1998). However, the samples may have included 14 
immune cells that were present in mucosa or secretions at the time of collection, especially since 15 
bleeding was observed in approximately 50% of patients upon cervical sample collection. Another 16 
study detected proviral HIV-1 DNA in three carcinoma cell lines (HEC1A, endometrium; CaSki, 17 
cervix; SiHa, uterus) and primary vaginal epithelial cells (Berlier et al., 2005). There was a 18 
preference for X4 integration, which was CXCR4 dependent since SDF-1, a CXCR4 ligand, 19 
blocked integration. X4 integration was probably the result of all three cell lines expressing high 20 
amounts of CXCR4 (~60%). Studies with primary gingival (oral) (Liu et al., 2003) and uterine 21 
(Asin et al., 2004) epithelial cells have also demonstrated preferential integration of X4 virus, but 22 
this may also have been due to  high surface expression of CXCR4 and GalCer, which together can 23 
be used as alternative receptors to CD4 for viral entry (Liu et al., 2003). However, other studies 24 
have failed to observe HIV-1 gag DNA in primary cervical epithelial cells or the cervical ME-180 25 
cell line (Dezzutti et al., 2001), or the ectocervix cell line (Ect1/E6E7) despite HIV-1 being 26 
  
 12 
captured and subsequently released (Wu et al., 2003). The latter study further confirmed a lack of 1 
viral integration using a luciferase reporter virus expressing CCR5 gp120 envelope (Wu et al., 2 
2003). Using a sensitive real-time PCR assay not used in any of the above studies we provide strong 3 
evidence that both X4 and R5 virus are unable to integrate their genomes into the DNA of A431 4 
vaginal epithelial cells. One explanation for this may be the very low surface expression levels of 5 
CXCR4 in A431 cells (~5%). In this regard, the origin of A431 cells (vulval), which is different to 6 
those used in the above studies, may account for the differences in CXCR4 expression and hence 7 
X4 viral integration. Another explanation may be that, unlike the above studies, our samples were 8 
rigorously treated with DNAse and DpnI digestion to prevent possible false positive integration 9 
events from contaminating HIV-1 DNA. Interestingly, another study showed that HIV-1 proviral 10 
DNA could be detected in differentiated colonic epithelial cell clones but not undifferentiated 11 
clones (Furuta et al., 1994). If applicable to vaginal epithelial cells, this may have implications for 12 
HIV-1 transmission in vivo, as the virus may more readily integrate into apical (differentiated) 13 
rather than basal (undifferentiated) epithelial cells. This may provide some explanation for why we 14 
did not detect proviral DNA in A431 cells as they are an undifferentiated cell line (Knuechel et al., 15 
1990). 16 
To further demonstrate if HIV-1 infection is supported in A431 vaginal epithelial cells we 17 
employed three different approaches; infection with HIV-1 gp160 pseudotyped virus, detection of 18 
spliced HIV-1 tat mRNA, and de novo production of p55 gag protein. However, we note that the 19 
HIV-1 tat assay does not ascertain if entry or internalization of the virus occurred since the tat 20 
mRNA PCR was not sensitive enough to detect the presence of low levels of spliced tat mRNA, 21 
which can be expressed from non-integrative viral DNA (Sloan et al., 2010; Wu & Marsh, 2003). 22 
Irrespective, we demonstrate that HIV-1 infection, de novo HIV-1 protein production and viral 23 
assembly is not supported in A431 vaginal cells. These observations, together with the general 24 
absence of CD4/CXCR4/CCR5 expression in A431 cells, support the view that productive HIV-1 25 
infection requires canonical receptor expression on the host cell. Our findings are in concordance 26 
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with the majority of other studies demonstrating a lack of productive HIV-1 infection in vaginal 1 
epithelial cells despite the presence of HSPGs and GalCer (Dezzutti et al., 2001; Greenhead et al., 2 
2000; Wu et al., 2003; Hu et al., 1998; Miller, 1998). However, they are in contrast with other 3 
studies which indicate that vaginal epithelial cells can support productive HIV-1 infection (Phillips 4 
et al., 1998; Furuta et al., 1994; Phillips et al., 1994; Tan et al., 1993). We have also demonstrated 5 
that trypsin treatment failed to remove all surface-bound HIV-1. This raises an important issue in 6 
other co-culture studies that have claimed infection of permissive cells as a result of de novo virus 7 
production in epithelial cells. In some of these studies it is possible that new viral progeny may have 8 
originated from trypsin-resistant bound HIV-1, which was transferred to the permissive cells from 9 
the epithelial cell surface, leading to their infection. 10 
Several studies have reported that HIV-1 may be sequestered in epithelial cytosolic endocytic 11 
compartments or transmitted by transmigration/transcytosis (Hladik & McElrath, 2008; Hocini & 12 
Bomsel, 1999; Hocini et al., 2001; Bobardt et al., 2007; Bomsel, 1997). Whether viral endocytosis 13 
into epithelial cells results in productive infection is uncertain. Whilst one study showed that HIV-1 14 
released by infected T-cells in vesicles were taken up by and productively infect cervical (ME100) 15 
carcinoma epithelial cells (Tan et al., 1993), another study showed a lack of productive infection 16 
after 18 days despite integrated proviral DNA being present (Berlier et al., 2005). To address 17 
whether HIV-1 entry via endocytosis results in productive infection we utilized a GFP-encoding 18 
VSV-G pseudotyped HIV-1 virus, which utilizes the endocytic pathway for cell entry and by-passes 19 
conventional CD4 receptor-mediated entry mechanisms. This virus was able to establish a 20 
productive infection in A431 cells that could be inhibited with AZT, demonstrating two key points. 21 
First, HIV-1 does not normally enter epithelial cells via the endocytic pathway (otherwise a 22 
productive infection would ensue with live virus) and that HIV-1 binding is probably mediated 23 
through non-canonical viral-specific receptors. Second, epithelial cells are able to assemble and 24 
secrete infectious viral progeny if receptor-mediated entry is by-passed (as VSV-G pseudotyped 25 
HIV-1 virus establishes productive infection). Together with the fact that HIV-1 infection of TZM-26 
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bl cells (epithelial-like cells engineered to express CD4, CXCR4 and CCR5) also results in the 1 
assembly and secretion of infectious viral progeny, our data suggests that vaginal epithelial cells are 2 
able to support productive viral infection only if HIV-1 gains entry into the cell through non-3 
conventional (endocytic) mechanisms. Our findings raise the intriguing possibility that if conditions 4 
arise in vivo that enable receptor-mediated entry to be by-passed, for example during inflammatory 5 
responses, productive HIV-1 infection may be supported in vaginal epithelial cells. 6 
We propose that under 'normal' conditions productive HIV-1 infection is unlikely to occur in 7 
vaginal epithelial cells. However, post-capture, infectious virus may remain immobilized on the 8 
surface giving rise to the possibility of transmission to permissive cells in the underlying mucosa. A 9 
number of studies support this hypothesis (Yeaman et al., 1998; Shen et al., 2011; Ballweber et al., 10 
2011; Kaldensjo et al., 2011; Shen et al., 2009; Miller & Shattock, 2003; Khanna et al., 2002; 11 
Bhoopat et al., 2001; Hu et al., 2000; Hu et al., 1998; Spira et al., 1996; Dezzutti et al., 2001; 12 
Howell et al., 1997; Wu et al., 2003), although others could not demonstrate viral transfer to 13 
permissive cells (PBMCs) by cell-cell contact (Berlier et al., 2005). Utilizing a cell overlay 14 
experiment we show that HIV-1 retains infectivity on the A431 epithelial cell surface and can be 15 
readily transferred to permissive TZM-bl cells to establish a productive infection. Although we are 16 
uncertain of the surface moieties that enable binding and transfer, others have demonstrated an 17 
important role for HSPGs, since heparin or heparin sulfate can inhibit gp120 binding to CD4 cells 18 
and heparinase treatment can reduce viral attachment (Mondor et al., 1998; Roderiquez et al., 1995; 19 
Bobardt et al., 2003; Wu et al., 2003). These findings have implications for HIV-1 infection in vivo 20 
as this may provide a window of opportunity for infectious immobilized virus to be transferred to 21 
susceptible immune cells in the sub-mucosa, thereby establishing an acute infection and 22 
disseminating the virus in the body. This is supported by both macaque and human studies, which 23 
indicate that viral transmission is facilitated by the presence of HIV-1 target cells (dendritic cells, 24 
Langerhans cells, CD4
+
 T cells and macrophages) in the uterus, endocervix, ectocervix and vagina 25 
(Yeaman et al., 1998; Shen et al., 2011; Ballweber et al., 2011; Kaldensjo et al., 2011; Shen et al., 26 
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2009; Miller & Shattock, 2003; Khanna et al., 2002; Bhoopat et al., 2001; Hu et al., 2000; Hu et al., 1 
1998; Spira et al., 1996; Maher et al., 2005; Hu et al., 2004; Greenhead et al., 2000; Hladik et al., 2 
2007; Zhang et al., 1999; Asin et al., 2004). 3 
In summary, although we caution that our experiments have been performed with a 4 
carcinoma cell line, our data conform to primary cell studies and support the view that HIV-1 is 5 
readily captured by vaginal epithelial cells (probably via non-canonical viral-specific receptors) but 6 
that genome integration and productive viral infection does not occur. However, vaginal epithelial 7 
cells possess the cellular machinery to support productive HIV-1 infection if the virus enters via the 8 
endocytic pathway or if conventional entry mechanisms are by-passed. Once captured, HIV-1 also 9 
remains infectious on the surface of epithelial cells, which may facilitate direct viral transfer to 10 
permissive cells in the sub-mucosa thereby establishing acute infection. 11 
 12 
Methods 13 
Cell lines, primary cells, viruses and virus-like particles 14 
The A431 cell line (epidermoid carcinoma of vulval origin) (Giard et al., 1973) and 293T (renal 15 
epithelial) cells were obtained from the American Type Culture Collection. Human glioma cells 16 
(NP2) expressing human CD4 and CXCR4 or CCR5 have been previously described (Soda et al., 17 
1999). The following reagents were obtained through the AIDS Research and Reference Reagent 18 
Program, Division of AIDS, NIAID, NIH: TZM-bl cells (catalogue no. 8129), PM1 cells (catalogue 19 
no. 3038), C8166 T cells (catalogue no. 404 donated by Robert Gallo), JTLRG-R5 (catalogue no. 20 
11586) and HIV-1 molecular clones pYU2 (R5-utilizing, catalogue no.1350) and pLAI.2 (X4-21 
utilizing, catalogue no. 2532). The HIV-1 gag-pol expression vector p8.91 and the vesicular 22 
stomatitis virus envelope protein (VSV-G) expression vector pMDG were kindly provided by 23 
Didier Trono (University of Geneva, Switzerland). The HIV gp160 envelope vectors (pHXB2 (X4), 24 
pYU2 (R5) and pSVIII 89.6 (dual tropic)) were a gift from Professor Greg Towers, University 25 
College London. The retroviral packaging vector pCSGW encoding GFP was a kind gift from 26 
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Adrian Thrasher, Institute of Child Health, University College London, UK. All cell lines were 1 
maintained in Dulbecco's Modified Eagle's Medium (DMEM, PAA) supplemented with 10% fetal 2 
bovine serum (FBS) (PAA), 100 U of penicillin per mL, and 100 µg of streptomycin per mL (PAA) 3 
at 37C and 5% CO2. NP2 cells were additionally supplemented with 1 mg/mL of G418 4 
(Invitrogen) and 1µg/mL
 
of puromycin (Invitrogen). 5 
 6 
Virus preparation 7 
Viral vectors used for production of VSV-G and HIV gp160 pseudotyped HIV were prepared by 8 
transient transfection of 293T cells using a protocol adapted from Besnier et al. (Besnier et al., 9 
2002). Briefly, 293T cells were seeded at 95% confluency
 
in a 10 cm dish and the following day 10 
cells were transfected with 3 g each of pMDG and p8.91 and 4.5 g of pCSGW using the 11 
polyanionic transfection reagent Jet PEI (Polyplus Transfection) according to the manufacturer’s 12 
instructions. After 24 h the media was replaced and 48, 72 and 96 h post-transfection virion-13 
containing culture supernatants were harvested and filtrated through a 0.45µm pore size membrane 14 
and stored in aliquots at -80C until required. Production of infectious stocks of live virus was 15 
performed by transient transfection of 293T cells as described above, with 5 µg of the infectious 16 
molecular clone pLAI.2 (X4) and or pYU2 (R5) used per transfection. For trypsin sensitivity 17 
experiments and detection of integration into epithelium, YU2 virus was grown in NP2-R5 and 18 
JLTRG-R5 cells while LAI virus was grown in C8166 cells for 1-2 weeks with addition of fresh 19 
medium until cells showed accumulation of cytopathic effects and were then harvested and frozen 20 
in aliquots. 21 
 22 
Virus titration 23 
Infectious virus stock (LAI and YU2) titers were determined by plaque assay. Briefly, TZM-bl cells 24 
(1 × 10
4
 cells/well) were cultured overnight (96-well plates) and incubated with eight replicates of 25 
ten serial dilutions (0.5 log) of virus stock in a total of 100 μL growth media per well. After 48 h, 26 
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virus supernatant was removed and the cells were fixed with 0.05% glutaraldehyde for 5 min at 1 
room temperature and washed twice with phosphate-buffered saline (PBS). Expression of β-2 
galactosidase was determined by staining cells with X-Gal stain [1mg/mL X-Gal in 5 mM 3 
KFe4(CN6) 3H2O, 5 mM KFe3(CN6) 3H2O, and 1 mM MgCl2] and incubating culture plates at 37°C 4 
for 2 h. Virus infectivity was
 
estimated as plaque forming units (PFU) per mL. Titration of VSV-G 5 
pseudotyped HIV-1 and HIV gp160 pseudotyped HIV-1 was carried out using 293T cells or NP2 6 
cells, respectively. Cells were seeded at 1 x 10
5
 cells/well (24 well plates) and cultured overnight at 7 
37°C. Serial dilutions (1:2) of virus supernatant were applied to the cells (500 L) and incubated 8 
overnight. The following day the media was exchanged and 48 h after transduction with virion-9 
containing culture supernatants the percentage of GFP-expressing cells was determined by flow 10 
cytometry using the FACSCanto machine (BD Biosciences). Data was analyzed with FACSDiva 11 
software and WinMDI (copyright 1993-2000 Joseph Trotter http://facs.scripps.edu) to calculate the 12 
infectious units per mL. 13 
 14 
HIV-1 receptor expression by quantitative reverse transcription-PCR 15 
RNA was isolated from resting TZM-bl and A431 cells using GenElute Mammalian Total RNA 16 
Miniprep Kit (Sigma), followed by treatment with Turbo DNA free DNAse (Ambion) according to 17 
the manufacturer’s instructions. All samples were confirmed DNA free prior to analysis. cDNA was 18 
synthesized from 1 g of RNA using HIV reverse transcriptase (Ambion) according to the 19 
manufacturer’s instructions. Primers were obtained from RTPrimerDB 20 
(http://medgen.ugent.be/rtprimerdb/) and PrimerBank (http://pga.mgh.harvard.edu/primerbank) 21 
(Lefever et al., 2009; Spandidos et al., 2010). Gene expression of CD4, CCR5, CXCR4, DC-SIGN, 22 
SDC-1 (syndecan-1) and SDC-4 (syndecan-4) was quantified by real-time PCR using SYBR Green 23 
JumpStart Taq Ready Mix (Sigma) with 4 pmol primers and 1 μL cDNA in 10 μL reactions on the 24 
Corbett Research Rotor-Gene 6000 (Qiagen) using the following cycling parameters: 95°C for 3 25 
min; followed by 95°C for 3 s, annealing for 10 s and extension for 20-30 s for 40 cycles. Data was 26 
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analyzed with Corbett Research Rotor-Gene 6000 Series Software 1.7 using the two standard curve 1 
method with β-actin used as the normalizer gene. Primer sequences, annealing and extension 2 
temperatures are listed in Table 1. 3 
 4 
HIV-1 receptor expression by flow cytometry 5 
A431 and TZM-bl resting cells were washed with PBS and incubated with 0.02% (W/V) EDTA for 6 
5-30 min. Detached cells were washed thoroughly with PBS supplemented with 1% BSA and 7 
0.01% azide (wash buffer), and resuspended at 1 × 10
6
 cells in 1 mL wash buffer. To identify 8 
surface expressed HIV-1 receptors and co-receptors, 100 L of cells were incubated at room 9 
temperature for 1 h with mouse anti-human CD4 (1:4 catalogue no.724), CCR5 (1:20, catalogue no. 10 
4090), CXCR4 (1:80, catalogue no. 4083), DC-SIGN (1:100 catalogue no. 6884) monoclonal 11 
antibodies (all obtained from the AIDS Research and Reference Reagent Program), GalCer (1:200, 12 
anti-galactocerebroside, Millipore) or heparan sulfate proteoglycan (1:200, Millipore) monoclonal 13 
antibodies. Primary antibodies were detected with goat anti-mouse IgG conjugated with fluorescein 14 
isothiocyanate (FITC) (Jackson ImmunoResearch). After thorough washing, cells were fixed in 200 15 
L 4% formaldehyde and the percentage of FITC-expressing cells was determined by flow 16 
cytometry. 17 
 18 
Detection of HIV-1 binding and replication by Western Blot 19 
A431 and TZM-bl cells were seeded at 5 x 10
5
 cells per well and the following day infected with 20 
YU2 (R5) or LAI (X4) virus at a multiplicity of infection (MOI) of 0.2. After overnight incubation at 21 
37
o
C the cells were washed to remove unbound virus. Cells were harvested in 250 L 1 x RIPA 22 
buffer [50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 20mM EDTA, 1% Triton X-100, 1% sodium 23 
deoxycholate and 0.1% SDS, supplemented with Halt complete protease inhibitor cocktail (Perbio 24 
Science)], placed on ice for 30 min, and stored at -80C until required. Total protein lysates 25 
(mammalian and viral) were normalized for protein content using the bicinchoninic acid (BCA) 26 
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assay (Pierce) and separated using 12% SDS-PAGE gels. Proteins were transferred to PVDF 1 
membranes, probed with anti-HIV-1 gag monoclonal antibody recognizing p24 and p55 isoforms 2 
(catalogue no.6457; AIDS Research and Reference Reagent Program) and secondary goat anti-3 
mouse IgG horseradish peroxidase (HRP)-conjugated antibody (Jackson ImmunoResearch), before 4 
developing using Immobilon-ECL (Millipore). -actin was used as a loading control. 5 
 6 
Detection of HIV-1 binding and packaged viral RNA by PCR 7 
A431 and TZM-bl cells were seeded at 5 x 10
5
 cells per well and the following day infected with 8 
YU2 (R5) virus at an MOI of 0.2. After overnight incubation at 37
o
C the cells were washed to 9 
remove unbound virus. Total RNA was isolated as above and confirmed DNA free prior to analysis. 10 
Equal amounts of total RNA was used to detect packaged viral RNA by first synthesizing cDNA 11 
using Superscript cDNA Synthesis Kit (Invitrogen) and an HIV-1 specific primer (5'-GTC ATG 12 
AAA CAA ACT TGG C-3'). A 2 L aliquot of cDNA was then subjected to nested PCR using 13 
primers to amplify a 2 kb fragment of the HIV pol gene. First round PCR was performed in a 20 µL 14 
reaction containing
 1 x PCR buffer, 100 µM dNTP’s, 1.5 mM MgSO4, 2.5 U Taq polymerase (New 15 
England Biolabs) and 10 pmol
 
 of each primer (Forward: 5'-AAT GAT GAC AGC ATG TCA GGG 16 
AGT-3'; Reverse: 5'-AGT CTT TCC CCA TAT TAC TAT GCT TTC-3'). Cycle
 
parameters were as 17 
follows: 95°C for 5 min; 94°C for 10 s, 55°C for 30 s, and 72°C for 1 min for 30 cycles; and an 18 
extension of 72°C for 10 min. For subsequent nested PCR, 1 L of the first round PCR reaction was 19 
used as a template to amplify an internal region of the pol gene and was performed in a 10 µL 20 
reaction containing 1 x SYBR Green JumpStart Taq Ready Mix (Sigma), and 3 pmol
 
of each primer 21 
(Forward: 5'-TTC TTC AGA GCA GAC CAG-3'; Reverse: 5'-ACT TTT GGG CCA TCC ATT-3'). 22 
Cycle parameters
 
were 95°C for 3 min; followed by 95°C for 1 min, 55°C for 30
 
s, and 72°C for 23 
1 min for 35 cycles; and an extension of 72°C for 10 min. PCR products were resolved on a 2% 24 
agarose
 




Whole virus binding and trypsin sensitivity 1 
A431 cells (5 x 10
4
) were infected with either YU2 (R5) or LAI (X4) virus at an MOI of 5 2 
overnight at 4C. Cells were washed three times with PBS and blocked in PBS/10% BSA for 10 3 
min at room temperature. To determine whether HIV-1 binding was trypsin sensitive, prior to 4 
blocking cells were treated with trypsin (0.05%)-EDTA (0.02%) (PAA, UK) for 5 min at 37C. 5 
Cells were gently removed by scraping and labeled with HIV-1 gp120 monoclonal antibody F425 6 
B4e8 (1:200) (AIDS Research and Reference Reagent Program) followed by Cy5-conjugated 7 
AffinityPure goat anti-human IgG secondary (1:400) (Jackson ImmunoResearch), each for 30 min 8 
at 4C. Cells were washed three times with PBS, resuspended in 4% formaldehyde and subjected to 9 
flow cytometry. Binding percentages for whole virus were calculated as increased Cy5 shift of 10 
HIV-1 infected labelled cells from uninfected labelled cells. Given the higher background with a 11 
new batch of antibody, binding percentages for the trypsin sensitivity data were calculated as 12 
increased Cy5 shift relative to HIV-1 infected secondary alone labelled cells.  13 
 14 
Productive viral infection by detection of spliced HIV-1 tat by PCR 15 
A431 and TZM-bl cells were seeded at 5 x 10
5
 cells per well and the following day infected with 16 
YU2 (R5) or LAI (X4) virus at an MOI of 0.2. After overnight incubation at 37
o
C unbound virus 17 
was removed by washing and total RNA isolated (GenElute Mammalian Total RNA Miniprep Kit; 18 
Sigma). Genomic DNA was removed with Turbo DNAse free (Ambion) according to the 19 
manufacturer’s instructions and samples were confirmed DNA free prior to analysis. Equal amounts 20 
of total RNA was used to synthesize viral cDNA transcripts using the HIV-specific oligo ART-7 5’- 21 
TTC TAT TCC TTC GGG CCT GTC G -3’. A 1 L aliquot of cDNA was then subjected to PCR 22 
using primers spanning the tat1 and 2 exon junctions (tat-junction forward: 5’- TAG ATC CTA 23 
GAC TAG AGC CC-3’ and tat-junction reverse 5’- TTG GGA GGT GGG TCT GAA ACG-3’) in a 24 
20 µL reaction containing
 
1 x PCR buffer, 100 µM dNTP’s, 1.5 mM MgSO4, 2.5 U Taq polymerase 25 
(New England Biolabs) and 10 pmol
 
of each primer. Cycle
 
parameters were as follows: 95°C for 5 26 
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min; followed by 94°C for 10 s, 55°C for 30 s, and 72°C for 1 min for 35 cycles; with a final 1 
extension of 72°C for 10 min. PCR products were resolved on a 2% agarose
 
gel and visualized by 2 
ethidium bromide staining. 3 
 4 
Detection of HIV-1 integration by primer-probe Alu-LTR PCR assay 5 
To determine whether HIV DNA was able to integrate into epithelial cells a real-time PCR assay 6 
was performed with HIV-1 LTR and human Alu-specific primers with a U5 specific probe as 7 
previously described (Mbisa et al., 2009). In this protocol the forward primer binds to the U5 region 8 
of the HIV-1 LTR, the reverse primer binds to the Alu repeat sequence in the host genome, and the 9 
internal FAM-TAMRA labelled probe binds in between these regions (but also binds the U5 region 10 
of the HIV-1 LTR). The specific utilisation of the U5 specific FAM-TAMRA probe also adds 11 
specificity to assay. During PCR, this assay amplifies the majority of the HIV-1 LTR together with 12 
some host genomic material, and a PCR product can only be amplified if the HIV-1 LTR has 13 
integrated into the host genome. A431 and PM-1 (control) cells were seeded at 5 x 10
5
 cells per 14 
well and the following day infected with YU2 (R5) or LAI (X4) virus, pre-treated with RNAse-free 15 
DNAse (Roche, UK) at 37C for 1 h with 4mM MgCl2. MOI’s ranged from 1 to 140. Heat-16 
inactivated virus (60C for 1 h) without DNAse treatment was used as a DNA contamination 17 
control. Cells and virus were incubated for 48 h at 37
o
C, after which cells were washed three times 18 
with PBS before DNA was extracted using the GenElute™ Mammalian Genomic DNA Miniprep 19 
Kit (Sigma, Poole, UK) according to the manufacturer’s instructions with Proteinase K digestion for 20 
20 min. Isolated DNA samples were digested with DpnI (New England Bioloabs, UK) to degrade 21 
any plasmid DNA contaminant. DNA was then quantified by Nanodrop and either 50 ng or 100 ng 22 
DNA was analysed by real-time PCR on a Rotorgene 6000 (Qiagen, UK) using primers 0.2 M 23 
MH535 forward (5’-AACTAGGGAACCCACTGCTTAAG-3’) and 0.8 M reverse SB704 (5’-24 
TGCTGGGATTACAGGCGTGAG-3’) with 0.2 M probe P-HUS-SS1 (5’FAM-25 
TAGTGTGTGCCCGTCTGTTGTGTGAC-TAMRA-3’) using Jumpstart Ready Mix (Sigma, 26 
  
 22 
Poole, UK) in 10 μL reactions. For each PCR reaction the same concentration of DNA was used for 1 
all samples isolated from individual cell lines. Samples were denatured for 10 min followed by 60 2 
cycles of 94C for 15 s, 60C for 30 s and 72C for 60 s. DNAse-treated virus exposed samples 3 
were compared with heat-inactivated virus exposed samples. Positive integration events were taken 4 
as a lower Ct in the DNAse treated virus exposed sample than the heat-inactivated virus control.  5 
 6 
HIV-1 integration and productive infection using pseudotyped virus-like particles 7 
A431, NP2-R5 and NP2-X4 cells were seeded at 1 x 10
5
 cells per well and cultured overnight at 8 
37°C. Serial dilutions (1:2) of HIV-1 gp160 pseudotyped (X4, R5 and dual tropic) and VSV-G 9 
pseudotyped HIV-1 were applied and incubated overnight at 37°C. HIV-1 integration and de novo 10 
virus protein production were determined by the presence of GFP-expressing cells by flow 11 
cytometry. To inhibit HIV-1 specific GFP expression, infections were also carried out in the 12 
presence of 500 μM of the HIV-1 reverse transcriptase inhibitor AZT (NIH AIDS Reagent Program 13 
Cat no.3485). 14 
 15 
Detection of de novo HIV-1 production by indicator cell infection 16 
A431 and TZM-bl cells were seeded at 5 x 10
5
 cells per well and the following day infected with 17 
YU2 (R5) or LAI (X4) virus at an MOI of 0.2. After overnight incubation at 37
o
C the cells were 18 
extensively washed with HBSS (Invitrogen) to remove unbound virus. Fresh media was applied to 19 
the cells and the plates were incubated at 37
o
C for up to 7 days to allow any de novo-produced 20 
infectious virus to be released into the medium. Culture medium (potentially containing infectious 21 
virus) was then applied to 3 x 10
5
 TZM-bl indicator cells and incubated for a further 24 h at 37
o
C. 22 
Cells were fixed, washed twice with PBS and stained for β-galactosidase expression with X-Gal 23 
stain. Individual wells were visualized by light microscopy at 100 X magnification. 24 
 25 
HIV-1 transfer assay 26 
  
 23 
A431 and TZM-bl cells were seeded at 1 x 10
5
 cells and the following day infected with YU2 (R5) 1 
or LAI (X4) virus at an MOI of 0.2. After overnight incubation at 37
o
C the cells were thoroughly 2 
washed in HBSS to remove any unbound virus. Controls included A431 cells without the addition 3 
of virus. TZM-bl cells (3 x 10
5
) were then overlaid onto the epithelial cells and the plates incubated 4 
for a further 48 h at 37
o
C. Cells were fixed and stained for β-galactosidase expression with X-Gal 5 
stain. Individual wells were photographed by light microscopy at 100 X magnification. 6 
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Figure Legends 1 
Figure 1. Basal HIV-1 receptor mRNA expression in resting vaginal epithelial cells. A431 and 2 
TZM-bl cells were examined for mRNA expression of CD4, CCR5, CXCR4, DC-SIGN and the 3 
HSPG’s syndecan-1 and -4 by quantitative RT-PCR. Data are presented as mRNA transcripts 4 
(arbitrary units) normalized to -actin in a minimum of three independent experiments. Bars 5 
indicate ± standard deviation from the mean. 6 
 7 
Figure 2. Basal HIV-1 receptor surface expression in resting vaginal epithelial cells. A431 and 8 
TZM-bl cells were examined for surface expression of CD4, CCR5, CXCR4, DC-SIGN, GalCer 9 
and HSPG’s by flow cytometry using monoclonal primary antibodies specific to each receptor with 10 
a FITC-labeled secondary antibody. Data are presented as percentage of cells expressing each 11 
receptor in a minimum of three independent experiments. Bars indicate ± standard error of the 12 
mean. 13 
 14 
Figure 3. HIV-1 R5 and X4 binding to vaginal epithelial cells. A431 and TZM-bl cells were 15 
incubated with cell free YU2 (R5) or LAI (X4) infectious virus overnight under identical conditions 16 
and extensively washed. (A) Detection of p24 gag protein by Western blotting using -actin as a 17 
loading control; (B) Detection of immobilized virus on the cell surface by flow cytometry. Bars 18 
indicate ± standard deviation from the mean; (C) Detection of packaged HIV R5 RNA by 19 
amplification of the HIV-1 pol gene using nested PCR. (D) Percentage reduction in detection of 20 
immobilized virus on the cell surface by flow cytometry after trypsin treatment. Virally exposed 21 
cells are compared with cells labeled with secondary alone. Data sets (A-D) are representative of 22 
three or four independent experiments.  23 
 24 
Figure 4. Post-integration HIV-1 mRNA transcription and de novo viral protein production in 25 
vaginal epithelial cells. (A) Detection of spliced HIV-1 tat mRNA in A431 and TZM-bl control 26 
  
 34 
cells by PCR 24 h post-infection with YU2 (R5) or LAI (X4) infectious virus. (B) p55 gag protein 1 
detection in A431 and TZM-bl control cells by Western blot after 24 h infection with R5 (YU2) and 2 
LAI (X4) virus. (C) Infection of A431 and NP2-R5/X4 control cells with GFP-linked single-cycle 3 
X4, R5 and dual tropic HIV-1 gp160 pseudotyped virus and detection of GFP incorporation into 4 
epithelial cell DNA by flow cytometry. Data are representative of three independent experiments. 5 
 6 
Figure 5. HIV-1 entry via the endocytic pathway results in productive viral infection in vaginal 7 
epithelial cells. Two fold serial dilutions of VSV-G pseudotyped HIV-1 (MOI 1 – 0.125) were 8 
added to A431 and TZM-bl control cells. Infection is measured by flow cytometry as % GFP 9 
expression (black bars). The effect of AZT (500mM) on GFP expression was also measured at the 10 
highest virus inoculum (white bar). Data are representative of three independent experiments 11 
 12 
Figure 6. Transfer of captured HIV-1 from vaginal epithelial cells to permissive cells. A431 and 13 
TZM-bl cells were incubated with R5 (YU2) and LAI (X4) virus for 24 h and following extensive 14 
washing TZM-bl indicator cells were added for a further 48 h. Controls included A431 cells without 15 





Table 1.  Primer sets detecting gene expression of HIV-1 associated receptors 1 
 2 














5’- ACTAAAGGTCCATCCAAGCTGA —3’ 
5’- GCAGTCAATCCGAACACTAGCA —3’ 





5’- TGGACCAAGCTATGCAGGTG —3’ 
5’- CGTGTCACAAGCCCACAGAT —3’ 




5’- CCTCATCCTGGCTTTCTTCG  —3’ 
5’- GAATGTCCACCTCGCTTTCC —3’ 





5’- TCAAGCAGTATTGGAACAGAGGA —3’ 








5’- TGAAACCTCGGGGGAGAATAC —3’ 
5’- GGTACAGCATGAAACCCACC —3’ 





5’- CAGGGTCTGGGAGCCAAGT —3’ 
5’- GCACAGTGCTGGACATTGACA —3’ 




5’- CATGTACGTTGCTATCCAGGC —3’ 
5’- CTCCTTAATGTCACGCACGAT —3’ 
58 75 250 
 3 




Table 2.  Detection of integrated HIV-1 genome in A431 vaginal epithelial cells 1 
 2 
Cell line R5-YU2 (MOI = 7.5) X4-LAI (MOI = 10) X4-LAI (MOI = 140) 
A431 ND ND ND 
C8166a n/a + (Ct = 33) + (Ct = 34) 
NP2-R5b + (Ct = 29) n/a n/a 
 3 
a
  C8166 cells express CXCR4 and were used for X4 viral infections only. 4 
b
  NP2-R5 cells express CCR5 and were used for R5 viral infections only. 5 
+,  Integrated HIV-1 product detected (cycle threshold detection in brackets). 6 
ND, Integrated HIV-1 product not detected. 7 
n/a, not applicable 8 
  9 
 10 
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Click here to download high resolution image
Figure 5
Click here to download high resolution image
Figure 6
Click here to download high resolution image
